

# ICENI

---

## INSTITUTE FOR CORONAVIRUS EMERGENCE NONPROFIT INTELLIGENCE

The Spartacus Letter – Rev. 3 (2021-10-08) | *Spartacus*

Hello,

My name is Spartacus, and I've had enough.

We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies.

Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic.

Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight.

We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw.

We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment.

What we have discovered would shock anyone to their core.

First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end.

---

### SUMMARY

- COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs.
- Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder.
- Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus and constitute a form of medical theater.

- Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs.
- The authorities have denied the usefulness of natural immunity against COVID-19, even though natural immunity confers protection against all of the virus's proteins, and not just one.
- Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV-2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal.
- There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology.
- COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface ("neural lace") tech, one of whom was indicted for taking grant money from China.
- Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present.
- The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables.

## COVID-19 PATHOPHYSIOLOGY

COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that.<sup>1-5</sup>

In severe cases, this leads to sepsis,<sup>6,7</sup> blood clots,<sup>8-10</sup> and multiple organ failure,<sup>11-13</sup> including hypoxic and inflammatory damage to various vital organs, such as the brain,<sup>14-17</sup> heart (COVID-19 was initially thought to cause myocarditis, but this has proven rare),<sup>18,19</sup> liver,<sup>20-22</sup> pancreas,<sup>23-26</sup> kidneys,<sup>27-29</sup> and intestines.<sup>30-32</sup>

Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, hyperferritinemia, and inflammatory cytokines, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion.<sup>33-39</sup>

COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body's vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack, stroke, or pulmonary embolism.<sup>40-47</sup> COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension.<sup>48,49</sup> This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus.<sup>50,51</sup>

The vast majority of COVID-19 cases are mild and do not cause significant disease.<sup>52-55</sup> 80% of known cases are mild and 20% are severe or critical.<sup>56-58</sup> However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and

morbidity rate are lower than a CFR may indicate.<sup>59-61</sup> However, COVID-19 spreads very quickly (especially in densely-populated areas with greater exposure to respiratory aerosols in public transport), meaning that there are a significant number of severely ill and critically ill patients appearing in a short time frame.<sup>62,63</sup>

The breakdown of the pathology is as follows:

SARS-CoV-2 Spike binds to ACE2.<sup>64,65</sup> Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS.<sup>66,67</sup> The RAAS is a hormone control system that moderates blood pressure and fluid volume (i.e. osmolarity) of the circulatory system by controlling vascular tone and salt retention and excretion.<sup>68-72</sup> This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can potentially infect, not just the lungs.<sup>73-75</sup>

SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus's proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell's own structures to produce more virus.<sup>76-78</sup>

SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinucleated giant cells).<sup>79,80</sup> They also have other pathogenic, harmful effects. SARS-CoV-2's viroporins, such as its Envelope and 3a proteins, act as calcium ion channels, introducing calcium into infected cells, a property that is shared with similar coronaviruses, such as SARS.<sup>81-83</sup> The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein and ORF3a can also directly activate the NLRP3 inflammasome.<sup>84-86</sup> Also, it suppresses the Nrf2 antioxidant pathway.<sup>87-90</sup> The suppression of ACE2 by binding with Spike is claimed to cause a buildup of bradykinin that would otherwise be broken down by ACE2, but this is also contradicted by studies that show that Spike-ACE2 binding can upregulate ACE2 activity.<sup>91-95</sup>

This constant calcium influx into the cells is correlated with noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction.<sup>96-98</sup> The vasoactive peptide bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity.<sup>99-107</sup> This, along with the ongoing expression of various SARS-CoV-2 viroporins, collectively results in prostaglandin release and vastly increased intracellular calcium signaling (including dumping of Ca<sup>2+</sup> stores from the endoplasmic reticulum), which promotes highly aggressive ROS release and ATP depletion.<sup>108-112</sup> NADPH oxidase releases superoxide into the extracellular space.<sup>113-115</sup> Superoxide radicals react with nitric oxide to form peroxynitrite.<sup>116-119</sup> Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and "uncoupling" the enzymes, causing nitric oxide synthase to synthesize more superoxide instead.<sup>120-122</sup> This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted.<sup>123,124</sup>


Dissolved nitric oxide gas produced constantly by eNOS serves many important functions,<sup>125-127</sup> but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors.<sup>128-130</sup> The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage.<sup>131-136</sup>

Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs.<sup>137-140</sup> Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO.<sup>141,142</sup> Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach.<sup>143-146</sup>

Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or NETosis.<sup>147,148</sup> In severe and critical COVID-19, there is actually rather severe NETosis.<sup>149-152</sup>

COVID-19's pathology is, from this point onward, dominated by extreme oxidative stress and neutrophil respiratory burst. Heme iron is stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O<sub>2</sub> due to HOCl outcompeting O<sub>2</sub> at its binding sites.<sup>153-155</sup> Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face.<sup>156,157</sup> Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber-Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely.<sup>158-165</sup>

Haber-Weiss Reaction:



Fenton Reaction:



Hydroxyl radicals are extremely reactive, have a very short half-life in the body, and cannot be detoxified by enzymatic action. They occur naturally in the upper atmosphere, where they destroy pollutants. They are also extremely destructive to biological matter and, in industrial applications, they are often generated on purpose and introduced into wastewater streams to sanitize them through their powerful oxidative effect.<sup>166-171</sup>

In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue.<sup>172-175</sup> In the mitochondria, succinate buildup due to sepsis-induced hypoxia does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals.<sup>176-179</sup> This is called ischemia-reperfusion injury, and it's why the majority of people who go on a ventilator are dying. Make no

mistake, intubation will kill people who have COVID-19 by greatly accelerating the oxidative damage caused by the virus's processes.<sup>180-183</sup>

The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to "rust" due to damage by oxidative stress.<sup>184,185</sup> This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes.<sup>186,187</sup> Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes.<sup>188,189</sup>

This condition is not unknown to medical science. The actual name for all of this is acute sepsis.<sup>190-192</sup>

We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various oxidative stress biomarkers such as nitrotyrosine, 4-HNE, and malondialdehyde.<sup>193-199</sup>

There are many other peculiarities involved in COVID-19, such as increases in gene activity associated with ubiquitination,<sup>200,201</sup> endothelial cell activation,<sup>200-203</sup> vWF release,<sup>204-206</sup> mast cell activation,<sup>207,208</sup> and complement system activation.<sup>209-212</sup> Overall, the inflammatory profile of COVID-19 is somewhat like a severe autoimmune reaction. It is reminiscent of lupus and rheumatoid arthritis, but centered in the vasculature.<sup>213-216</sup>

Hyperinflammatory COVID-19 is a severe, SARS-like inflammatory syndrome that can put a sufferer in the ICU. It is not to be trifled with. However, if hyperinflammatory COVID-19 and the associated sepsis can be effectively treated, then the lethality of the virus will be lessened significantly.

---

## COVID-19 TREATMENTS

In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19.<sup>217-219</sup> When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O<sub>2</sub>. It's a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O<sub>2</sub> is also the precursor of all these damaging radicals that lead to lipid peroxidation.<sup>220-224</sup>

The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically ill COVID-19 patients are antioxidants.<sup>225,226</sup> N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants.<sup>227-238</sup> Indomethacin prevents iron-driven oxidation of arachidonic acid to isoprostanes.<sup>239</sup> There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues.<sup>240-242</sup>

Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020.<sup>243</sup> In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis.<sup>244</sup> By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis.<sup>245,246</sup> They also know that sepsis can be effectively treated with antioxidants.<sup>247-249</sup> None of

this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice.<sup>250,251</sup>

Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford's ludicrous RECOVERY study, the intervention is too late to have any positive effect.<sup>252,253</sup>

The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing.<sup>254</sup> If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response.<sup>255</sup>

In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19.<sup>256</sup> These clinical trials being cited by the media as evidence of the ineffectiveness of antivirals do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling.<sup>257-261</sup>

India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19.<sup>262,263</sup> The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin.<sup>264,265</sup>

Ivermectin is not "horse dewormer". Yes, it is sold in veterinary form as a dewormer for animals.<sup>266</sup> It has also been available in pill form for humans for decades, as an antiparasitic drug.<sup>267</sup>

The media and the FDA have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antiviral.<sup>268,269</sup> This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral.<sup>270-274</sup>

In Bangladesh, Ivermectin costs \$1.80 for an entire 5-day course.<sup>275</sup> Remdesivir, which is toxic to the liver, costs \$3,120 for a 5-day course of the drug.<sup>276</sup> Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer's dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all.<sup>261</sup>

The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis.<sup>277-279</sup>

There is mounting evidence that histamine blockers such as diphenhydramine, famotidine, ranitidine, and cimetidine may have utility in treating COVID-19, possibly by direct antiviral effects, or acting to reduce mast cell activation, in addition to modulating redox activity.<sup>280–283</sup>

Melatonin has been found to have some utility as an adjunct treatment for COVID-19.<sup>284,285</sup> So have indomethacin, budesonide, and other immunomodulatory treatments.<sup>286–288</sup> Indomethacin was known to be directly antiviral against SARS-CoV.<sup>289</sup>

---

## COVID-19 TRANSMISSION

COVID-19 is airborne. Initially, the WHO carried water for China by claiming that the virus was only droplet-borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible.<sup>290–293</sup>

The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant.<sup>294</sup>

The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe.<sup>295–297</sup>

Surgical masks and cloth masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud.<sup>298,299</sup>

The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped.<sup>300–303</sup>

Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission.<sup>304–306</sup> During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments.<sup>307–309</sup>

---

## COVID-19 VACCINE DANGERS

The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around.<sup>310–313</sup>

Natural immunity to COVID-19 from a past infection is far more robust than vaccine-induced immunity. This is because the immune system is exposed to all of the pathogen’s proteins, not just one single protein in isolation.<sup>314,315</sup>

All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown.<sup>316,317</sup>

Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA.<sup>318–321</sup> The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins *in vivo*.<sup>322,323</sup>

These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus.<sup>324,325</sup> The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle.<sup>326</sup> These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to.<sup>327,328</sup>

SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body.<sup>328,329</sup>

It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS-CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells.<sup>330,331</sup> However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place.<sup>332</sup> These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that.<sup>333,334</sup>

Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome.<sup>335</sup> COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it.<sup>336,337</sup> In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies.<sup>338–340</sup>

Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them.<sup>341</sup> There is a possibility that S1 may be proteolytically cleaved from S2, causing



active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein.<sup>342–347</sup>

SARS-CoV-2 Spike has a Superantigenic region (SAG), which may promote extreme inflammation.<sup>348,349</sup> In one study, the Pfizer BNT162b2 vaccine was found to reprogram adaptive and innate immune responses in such a way that TLR4 surveillance is reduced.<sup>350</sup> Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells.<sup>351</sup> Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue.<sup>352–355</sup>

SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well.<sup>356–360</sup> SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity.<sup>361</sup>

SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering.<sup>362–364</sup>

SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness.<sup>365–367</sup> The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases.<sup>368</sup> This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules.<sup>369–371</sup>

SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease.<sup>372–379</sup> For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly-encountered ones.<sup>380,381</sup>

In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill.<sup>382,383</sup>

If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naïve.<sup>384–387</sup>

In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs.<sup>388</sup>

We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it persists inside cells for a longer period of time, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives.<sup>389-391</sup>

By inoculating people with a vaccine that causes their cells to express Spike proteins, they are being inoculated with a pathogenic protein. A toxin that may cause inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately.

---

## COVID-19 CRIMINAL CONSPIRACY

The vaccine and the virus were made by the same people.

In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017.<sup>392-394</sup> This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina.<sup>395,396</sup>

This was a lie. Anthony Fauci lied before Congress. A felony.

Ralph Baric and Shi Zhengli are colleagues and have co-written papers together.<sup>397</sup> Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2.<sup>398-401</sup>

The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars.<sup>402-405</sup>

EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used

when working with dangerous viruses.<sup>406–411</sup> Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose.<sup>412</sup>

In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials.<sup>413,414</sup>

December 12<sup>th</sup>, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH.<sup>415,416</sup> It wasn’t until a whole month later, on January 11<sup>th</sup>, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2.<sup>417,418</sup> Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours.<sup>419–421</sup>

Stéphane Bancel, the current CEO of Moderna, was formerly the CEO of bioMérieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Mérieux.<sup>422,423</sup> Alain Mérieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab.<sup>424–426</sup>

The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. For a virus as significant as RaTG13 appears to be to lie fallow for the better part of a decade with no research papers acknowledging its existence at all is an absurdity.<sup>427–429</sup>

The animal reservoir of SARS-CoV-2 has never been found.<sup>430,431</sup>

26 of the 27 people involved in penning the Lancet letter decrying the lab leak were connected directly to researchers linked to the Wuhan Institute of Virology, a massive conflict of interest.<sup>432</sup> One of those was Peter Daszak himself, who was also a WHO investigator on the ground in Wuhan, and also served as a Facebook fact-checker.<sup>433–439</sup> Peter Daszak and Aleksei Chmura penned an absolutely psychotic letter about animal reservoirs of viruses in 2008.<sup>440</sup> Aleksei Chmura, for his part, was directly involved in capturing bats and collecting samples from them.<sup>441–449</sup>

Dr. David E. Martin showed, beyond a shadow of a doubt, with his research into biotech patents with his company, M-CAM, that literally every aspect of SARS and its variations are patented technologies.<sup>450</sup>

The government response to the pandemic has varied from the farcical to the downright criminal:

Residents in Wuhan were welded inside their apartments by the authorities to enforce a quarantine.<sup>451</sup> In New York, sick COVID-19 patients were transferred into nursing homes to keep them out of hospitals, resulting in thousands of elderly and vulnerable people dying of COVID-19 due to nosocomial infections.<sup>452–454</sup> In the UK, a whistleblower by the name of Wayne Smith claimed that the elderly were murdered by dosing them with large quantities of midazolam, and then the deaths were blamed on COVID-19; he was later found dead, supposedly of COVID-19.<sup>455–457</sup>

While the COVID-19 outbreak ravaged Wuhan, officials in the US completely dropped the ball by failing to stockpile N95 masks and other equipment for healthcare workers, leaving them short on supplies.<sup>458,459</sup> Many masks sat unused in warehouses.<sup>460</sup> Companies in the US offered to manufacture masks locally, but were rebuffed by the government.<sup>461,462</sup> Fearing a run on masks, Anthony Fauci deliberately misinformed the public by claiming that N95 masks have no utility against the virus whatsoever, even though their performance is fair, albeit inferior to a proper respirator.<sup>463</sup>

COVID-19 has been diagnosed with PCR tests with extremely high cycle thresholds. A PCR test cannot actually diagnose an infection. All a PCR test indicates is that a targeted amino acid sequence is present in a sample, indicating that something like a fragment of a virus might exist in a person. A cycle threshold of 40 or greater being used to diagnose a viral infection is fraudulent. The sample is amplified over a trillion times. The targeted AA sequence could appear in practically any organic sample, at that rate. The false positive rate would be enormous.<sup>464-469</sup> The CDC quietly reduced the Ct to 28 after people started getting vaccinated for COVID-19. This would show a high rate of false negatives, thus causing the vaccine to appear more effective than it really is. In essence, the apparent rate of COVID-19 infections can be adjusted by the authorities by altering the sensitivity of tests.<sup>470,471</sup>

The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using was Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik.<sup>225,472-476</sup>

The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination.<sup>477,478</sup> Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19.<sup>232,479</sup>

The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront.<sup>480-483</sup>

This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a willful criminal conspiracy against the American public?

The lab leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane world, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stéphane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators.

This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well-established. The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable.

---

## COVID-19 VACCINE DEVELOPMENT AND LINKS TO TRANSHUMANISM

This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment's reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells.

On June 9<sup>th</sup>, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud.<sup>484</sup> Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE.<sup>485</sup> His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years.<sup>486</sup> He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells.<sup>487-489</sup>

The indictment was over his collaboration with the Wuhan University of Technology. He had double-dipped, against the terms of his DOD grants, and taken money from the PRC's Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage.<sup>490-496</sup>

Charles Lieber's own papers describe the use of silicon nanowires for brain-computer interfaces, or "neural lace" technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity.<sup>497-499</sup>

Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely.<sup>500,501</sup>

Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna.<sup>502</sup> His net worth is now \$5.1 billion USD thanks to Moderna's mRNA-1273 vaccine sales.<sup>503,504</sup>

Both Charles Lieber and Robert Langer's bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism.<sup>505,506</sup> Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called "Great Reset", has long spoken of the "blending of biology and machinery" in his books.<sup>507,508</sup>

Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles.<sup>509-516</sup> Japanese researchers have also found unexplained contaminants in COVID-19 vaccines.<sup>517-519</sup>

Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains.<sup>520,521</sup> Indeed, given SARS-CoV-2 Spike's propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain.<sup>522-526</sup> Graphene is also highly conductive and, in some circumstances, paramagnetic.<sup>527-530</sup>

In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the

development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed.<sup>531</sup>

Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one's mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing.<sup>532</sup>

However, the notion of the widespread use of BCI technology, such as Elon Musk's Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people's brain data, and then exploit it for nefarious purposes.<sup>533–537</sup>

However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one's mind for innocuous purposes, such as projecting a heads-up display onto their brain's visual center or sending audio into one's auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone's very will, rendering them utterly obedient to authority. This technology would be a tyrant's wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels.<sup>538,539</sup>

BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people's thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone's entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow's Hierarchy of Needs. Anything is possible when you have direct access to someone's brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don't even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling.<sup>540–542</sup>

For the wealthy, neural laces would be an unequalled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an "exocortex"), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse.<sup>543,544</sup>

If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. The people who rule over us are Dark Triad types who cannot be trusted with such unimaginable power.<sup>545–550</sup>

Our flaws are what make us human. A utopia arrived at by removing people's free will is not a utopia at all. It is a monomaniacal nightmare. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master.<sup>551</sup>

The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or even bothering to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it.

---

## CONCLUSIONS

The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise.

This research was conducted under the absolutely ridiculous euphemism of "gain-of-function" research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them.

Gain-of-function/gain-of-threat research, a.k.a. "Dual-Use Research of Concern", or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so.

These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago.

Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people's health and their livelihoods.

This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable "smart dust", or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect.

Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we've been extorted by these maniacs.

The pandemic and its response served multiple purposes for the Elite:

- Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are.
- Destroying small businesses and eroding the middle class.
- Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests.
- Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization.
- Creating a *casus belli* for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon.
- Establishing technological and biosecurity frameworks for population control and technocratic-socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation.

Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values.

What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories.

The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism.

What is the most convenient means of accomplishing this? First, scare the public, globally, with an engineered pandemic virus. Then, convince people that the only way they can have their bread and circuses back is if they agree to have poison injected into their shoulder. Naturally, people would panic if they saw everyone around them dying or becoming infertile, so the shot would also necessarily contain something to keep them docile and content.

Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. Depopulating the Earth is atrocious in any context, but doing so without the knowledge or consent of the public is monstrous.



It is the opinion of ICENI, and other independent researchers, that the world's governments are covertly engaged in an act of genocide against their own populations. This will not be tolerated.

To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens.

To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words.

Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that.

---

## REFERENCES

1. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J*. 2020;41(32):3038-3044. doi:10.1093/eurheartj/ehaa623
2. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
3. Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. *EMBO Rep*. 2021;22(6):e52744. doi:10.15252/embr.202152744
4. Cui X, Chen W, Zhou H, et al. Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential. *Front Pharmacol*. 2021;12:1444. doi:10.3389/fphar.2021.664349
5. Zwaveling S, Wijk RG van, Karim F. Pulmonary edema in COVID-19: Explained by bradykinin? *J Allergy Clin Immunol*. 2020;146(6):1454-1455. doi:10.1016/j.jaci.2020.08.038
6. Frontiers | Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19 | Immunology. Accessed September 27, 2021. <https://www.frontiersin.org/articles/10.3389/fimmu.2021.602848/full>
7. Vincent J-L. COVID-19: it's all about sepsis. *Future Microbiol*. 2021;16(3):131-133. doi:10.2217/fmb-2020-0312
8. Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and Coagulopathy in COVID-19. *Curr Probl Cardiol*. 2021;46(3):100742. doi:10.1016/j.cpcardiol.2020.100742
9. Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. *Blood*. 2020;136(4):381-383. doi:10.1182/blood.2020007335
10. Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. *J Am Heart Assoc*. 2021;10(3):e019650. doi:10.1161/JAHA.120.019650
11. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. *J Mol Histol*. Published online October 4, 2020:1-16. doi:10.1007/s10735-020-09915-3
12. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. *Curr Probl Cardiol*. 2020;45(8):100618. doi:10.1016/j.cpcardiol.2020.100618
13. Frontiers | Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies | Physiology. Accessed September 27, 2021. <https://www.frontiersin.org/articles/10.3389/fphys.2021.593223/full>
14. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry*. 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500

15. Parry AH, Wani AH, Yaseen M. Neurological Dysfunction in Coronavirus Disease-19 (COVID-19). *Acad Radiol.* 2020;27(9):1329-1330. doi:10.1016/j.acra.2020.05.024
16. Schwabenland M, Salié H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity.* 2021;54(7):1594-1610.e11. doi:10.1016/j.immuni.2021.06.002
17. Rogers JP, Watson CJ, Badenoch J, et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. *J Neurol Neurosurg Psychiatry.* 2021;92(9):932-941. doi:10.1136/jnnp-2021-326405
18. Abbasi J. Researchers Investigate What COVID-19 Does to the Heart. *JAMA.* 2021;325(9):808-811. doi:10.1001/jama.2021.0107
19. COVID-19 as a Possible Cause of Myocarditis and Pericarditis. American College of Cardiology. Accessed September 27, 2021. <https://www.acc.org/latest-in-cardiology/articles/2021/02/05/19/37/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2021%2f02%2f05%2f19%2f37%2fcovid-19-as-a-possible-cause-of-myocarditis-and-pericarditis>
20. Bzeizi K, Abdulla M, Mohammed N, Alqamish J, Jamshidi N, Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):10599. doi:10.1038/s41598-021-89513-9
21. Moon AM, Barritt AS. Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. *Dig Dis Sci.* Published online September 2, 2020:1-3. doi:10.1007/s10620-020-06585-9
22. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. *Atherosclerosis.* 2020;313:126-136. doi:10.1016/j.atherosclerosis.2020.09.008
23. Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. *Nat Commun.* 2021;12(1):3534. doi:10.1038/s41467-021-23886-3
24. Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of  $\beta$ -Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. *Cells.* 2020;9(11):2475. doi:10.3390/cells9112475
25. Mukherjee S, Banerjee O, Singh S, Maji BK. COVID 19 could trigger global diabetes burden – A hypothesis. *Diabetes Metab Syndr.* 2020;14(5):963-964. doi:10.1016/j.dsx.2020.06.049
26. Wu C-T, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic  $\beta$  cells and elicits  $\beta$  cell impairment. *Cell Metab.* 2021;33(8):1565-1576.e5. doi:10.1016/j.cmet.2021.05.013
27. Legrand M, Bell S, Forni L, et al. Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol.* Published online July 5, 2021:1-14. doi:10.1038/s41581-021-00452-0
28. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. *JAMA Netw Open.* 2021;4(3):e211095. doi:10.1001/jamanetworkopen.2021.1095
29. Chen Z, Hu J, Liu L, et al. SARS-CoV-2 Causes Acute Kidney Injury by Directly Infecting Renal Tubules. *Front Cell Dev Biol.* 2021;9:1245. doi:10.3389/fcell.2021.664868
30. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission. *Gastroenterology.* 2020;158(6):1518-1519. doi:10.1053/j.gastro.2020.02.054
31. Lehmann M, Allers K, Heldt C, et al. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells. *Mucosal Immunol.* Published online August 21, 2021:1-12. doi:10.1038/s41385-021-00437-z
32. Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. *Gut.* 2020;69(6):1010-1018. doi:10.1136/gutjnl-2020-320953

33. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta Int J Clin Chem*. 2020;510:475-482. doi:10.1016/j.cca.2020.08.019
34. Zhang Z-L, Hou Y-L, Li D-T, Li F-Z. Laboratory findings of COVID-19: a systematic review and meta-analysis. *Scand J Clin Lab Invest*. 2020;80(6):441-447. doi:10.1080/00365513.2020.1768587
35. Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. *BMC Infect Dis*. 2020;20(1):640. doi:10.1186/s12879-020-05371-2
36. Xiang Q, Feng Z, Diao B, et al. SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs. *Front Immunol*. 2021;12:1292. doi:10.3389/fimmu.2021.661052
37. Rha M-S, Shin E-C. Activation or exhaustion of CD8+ T cells in patients with COVID-19. *Cell Mol Immunol*. Published online August 19, 2021:1-9. doi:10.1038/s41423-021-00750-4
38. Kusnadi A, Ramírez-Suástegui C, Fajardo V, et al. Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells. *Sci Immunol*. 2021;6(55):eabe4782. doi:10.1126/sciimmunol.abe4782
39. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9
40. What explains the non-respiratory symptoms seen in some COVID-19 patients? Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/biological-chemistry/infectious-disease/What-explains-non-respiratory-symptoms-seen-in-some-COVID-19-patients/98/web/2020/04>
41. Protean manifestations of COVID-19: "Our ignorance is profound." Accessed September 28, 2021. <https://www.mdedge.com/chestphysician/article/220899/coronavirus-updates/protean-manifestations-covid-19-our-ignorance>
42. Jarrahi A, Ahluwalia M, Khodadadi H, et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? *J Neuroinflammation*. 2020;17(1):286. doi:10.1186/s12974-020-01957-4
43. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. *JAMA Neurol*. 2020;77(8):1018-1027. doi:10.1001/jamaneurol.2020.2065
44. Qureshi AI, Baskett WI, Huang W, et al. Acute Ischemic Stroke and COVID-19. *Stroke*. 2021;52(3):905-912. doi:10.1161/STROKEAHA.120.031786
45. Riyahi S, Dev H, Behzadi A, et al. Pulmonary Embolism in Hospitalized Patients with COVID-19: A Multicenter Study. *Radiology*. Published online July 13, 2021:210777. doi:10.1148/radiol.2021210777
46. Zhong P, Xu J, Yang D, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. *Signal Transduct Target Ther*. 2020;5(1):1-8. doi:10.1038/s41392-020-00373-7
47. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol*. 2020;17(9):543-558. doi:10.1038/s41569-020-0413-9
48. Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: Impact of obesity and diabetes on disease severity. *Clin Obes*. Published online October 20, 2020:e12414. doi:10.1111/cob.12414
49. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. *Lancet Diabetes Endocrinol*. 2021;9(6):350-359. doi:10.1016/S2213-8587(21)00089-9

50. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. *Signal Transduct Target Ther*. 2020;5(1):1-13. doi:10.1038/s41392-020-00454-7
51. Green SJ. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. *Microbes Infect*. 2020;22(4):149-150. doi:10.1016/j.micinf.2020.05.006
52. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020;35(12):1123-1138. doi:10.1007/s10654-020-00698-1
53. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html>
54. Covid IFR Analysis. Accessed September 28, 2021. <http://epimonitor.net/Covid-IFR-Analysis.htm>
55. Seoane B. A scaling approach to estimate the age-dependent COVID-19 infection fatality ratio from incomplete data. *PLOS ONE*. 2021;16(2):e0246831. doi:10.1371/journal.pone.0246831
56. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7
57. Xia L, Chen J, Friedemann T, et al. The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge. *Open Forum Infect Dis*. 2020;7(9). doi:10.1093/ofid/ofaa286
58. Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol*. Published online April 15, 2020:10.14309/ajg.0000000000000664. doi:10.14309/ajg.0000000000000664
59. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>
60. Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. *Nat Commun*. 2020;11(1):4507. doi:10.1038/s41467-020-18272-4
61. Irons NJ, Raftery AE. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys. *Proc Natl Acad Sci*. 2021;118(31). doi:10.1073/pnas.2103272118
62. Achaiah NC, Subbarajasetty SB, Shetty RM. R0 and Re of COVID-19: Can We Predict When the Pandemic Outbreak will be Contained? *Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med*. 2020;24(11):1125-1127. doi:10.5005/jp-journals-10071-23649
63. Ives AR, Bozzuto C. Estimating and explaining the spread of COVID-19 at the county level in the USA. *Commun Biol*. 2021;4(1):1-9. doi:10.1038/s42003-020-01609-6
64. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020;581(7807):215-220. doi:10.1038/s41586-020-2180-5
65. Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun*. 2020;11(1):4541. doi:10.1038/s41467-020-18319-6
66. ACE2 angiotensin converting enzyme 2 [Homo sapiens (human)] - Gene - NCBI. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/gene/59272>
67. Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. *Front Cell Infect Microbiol*. 2020;10:317. doi:10.3389/fcimb.2020.00317
68. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed Pharmacother*. 2017;94:317-325. doi:10.1016/j.biopha.2017.07.091
69. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. *Nat Rev Endocrinol*. 2015;11(4):242-252. doi:10.1038/nrendo.2015.6
70. The Renin-Angiotensin-Aldosterone-System. TeachMePhysiology. Accessed September 28, 2021. <https://teachmephysiology.com/urinary-system/regulation/the-renin-angiotensin-aldosterone-system/>

71. Fountain JH, Lappin SL. Physiology, Renin Angiotensin System. In: *StatPearls*. StatPearls Publishing; 2021. Accessed September 28, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK470410/>
72. Renin Angiotensin Aldosterone System - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/renin-angiotensin-aldosterone-system>
73. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203(2):631-637. doi:10.1002/path.1570
74. Tissue expression of ACE2 - Summary - The Human Protein Atlas. Accessed September 28, 2021. <https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue>
75. The protein expression profile of ACE2 in human tissues. *Mol Syst Biol*. 2020;16(7):e9610. doi:10.15252/msb.20209610
76. Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacol Sin*. 2020;41(9):1141-1149. doi:10.1038/s41401-020-0485-4
77. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci*. 2020;117(21):11727-11734. doi:10.1073/pnas.2003138117
78. Xie Y, Karki CB, Du D, et al. Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. *Front Mol Biosci*. 2020;7:392. doi:10.3389/fmolb.2020.591873
79. Syncytia formation by SARS-CoV-2-infected cells. *EMBO J*. 2020;39(23):e106267. doi:10.15252/embj.2020106267
80. Ma H, Zhu Z, Lin H, et al. Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells. *Cell Discov*. 2021;7(1):1-4. doi:10.1038/s41421-021-00310-0
81. Xia B, Shen X, He Y, et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. *Cell Res*. 2021;31(8):847-860. doi:10.1038/s41422-021-00519-4
82. Nieto-Torres JL, Verdía-Báguena C, Jimenez-Guardeño JM, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. *Virology*. 2015;485:330-339. doi:10.1016/j.virol.2015.08.010
83. Minakshi R, Padhan K, Rehman S, Hassan Mdl, Ahmad F. The SARS Coronavirus 3a protein binds calcium in its cytoplasmic domain. *Virus Res*. 2014;191:180-183. doi:10.1016/j.virusres.2014.08.001
84. Pan P, Shen M, Yu Z, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. *Nat Commun*. 2021;12(1):4664. doi:10.1038/s41467-021-25015-6
85. Shah A. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. *Front Immunol*. 2020;11:1021. doi:10.3389/fimmu.2020.01021
86. Xu H, Chitre SA, Akinyemi IA, et al. SARS-CoV-2 Viroporin Triggers the NLRP3 Inflammatory Pathway.; 2020:2020.10.27.357731. doi:10.1101/2020.10.27.357731
87. Olnagier D, Farahani E, Thyrssted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. *Nat Commun*. 2020;11(1):4938. doi:10.1038/s41467-020-18764-3
88. Bousquet J, Cristol J-P, Czarlewski W, et al. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. *Clin Transl Allergy*. 2020;10(1):58. doi:10.1186/s13601-020-00362-7
89. Cuadrado A, Pajares M, Benito C, et al. Can Activation of NRF2 Be a Strategy against COVID-19? *Trends Pharmacol Sci*. 2020;41(9):598-610. doi:10.1016/j.tips.2020.07.003
90. Bousquet J, Czarlewski W, Zuberbier T, et al. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. *Int Arch Allergy Immunol*. 2021;182(4):324-338. doi:10.1159/000514204

91. McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC. A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications. *Vascul Pharmacol.* 2021;137:106826. doi:10.1016/j.vph.2020.106826
92. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. *Circ Res.* 2021;128(9):1323-1326. doi:10.1161/CIRCRESAHA.121.318902
93. Silhol F, Sarlon G, Deharo J-C, Vaisse B. Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system? *Hypertens Res.* 2020;43(8):854-856. doi:10.1038/s41440-020-0476-3
94. Ciulla MM. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs. *Hypertens Res.* 2020;43(9):985-986. doi:10.1038/s41440-020-0488-z
95. Lu J, Sun PD. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. *J Biol Chem.* 2020;295(52):18579-18588. doi:10.1074/jbc.RA120.015303
96. Osman W, Fahdi FA, Salmi IA, Khalili HA, Gokhale A, Khamis F. Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman. *Int J Infect Dis.* 2021;107:153-163. doi:10.1016/j.ijid.2021.04.050
97. Raesi A, Saedi Dezaki E, Moosapour H, et al. Hypocalcemia in Covid-19: A Prognostic Marker for Severe Disease. *Iran J Pathol.* 2021;16(2):144-153. doi:10.30699/IJP.2020.130491.2442
98. Bennouar S, Cherif AB, Kessira A, Bennouar D-E, Abdi S. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. *J Am Coll Nutr.* 2021;40(2):104-110. doi:10.1080/07315724.2020.1856013
99. Blaes N, Girolami J-P. Targeting the “Janus face” of the B2-bradykinin receptor. *Expert Opin Ther Targets.* 2013;17. doi:10.1517/14728222.2013.827664
100. Siragy H, Jaffa A, Margolius H. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. *Hypertension.* Published online 1997. doi:10.1161/01.HYP.29.3.757
101. Pyne NJ, Tolan D, Pyne S. Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle. *Biochem J.* 1997;328(Pt 2):689-694. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1218972/>
102. Dixon BS, Breckon R, Fortune J, Sutherland E, Simon FR, Anderson RJ. Bradykinin activates protein kinase C in cultured cortical collecting tubular cells. *Am J Physiol-Ren Physiol.* 1989;257(5):F808-F817. doi:10.1152/ajprenal.1989.257.5.F808
103. Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. *J Pharmacol Exp Ther.* 1990;252(2):581-585.
104. Gholamreza-Fahimi E, Bisha M, Hahn J, et al. Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans. *Biomed Pharmacother.* 2020;123:109797. doi:10.1016/j.biopha.2019.109797
105. Fong P, Stafforini DM, Brown NJ, Pretorius M. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. *Free Radic Biol Med.* 2010;49(2):301-305. doi:10.1016/j.freeradbiomed.2010.04.023
106. Portilla D, Morrissey J, Morrison AR. Bradykinin-activated membrane-associated phospholipase C in Madin-Darby canine kidney cells. *J Clin Invest.* 1988;81(6):1896-1902. doi:10.1172/JCI113536
107. Cruzblanca H, Koh D-S, Hille B. Bradykinin inhibits M current via phospholipase C and Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive Ca<sup>2+</sup> stores in rat sympathetic neurons. *Proc Natl Acad Sci.* 1998;95(12):7151-7156. doi:10.1073/pnas.95.12.7151
108. Bradykinin - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/chemistry/bradykinin>

109. Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. *Life Sci.* 2020;255:117842. doi:10.1016/j.lfs.2020.117842
110. Danta CC. SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and Therapeutic Options. *ACS Pharmacol Transl Sci.* 2021;4(1):400-402. doi:10.1021/acspsci.0c00219
111. Shaban MS, Müller C, Mayr-Buro C, et al. Multi-level inhibition of coronavirus replication by chemical ER stress. *Nat Commun.* 2021;12(1):5536. doi:10.1038/s41467-021-25551-1
112. Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: A case-control study. *Life Sci.* 2021;265:118781. doi:10.1016/j.lfs.2020.118781
113. Dubiella U, Seybold H, Durian G, et al. Calcium-dependent protein kinase/NADPH oxidase activation circuit is required for rapid defense signal propagation. *Proc Natl Acad Sci.* 2013;110(21):8744-8749. doi:10.1073/pnas.1221294110
114. Görlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: A mutual interplay. *Redox Biol.* 2015;6:260-271. doi:10.1016/j.redox.2015.08.010
115. Feno S, Butera G, Vecellio Reane D, Rizzuto R, Raffaello A. Crosstalk between Calcium and ROS in Pathophysiological Conditions. *Oxid Med Cell Longev.* 2019;2019:e9324018. doi:10.1155/2019/9324018
116. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol.* 1996;271(5 Pt 1):C1424-1437. doi:10.1152/ajpcell.1996.271.5.C1424
117. PACHER P, BECKMAN JS, LIAUDET L. Nitric Oxide and Peroxynitrite in Health and Disease. *Physiol Rev.* 2007;87(1):315-424. doi:10.1152/physrev.00029.2006
118. Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. *Proc Natl Acad Sci.* 2018;115(23):5839-5848. doi:10.1073/pnas.1804932115
119. Guzik TJ, West NEJ, Pillai R, Taggart DP, Channon KM. Nitric Oxide Modulates Superoxide Release and Peroxynitrite Formation in Human Blood Vessels. *Hypertension.* 2002;39(6):1088-1094. doi:10.1161/01.HYP.0000018041.48432.B5
120. Roe ND, Ren J. Nitric oxide synthase uncoupling: A therapeutic target in cardiovascular diseases. *Vascul Pharmacol.* 2012;57(5):168-172. doi:10.1016/j.vph.2012.02.004
121. Luo S, Lei H, Qin H, Xia Y. Molecular mechanisms of endothelial NO synthase uncoupling. *Curr Pharm Des.* 2014;20(22):3548-3553. doi:10.2174/13816128113196660746
122. Chen W, Druhan LJ, Chen C-A, et al. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial nitric oxide synthase: transition from reversible to irreversible enzyme inhibition. *Biochemistry.* 2010;49(14):3129-3137. doi:10.1021/bi9016632
123. Ozdemir B, Yazici A. Could the decrease in the endothelial nitric oxide (NO) production and NO bioavailability be the crucial cause of COVID-19 related deaths? *Med Hypotheses.* 2020;144:109970. doi:10.1016/j.mehy.2020.109970
124. Guan SP, Seet RCS, Kennedy BK. Does eNOS derived nitric oxide protect the young from severe COVID-19 complications? *Ageing Res Rev.* 2020;64:101201. doi:10.1016/j.arr.2020.101201
125. Nitric Oxide - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/nitric-oxide>
126. Levine AB, Punahaole D, Levine TB. Characterization of the Role of Nitric Oxide and Its Clinical Applications. *Cardiology.* 2012;122(1):55-68. doi:10.1159/000338150
127. Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. *Hum Reprod Update.* 1998;4(1):3-24. doi:10.1093/humupd/4.1.3
128. Mel A de. Potential roles of nitric oxide in COVID-19: A perspective. *Integr Mol Med.* 2020;7(3). doi:10.15761/IMM.1000403
129. Ricciardolo FLM, Bertolini F, Carriero V, Högman M. Nitric oxide's physiologic effects and potential as a therapeutic agent against COVID-19. *J Breath Res.* 2020;15(1):014001. doi:10.1088/1752-7163/abc302

130. Åkerström S, Gunalan V, Keng CT, Tan Y-J, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. *Virology*. 2009;395(1):1-9. doi:10.1016/j.virol.2009.09.007
131. Hadi HA, Carr CS, Al Suwaidi J. Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome. *Vasc Health Risk Manag*. 2005;1(3):183-198. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993955/>
132. Bonetti PO, Lerman LO, Lerman A. Endothelial Dysfunction. *Arterioscler Thromb Vasc Biol*. 2003;23(2):168-175. doi:10.1161/01.ATV.0000051384.43104.FC
133. Endothelial Dysfunction in Diabetes | Diabetes Care. Accessed September 28, 2021. [https://care.diabetesjournals.org/content/34/Supplement\\_2/S285](https://care.diabetesjournals.org/content/34/Supplement_2/S285)
134. Patel PD, Velazquez JL, Arora RR. Endothelial dysfunction in African-Americans. *Int J Cardiol*. 2009;132(2):157-172. doi:10.1016/j.ijcard.2008.10.007
135. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. *Circulation*. 2004;109(21):2511-2517. doi:10.1161/01.CIR.0000129087.81352.7A
136. Ungvari Z, Tarantini S, Kiss T, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. *Nat Rev Cardiol*. 2018;15(9):555-565. doi:10.1038/s41569-018-0030-z
137. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. *Front Immunol*. 2021;12:952. doi:10.3389/fimmu.2021.652470
138. Cavalcante-Silva LHA, Carvalho DCM, Lima É de A, et al. Neutrophils and COVID-19: The road so far. *Int Immunopharmacol*. 2021;90:107233. doi:10.1016/j.intimp.2020.107233
139. Knoll R, Schultze JL, Schulte-Schrepping J. Monocytes and Macrophages in COVID-19. *Front Immunol*. 2021;12:2952. doi:10.3389/fimmu.2021.720109
140. Meidaninikjeh S, Sabouni N, Marzouni HZ, Bengar S, Khalili A, Jafari R. Monocytes and macrophages in COVID-19: Friends and foes. *Life Sci*. 2021;269:119010. doi:10.1016/j.lfs.2020.119010
141. Phagocytes - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/immunology-and-microbiology/phagocytes>
142. Respiratory Burst - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/respiratory-burst>
143. Superoxide Dismutase - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/neuroscience/superoxide-dismutase>
144. Myeloperoxidase - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/myeloperoxidase>
145. Spickett CM, Jerlich A, Panasenko OM, et al. The reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with lipids. *Acta Biochim Pol*. 2000;47(4):889-899.
146. Hypochlorous\_acid. Accessed September 28, 2021. [https://www.bionity.com/en/encyclopedia/Hypochlorous\\_acid.html](https://www.bionity.com/en/encyclopedia/Hypochlorous_acid.html)
147. Neutrophil extracellular traps in immunity and disease | Nature Reviews Immunology. Accessed September 28, 2021. <https://www.nature.com/articles/nri.2017.105>
148. Kaplan MJ, Radic M. Neutrophil extracellular traps (NETs): Double-edged swords of innate immunity. *J Immunol Baltim Md 1950*. 2012;189(6):2689-2695. doi:10.4049/jimmunol.1201719
149. Gillot C, Favresse J, Mullier F, Lecompte T, Dogné J-M, Douxfils J. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. *Front Pharmacol*. 2021;12:1999. doi:10.3389/fphar.2021.708302
150. Arcanjo A, Logullo J, Menezes CCB, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). *Sci Rep*. 2020;10(1):19630. doi:10.1038/s41598-020-76781-0



151. Middleton EA, He X-Y, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood*. 2020;136(10):1169-1179. doi:10.1182/blood.2020007008
152. Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. *Adv Biol Regul*. 2020;77:100741. doi:10.1016/j.jbior.2020.100741
153. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. *Int J Biol Sci*. 2021;17(1):62-72. doi:10.7150/ijbs.51811
154. Edeas M, Saleh J, Peyssonnaud C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? *Int J Infect Dis*. 2020;97:303-305. doi:10.1016/j.ijid.2020.05.110
155. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. *Biomed Pharmacother*. 2021;136:111228. doi:10.1016/j.biopha.2021.111228
156. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MdA, Hosen MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. *Mol Biol Rep*. Published online April 23, 2021:1-7. doi:10.1007/s11033-021-06358-1
157. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. *Am J Respir Crit Care Med*. 2020;202(3):356-360. doi:10.1164/rccm.202006-2157CP
158. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. *Toxicology*. 2000;149(1):43-50. doi:10.1016/s0300-483x(00)00231-6
159. Wardman P, Candeias LP. Fenton Chemistry: An Introduction. *Radiat Res*. 1996;145(5):523-531. doi:10.2307/3579270
160. Sharpe MA, Robb SJ, Clark JB. Nitric oxide and Fenton/Haber-Weiss chemistry: nitric oxide is a potent antioxidant at physiological concentrations. *J Neurochem*. 2003;87(2):386-394. doi:10.1046/j.1471-4159.2003.02001.x
161. Kanti Das T, Wati MR, Fatima-Shad K. Oxidative Stress Gated by Fenton and Haber Weiss Reactions and Its Association With Alzheimer's Disease. *Arch Neurosci*. 2015;2(2). doi:10.5812/archneurosci.20078
162. Barciszewska A-M. Elucidating of oxidative distress in COVID-19 and methods of its prevention. *Chem Biol Interact*. 2021;344:109501. doi:10.1016/j.cbi.2021.109501
163. Ntyonga-Pono M-P. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment? *Pan Afr Med J*. 2020;35(Suppl 2):12. doi:10.11604/pamj.2020.35.2.22877
164. Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. *Front Cell Infect Microbiol*. 2021;11:457. doi:10.3389/fcimb.2021.654813
165. Cumpstey AF, Clark AD, Santolini J, Jackson AA, Feelisch M. COVID-19: A Redox Disease—What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. *Antioxid Redox Signal*. Published online June 29, 2021. doi:10.1089/ars.2021.0017
166. Hydroxyl Radical - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/earth-and-planetary-sciences/hydroxyl-radical>
167. Gligorovski S, Strekowski R, Barbati S, Vione D. Environmental Implications of Hydroxyl Radicals ( $\bullet$ OH). *Chem Rev*. 2015;115(24):13051-13092. doi:10.1021/cr500310b
168. Lyngsie G, Krumina L, Tunlid A, Persson P. Generation of hydroxyl radicals from reactions between a dimethoxyhydroquinone and iron oxide nanoparticles. *Sci Rep*. 2018;8(1):10834. doi:10.1038/s41598-018-29075-5

169. Takeda K, Fujisawa K, Nojima H, Kato R, Ueki R, Sakugawa H. Hydroxyl radical generation with a high power ultraviolet light emitting diode (UV-LED) and application for determination of hydroxyl radical reaction rate constants. *J Photochem Photobiol Chem*. 2017;340:8-14. doi:10.1016/j.jphotochem.2017.02.020
170. Kord Forooshani P, Pinnaratip R, Polega E, et al. Hydroxyl Radical Generation through the Fenton-like Reaction of Hematin- and Catechol-Functionalized Microgels. *Chem Mater*. 2020;32(19):8182-8194. doi:10.1021/acs.chemmater.0c01551
171. Deng Y, Zhao R. Advanced Oxidation Processes (AOPs) in Wastewater Treatment. *Curr Pollut Rep*. 2015;1(3):167-176. doi:10.1007/s40726-015-0015-z
172. Hypoxanthine - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/chemistry/hypoxanthine>
173. Dowell FJ, Hamilton CA, McMurray J, Reid JL. Effects of a xanthine oxidase/hypoxanthine free radical and reactive oxygen species generating system on endothelial function in New Zealand white rabbit aortic rings. *J Cardiovasc Pharmacol*. 1993;22(6):792-797. doi:10.1097/00005344-199312000-00003
174. Fig. 1. Generation of superoxide by xanthine-hypoxanthine oxidase and... ResearchGate. Accessed September 28, 2021. [https://www.researchgate.net/figure/Generation-of-superoxide-by-xanthine-hypoxanthine-oxidase-and-NADH-SMP-systems-a-The\\_fig1\\_7927959](https://www.researchgate.net/figure/Generation-of-superoxide-by-xanthine-hypoxanthine-oxidase-and-NADH-SMP-systems-a-The_fig1_7927959)
175. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. *Am J Physiol*. 1988;255(6 Pt 2):H1269-1275. doi:10.1152/ajpheart.1988.255.6.H1269
176. Mao H, Yang A, Zhao Y, Lei L, Li H. Succinate Supplement Elicited "Pseudohypoxia" Condition to Promote Proliferation, Migration, and Osteogenesis of Periodontal Ligament Cells. *Stem Cells Int*. 2020;2020:e2016809. doi:10.1155/2020/2016809
177. Lukyanova LD, Kirova YI. Mitochondria-controlled signaling mechanisms of brain protection in hypoxia. *Front Neurosci*. 2015;9:320. doi:10.3389/fnins.2015.00320
178. Messner KR, Imlay JA. Mechanism of superoxide and hydrogen peroxide formation by fumarate reductase, succinate dehydrogenase, and aspartate oxidase. *J Biol Chem*. 2002;277(45):42563-42571. doi:10.1074/jbc.M204958200
179. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial Complex II Can Generate Reactive Oxygen Species at High Rates in Both the Forward and Reverse Reactions. *J Biol Chem*. 2012;287(32):27255-27264. doi:10.1074/jbc.M112.374629
180. Cowled P, Fritridge R. Pathophysiology of Reperfusion Injury. In: Fritridge R, Thompson M, eds. *Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists*. University of Adelaide Press; 2011. Accessed September 28, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK534267/>
181. Sun Z-Y, Xia H-G, Zhu D-Q, Deng L-M, Zhu P-Z, Wang D-B. Clinical significance of mechanical ventilation on ischemic-reperfusion injury caused by lung chest trauma and VEGF expression levels in peripheral blood. *Exp Ther Med*. 2017;14(3):2531-2535. doi:10.3892/etm.2017.4825
182. Gielis JF, Beckers PAJ, Briedé JJ, Cos P, Schil PEV. Oxidative and nitrosative stress during pulmonary ischemia-reperfusion injury: from the lab to the OR. *Ann Transl Med*. 2017;5(6):4-4. doi:10.21037/atm.2017.03.32
183. Wu N-C, Liao F-T, Cheng H, Sung S-H, Yang Y-C, Wang J-J. Intravenous superoxide dismutase as a protective agent to prevent impairment of lung function induced by high tidal volume ventilation. *BMC Pulm Med*. 2017;17:105. doi:10.1186/s12890-017-0448-9
184. Lipid Peroxidation - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/neuroscience/lipid-peroxidation>
185. Ayala A, Muñoz MF, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxid Med Cell Longev*. 2014;2014:360438. doi:10.1155/2014/360438

186. Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. *Nat Rev Immunol*. 2016;16(8):485-497. doi:10.1038/nri.2016.63
187. Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. *Curr Opin Pharmacol*. 2013;13(2):10.1016/j.coph.2013.02.005. doi:10.1016/j.coph.2013.02.005
188. Miller YI, Choi S-H, Wiesner P, et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. *Circ Res*. 2011;108(2):235-248. doi:10.1161/CIRCRESAHA.110.223875
189. Zhivaki D, Kagan JC. Innate immune detection of lipid oxidation as a threat assessment strategy. *Nat Rev Immunol*. Published online September 21, 2021:1-9. doi:10.1038/s41577-021-00618-8
190. Macdonald J, Galley HF, Webster NR. Oxidative stress and gene expression in sepsis. *Br J Anaesth*. 2003;90(2):221-232. doi:10.1093/bja/aeg034
191. Mantzaris K, Tsolaki V, Zakynthinos E. Role of Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential Therapies. *Oxid Med Cell Longev*. 2017;2017:e5985209. doi:10.1155/2017/5985209
192. Toufekoula C, Papadakis V, Tsaganos T, et al. Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant gram-negative bacteria: experimental and clinical evidence. *Crit Care*. 2013;17(1):R6. doi:10.1186/cc11930
193. Dominic P, Ahmad J, Bhandari R, et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. *Redox Biol*. 2021;43:101982. doi:10.1016/j.redox.2021.101982
194. Yang M, Lai CL. SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? *Cell Death Discov*. 2020;6(1):1-6. doi:10.1038/s41420-020-00369-w
195. Jacobs W, Lammens M, Kerckhofs A, et al. Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. *ESC Heart Fail*. 2020;7(6):3772-3781. doi:10.1002/ehf2.12958
196. Tavakol S, Seifalian AM. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment. *Biotechnol Appl Biochem*. n/a(n/a). doi:10.1002/bab.2176
197. Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study. *Respir Res*. 2020;21(1):276. doi:10.1186/s12931-020-01546-2
198. Žarković N, Orehovec B, Milković L, et al. Preliminary Findings on the Association of the Lipid Peroxidation Product 4-Hydroxynonenal with the Lethal Outcome of Aggressive COVID-19. *Antioxidants*. 2021;10(9):1341. doi:10.3390/antiox10091341
199. Mehri F, Rahbar AH, Ghane ET, Soury B, Esfahani M. The comparison of oxidative markers between Covid-19 patients and healthy subjects. *Arch Med Res*. Published online June 7, 2021. doi:10.1016/j.arcmed.2021.06.004
200. Cao Z, Xia H, Rajsbaum R, Xia X, Wang H, Shi P-Y. Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response. *Cell Mol Immunol*. 2021;18(3):746-748. doi:10.1038/s41423-020-00603-6
201. Zhang H, Zheng H, Zhu J, et al. Ubiquitin-Modified Proteome of SARS-CoV-2-Infected Host Cells Reveals Insights into Virus-Host Interaction and Pathogenesis. *J Proteome Res*. Published online March 5, 2021:acs.jproteome.0c00758. doi:10.1021/acs.jproteome.0c00758
202. Shi H, Zuo Y, Navaz S, et al. Endothelial cell-activating antibodies in COVID-19. *MedRxiv Prepr Serv Health Sci*. Published online July 9, 2021:2021.01.18.21250041. doi:10.1101/2021.01.18.21250041
203. Chang R, Mamun A, Dominic A, Le N-T. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. *Front Physiol*. 2021;11:1752. doi:10.3389/fphys.2020.605908
204. Mei ZW, van Wijk XMR, Pham HP, Marin MJ. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. *J Appl Lab Med*. 2021;6(5):1305-1315. doi:10.1093/jalm/jfab042

205. Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. *J Thromb Haemost JTH*. 2021;19(2):513-521. doi:10.1111/jth.15191
206. Ladikou EE, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? *Clin Med*. 2020;20(5):e178-e182. doi:10.7861/clinmed.2020-0346
207. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020;100:327-332. doi:10.1016/j.ijid.2020.09.016
208. Gebremeskel S, Schanin J, Coyle KM, et al. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. *Front Immunol*. 2021;12:641. doi:10.3389/fimmu.2021.650331
209. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? *JCI Insight*. 5(15):e140711. doi:10.1172/jci.insight.140711
210. Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. *Kidney Int*. 2020;98(2):314-322. doi:10.1016/j.kint.2020.05.013
211. Holter JC, Pischke SE, Boer E de, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. *Proc Natl Acad Sci*. 2020;117(40):25018-25025. doi:10.1073/pnas.2010540117
212. Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. *Eur J Immunol*. 2021;51(7):1652-1659. doi:10.1002/eji.202048959
213. López-Pedraza C, Barbarroja N, Jimenez-Gomez Y, Collantes-Estevéz E, Aguirre MA, Cuadrado MJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. *Rheumatol Oxf Engl*. 2016;55(12):2096-2108. doi:10.1093/rheumatology/kew054
214. Farris AD, Guthridge JM. Overlapping B cell pathways in severe COVID-19 and lupus. *Nat Immunol*. 2020;21(12):1478-1480. doi:10.1038/s41590-020-00822-z
215. MacDonald L, Alivernini S, Tolusso B, et al. COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1<sup>+</sup> neutrophils and CD14<sup>+</sup> monocytes. *JCI Insight*. 2021;6(13). doi:10.1172/jci.insight.147413
216. Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. *Nat Rev Rheumatol*. 2020;16(8):465-470. doi:10.1038/s41584-020-0451-z
217. Luo M, Cao S, Wei L, et al. Intubation, mortality, and risk factors in critically ill Covid-19 patients: A pilot study. *J Clin Anesth*. 2020;67:110039. doi:10.1016/j.jclinane.2020.110039
218. Tandon A, Pandey L. COVID-19, steroids, and mucormycosis: What an ophthalmologist should know. *Indian J Ophthalmol*. 2021;69(7):1970. doi:10.4103/ijo.IJO\_1143\_21
219. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021;385(9):777-789. doi:10.1056/NEJMoa2103417
220. Free radicals: What are they and why should nurses care about them? American Nurse. Published April 11, 2011. Accessed September 28, 2021. <https://www.myamericannurse.com/free-radicals-what-are-they-and-why-should-nurses-care-about-them/>
221. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. *Clin Exp Immunol*. 2003;131(3):398-404. doi:10.1046/j.1365-2249.2003.02104.x
222. 8.2: Generation of Free Radicals in the Body. Medicine LibreTexts. Published July 29, 2016. Accessed September 28, 2021. [https://med.libretexts.org/Bookshelves/Nutrition/Book%3A\\_An\\_Introduction\\_to\\_Nutrition\\_\(Zimmerman\)/08%3A\\_Nutrients\\_Important\\_as\\_Antioxidants/8.02%3A\\_Generation\\_of\\_Free\\_Radicals\\_in\\_the\\_Body](https://med.libretexts.org/Bookshelves/Nutrition/Book%3A_An_Introduction_to_Nutrition_(Zimmerman)/08%3A_Nutrients_Important_as_Antioxidants/8.02%3A_Generation_of_Free_Radicals_in_the_Body)

223. Daiber A, Oelze M, Daub S, et al. Vascular Redox Signaling, Redox Switches in Endothelial Nitric Oxide Synthase (eNOS Uncoupling), and Endothelial Dysfunction. In: Laher I, ed. *Systems Biology of Free Radicals and Antioxidants*. Springer; 2014:1177-1211. doi:10.1007/978-3-642-30018-9\_48
224. Gladyshev VN. The Free Radical Theory of Aging Is Dead. Long Live the Damage Theory! *Antioxid Redox Signal*. 2014;20(4):727-731. doi:10.1089/ars.2013.5228
225. Junghanns FB. MATH+ Protocol. FLCCC | Front Line COVID-19 Critical Care Alliance. Accessed September 28, 2021. <https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/>
226. Lammi C, Arnoldi A. Food-derived antioxidants and COVID-19. *J Food Biochem*. 2021;45(1):e13557. doi:10.1111/jfbc.13557
227. Żukowski P, Maciejczyk M, Matczuk J, et al. Effect of N-Acetylcysteine on Antioxidant Defense, Oxidative Modification, and Salivary Gland Function in a Rat Model of Insulin Resistance. *Oxid Med Cell Longev*. 2018;2018:e6581970. doi:10.1155/2018/6581970
228. Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. *Free Radic Res*. 2018;52(7):751-762. doi:10.1080/10715762.2018.1468564
229. Zhitkovich A. N-Acetylcysteine: Antioxidant, Aldehyde Scavenger, and More. *Chem Res Toxicol*. 2019;32(7):1318-1319. doi:10.1021/acs.chemrestox.9b00152
230. Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabó C. Melatonin is a scavenger of peroxynitrite. *Life Sci*. 1997;60(10):PL169-174. doi:10.1016/s0024-3205(97)00008-8
231. Shaeib F, Khan SN, Ali I, et al. Melatonin Prevents Myeloperoxidase Heme Destruction and the Generation of Free Iron Mediated by Self-Generated Hypochlorous Acid. *PLOS ONE*. 2015;10(4):e0120737. doi:10.1371/journal.pone.0120737
232. Elsaed WM, Alahmadi AM, Al-Ahmadi BT, Taha JA, Tarabishi RM. Gastroprotective and antioxidant effects of fluvoxamine on stress-induced peptic ulcer in rats. *J Taibah Univ Med Sci*. 2018;13(5):422-431. doi:10.1016/j.jtumed.2018.04.010
233. Dallé E, Daniels WMU, Mabandla MV. Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson's Disease. *Oxid Med Cell Longev*. 2020;2020:e1941480. doi:10.1155/2020/1941480
234. Braga PC, Dal Sasso M, Culici M, Bianchi T, Guffanti EE. Budesonide reduces superoxide and peroxynitrite anion chemiluminescence during human neutrophil bursts. *Pharmacology*. 2005;75(4):179-186. doi:10.1159/000088623
235. Mikolka P, Kopincova J, Tomcikova Mikusiakova L, et al. Effects of surfactant/budesonide therapy on oxidative modifications in the lung in experimental meconium-induced lung injury. *J Physiol Pharmacol Off J Pol Physiol Soc*. 2016;67(1):57-65.
236. Lamothe PH, Rao E, Serra AJ, et al. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery. *Gastroenterology*. 1991;100(6):1515-1520. doi:10.1016/0016-5085(91)90647-4
237. van Zyl JM, Kriegler A, van der Walt BJ. Anti-oxidant properties of H2-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. *Biochem Pharmacol*. 1993;45(12):2389-2397. doi:10.1016/0006-2952(93)90218-l
238. Ching T-L, Haenen GRMM, Bast A. Cimetidine and other H2 receptor antagonists as powerful hydroxyl radical scavengers. *Chem Biol Interact*. 1993;86(2):119-127. doi:10.1016/0009-2797(93)90116-G
239. Peterson DA, Gerrard JM, Rao GHR, White JG. Inhibition of ferrous iron induced oxidation of arachidonic acid by indomethacin. *Prostaglandins Med*. 1979;2(2):97-108. doi:10.1016/0161-4630(79)90044-2
240. Cross AL, Hawkes J, Wright HL, Moots RJ, Edwards SW. APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits

TNF $\alpha$  expression and signalling. *Inflammopharmacology*. 2020;28(5):1223-1235. doi:10.1007/s10787-020-00715-5

241. Heumüller S, Wind S, Barbosa-Sicard E, et al. Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant. *Hypertension*. 2008;51(2):211-217.

doi:10.1161/HYPERTENSIONAHA.107.100214

242. de Almeida AC, dos Santos Vilela MM, Condino-Neto A, Ximenes VF. The Importance of Myeloperoxidase in Apocynin-Mediated NADPH Oxidase Inhibition. *ISRN Inflamm*. 2012;2012:260453. doi:10.5402/2012/260453

243. NADPH oxidase Covid-19 Oxygen treatment? ResearchGate. Accessed September 28, 2021. [https://www.researchgate.net/post/NADPH\\_oxidase\\_Covid-19\\_Oxygen\\_treatment](https://www.researchgate.net/post/NADPH_oxidase_Covid-19_Oxygen_treatment)

244. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5

245. COVID19. Global Sepsis Alliance. Accessed September 28, 2021. <https://www.global-sepsis-alliance.org/covid19>

246. HealthLeaders. Expert: Severe COVID-19 Illness Is Viral Sepsis. Accessed September 28, 2021. <https://www.healthleadersmedia.com/clinical-care/expert-severe-covid-19-illness-viral-sepsis>

247. Aisa-Alvarez A, Soto ME, Guarner-Lans V, et al. Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. *Med Kaunas Lith*. 2020;56(11):E619.

doi:10.3390/medicina56110619

248. Aisa-Alvarez A, Perez-Torres I, Camarena-Alejo G, et al. A Randomized clinical trial of antioxidant therapy in patients with septic shock. Reference study to propose adjuvant therapy in patients with critical organic damage by COVID-19. Published online September 28, 2021. doi:10.21203/rs.3.rs-52169/v1

249. Kashiouris MG, L'Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The Emerging Role of Vitamin C as a Treatment for Sepsis. *Nutrients*. 2020;12(2):E292. doi:10.3390/nu12020292

250. That “damn machine”: mechanical ventilators in the ICU. STAT. Published August 20, 2021. Accessed September 28, 2021. <https://www.statnews.com/2021/08/20/that-damn-machine-the-dark-side-of-mechanical-ventilators-in-the-icu/>

251. Ferreira JC, Ho Y-L, Besen BAMP, et al. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. *Ann Intensive Care*. 2021;11(1):92. doi:10.1186/s13613-021-00882-w

252. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926

253. Popp M, Stegemann M, Metzendorf M-I, et al. Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev*. 2021;7:CD015017. doi:10.1002/14651858.CD015017.pub2

254. Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an aging population. *Eur Respir J*. Published online January 1, 2020. doi:10.1183/13993003.02049-2020

255. dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. *Biomed Pharmacother*. 2020;129:110493. doi:10.1016/j.biopha.2020.110493

256. Dölken L, Stich A, Spinner CD. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned. *Viruses*. 2021;13(6):963. doi:10.3390/v13060963

257. Hydroxychloroquine does not benefit adults hospitalized with COVID-19. National Institutes of Health (NIH). Published November 9, 2020. Accessed September 28, 2021. <https://www.nih.gov/news-events/news-releases/hydroxychloroquine-does-not-benefit-adults-hospitalized-covid-19>

258. Ivermectin Won't Treat Covid-19 but Demand for Drug Surges - The New York Times. Accessed September 28, 2021. <https://www.nytimes.com/2021/08/30/health/covid-ivermectin-prescriptions.html>

259. What the FDA wants doctors to tell patients asking for ivermectin. American Medical Association. Accessed September 28, 2021. <https://www.ama-assn.org/delivering-care/public-health/what-fda-wants-doctors-tell-patients-asking-ivermectin>
260. AbbVie's Kaletra doesn't work in COVID-19, say Chinese scientists -. Accessed September 28, 2021. <https://pharmaphorum.com/news/abbvies-kaletra-doesnt-work-in-covid-19-say-chinese-scientists/>
261. Chamary JV. The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work. Forbes. Accessed September 28, 2021. <https://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/>
262. Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low. The Indian Express. Published May 12, 2021. Accessed September 28, 2021. <https://indianexpress.com/article/cities/lucknow/uttar-pradesh-government-says-ivermectin-helped-to-keep-deaths-low-7311786/>
263. India Claims Ivermectin is Effective Against COVID – Orion's Cold Fire. Accessed September 28, 2021. <https://orionscoldfire.com/index.php/2021/09/16/india-claims-ivermectin-is-effective-against-covid/>
264. Dr. Soumya Swaminathan deletes her controversial tweet - Indian Bar Association. Accessed September 28, 2021. <https://indianbarassociation.in/indian-bar-associationiba-vs-dr-soumyaswaminathan/>
265. Indian Bar Association Charges WHO Chief Scientist for Mass Murder - PaulCraigRoberts.org. Accessed September 28, 2021. <https://www.paulcraigroberts.org/2021/08/23/indian-bar-association-charges-who-chief-scientist-for-mass-murder/>
266. Ivomec® (ivermectin) – Effective dewormer, trusted for more than 35 years. Boehringer Ingelheim Vetmedica. Published April 10, 2019. Accessed September 28, 2021. <https://www.bi-vetmedica.com/species/cattle/products/ivomec.html>
267. CRUMP A, ŌMURA S. Ivermectin, 'Wonder drug' from Japan: the human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci*. 2011;87(2):13-28. doi:10.2183/pjab.87.13
268. Camero K. Some people are taking an anti-parasitic to treat COVID. Here's why that's a bad idea. Miami Herald. Accessed September 28, 2021. <https://www.miamiherald.com/news/coronavirus/article253290108.html>
269. Editor AD News. University experts weigh in on using ivermectin 'horse dewormer' as COVID-19 treatment. Technician. Accessed September 28, 2021. [https://www.technicianonline.com/news/university-experts-weigh-in-on-using-ivermectin-horse-dewormer-as-covid-19-treatment/article\\_319584f2-15dc-11ec-a985-5b35a9dc71ff.html](https://www.technicianonline.com/news/university-experts-weigh-in-on-using-ivermectin-horse-dewormer-as-covid-19-treatment/article_319584f2-15dc-11ec-a985-5b35a9dc71ff.html)
270. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin  $\alpha/\beta$  heterodimer. *Antiviral Res*. 2020;177:104760. doi:10.1016/j.antiviral.2020.104760
271. Kosyna FK, Nagel M, Kluxen L, Kraushaar K, Depping R. The importin  $\alpha/\beta$ -specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways. *Biol Chem*. 2015;396(12):1357-1367. doi:10.1515/hsz-2015-0171
272. Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. *Clin Ther*. 2021;43(6):1007-1019. doi:10.1016/j.clinthera.2021.04.007
273. Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. *J Antibiot (Tokyo)*. Published online June 15, 2021:1-13. doi:10.1038/s41429-021-00430-5
274. Ivermectin for COVID-19: real-time meta analysis of 65 studies. Accessed September 28, 2021. <https://ivmmeta.com/>

275. Israeli scientist says COVID-19 could be treated for under \$1/day. The Jerusalem Post | JPost.com. Accessed September 28, 2021. <https://www.jpost.com/health-science/israeli-scientist-says-covid-19-could-be-treated-for-under-1day-675612>
276. Feuer W. Gilead's coronavirus treatment remdesivir to cost \$3,120 per U.S. patient with private insurance. CNBC. Published June 29, 2020. Accessed September 28, 2021. <https://www.cnbc.com/2020/06/29/gileads-coronavirus-treatment-remdesivir-to-cost-3120-for-us-insured-patients.html>
277. Pharmaceutical companies pay low taxes and reap enormous profit from COVID vaccines. American Friends Service Committee. Published September 15, 2021. Accessed September 28, 2021. <https://www.afsc.org/newsroom/pharmaceutical-companies-pay-low-taxes-and-reap-enormous-profit-covid-vaccines>
278. Obscene global vaccine profiteering by pharmaceutical companies. World Socialist Web Site. Accessed September 28, 2021. <https://www.wsws.org/en/articles/2021/04/01/vacc-a01.html>
279. Pharmaceutical Companies Reaping Immoral Profits From COVID Vaccines Yet Paying Low Tax Rates. Common Dreams. Accessed September 28, 2021. <https://www.commondreams.org/newswire/2021/09/15/pharmaceutical-companies-reaping-immoral-profits-covid-vaccines-yet-paying-low>
280. Ennis M, Tiligada K. Histamine receptors and COVID-19. *Inflamm Res*. Published online November 18, 2020:1-9. doi:10.1007/s00011-020-01422-1
281. Hogan II RB, Hogan III RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. *Pulm Pharmacol Ther*. 2020;63:101942. doi:10.1016/j.pupt.2020.101942
282. Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. *Signal Transduct Target Ther*. 2021;6(1):1-3. doi:10.1038/s41392-021-00689-y
283. Ishola AA, Joshi T, Abdulai SI, Tijjani H, Pundir H, Chandra S. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19. *J Biomol Struct Dyn*. 2021;0(0):1-18. doi:10.1080/07391102.2021.1873191
284. Cross KM, Landis DM, Sehgal L, Payne JD. Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy. *Endocr Pract*. 2021;27(8):850-855. doi:10.1016/j.eprac.2021.06.001
285. Camp OG, Bai D, Gonullu DC, Nayak N, Abu-Soud HM. Melatonin interferes with COVID-19 at several distinct ROS-related steps. *J Inorg Biochem*. 2021;223:111546. doi:10.1016/j.jinorgbio.2021.111546
286. Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. *Int J Clin Pract*. 2020;74(9):e13535. doi:10.1111/ijcp.13535
287. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet*. 2021;398(10303):843-855. doi:10.1016/S0140-6736(21)01744-X
288. Ebell MH. Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19. *Am Fam Physician*. 2021;104(2):207-208. Accessed September 28, 2021. <https://www.aafp.org/afp/2021/0800/p207.html>
289. Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antivir Ther*. 2006;11(8):1021-1030.
290. Droplets vs Aerosols: What's More Important in COVID-19 Spread? Published May 13, 2021. Accessed September 28, 2021. <https://www.medpagetoday.com/special-reports/exclusives/92564>



291. COVID-19: Droplet or Airborne Transmission? Penn Medicine Epidemiologists Issue Statement - Penn Medicine. Accessed September 28, 2021. <https://www.pennmedicine.org/updates/blogs/penn-physician-blog/2020/august/airborne-droplet-debate-article>
292. 239 Experts With One Big Claim: The Coronavirus Is Airborne - The New York Times. Accessed September 28, 2021. <https://www.nytimes.com/2020/07/04/health/239-experts-with-one-big-claim-the-coronavirus-is-airborne.html>
293. Goldman E. Exaggerated risk of transmission of COVID-19 by fomites. *Lancet Infect Dis*. 2020;20(8):892-893. doi:10.1016/S1473-3099(20)30561-2
294. Lewis D. COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? *Nature*. 2021;590(7844):26-28. doi:10.1038/d41586-021-00251-4
295. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv. Accessed September 28, 2021. <https://www.medrxiv.org/content/10.1101/2020.08.03.20167395v1>
296. PolitiFact JG. What We Know About the Airborne Spread of the Coronavirus. Kaiser Health News. Published September 30, 2020. Accessed September 28, 2021. <https://khn.org/news/fact-check-airborne-transmission-coronavirus-science-behind-aerosol-spread/>
297. A guideline to limit indoor airborne transmission of COVID-19 | PNAS. Accessed September 28, 2021. <https://www.pnas.org/content/118/17/e2018995118>
298. Chen CC, Willeke K. Aerosol penetration through surgical masks. *Am J Infect Control*. 1992;20(4):177-184. doi:10.1016/s0196-6553(05)80143-9
299. Konda A, Prakash A, Moss GA, Schmoltdt M, Grant GD, Guha S. Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano*. 2020;14(5):6339-6347. doi:10.1021/acsnano.0c03252
300. Guide for the Selection of Personal Protective Equipment for Emergency First Responders (Percutaneous Protection--Apparel), NIJ Guide 102-00, Volume IIc. National Institute of Justice. Accessed September 28, 2021. <https://nij.ojp.gov/library/publications/guide-selection-personal-protective-equipment-emergency-first-responders-1>
301. US EPA O. EPA Researchers Test Effectiveness of Face Masks, Disinfection Methods Against COVID-19. Published April 5, 2021. Accessed September 28, 2021. <https://www.epa.gov/sciencematters/epa-researchers-test-effectiveness-face-masks-disinfection-methods-against-covid-19>
302. Caruhel J-B, Sigaux N, Crambert A, et al. Military gas mask to protect surgeons when performing tracheotomies on patients with COVID-19. *BMJ Mil Health*. Published online August 2020:bmjmilitary-2020-001547. doi:10.1136/bmjilitary-2020-001547
303. Coronavirus Protection Made Easy with the MaxAir CAPR®. Mopec. Published March 2, 2020. Accessed September 28, 2021. <https://www.mopec.com/coronavirus-protection-made-easy-with-the-maxair-capr/>
304. Kitajima M, Ahmed W, Bibby K, et al. SARS-CoV-2 in wastewater: State of the knowledge and research needs. *Sci Total Environ*. 2020;739:139076. doi:10.1016/j.scitotenv.2020.139076
305. Sharif S, Ikram A, Khurshid A, et al. Detection of SARS-CoV-2 in wastewater using the existing environmental surveillance network: A potential supplementary system for monitoring COVID-19 transmission. *PLOS ONE*. 2021;16(6):e0249568. doi:10.1371/journal.pone.0249568
306. Peccia J, Zulli A, Brackney DE, et al. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nat Biotechnol*. 2020;38(10):1164-1167. doi:10.1038/s41587-020-0684-z
307. McKinney KR, Gong YY, Lewis TG. Environmental transmission of SARS at Amoy Gardens. *J Environ Health*. 2006;68(9):26-30; quiz 51-52.
308. Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? *J R Soc Med*. 2003;96(8):374-378. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539564/>

309. COVID-19 Could Spread Through Dry Floor Drains. CleanLink. Accessed September 28, 2021. <https://www.cleanlink.com/news/article/COVID-19-Could-Spread-Through-Dry-Floor-Drains--25600>
310. 'Leaky' Vaccines Can Produce Stronger Versions of Viruses. Healthline. Published July 27, 2015. Accessed September 28, 2021. <https://www.healthline.com/health-news/leaky-vaccines-can-produce-stronger-versions-of-viruses-072715>
311. MD BH. Let's Stop Pretending About the Covid-19 Vaccines | RealClearScience. Published August 23, 2021. Accessed September 28, 2021. [https://www.realclearscience.com/articles/2021/08/23/lets\\_stop\\_pretending\\_about\\_the\\_covid-19\\_vaccines\\_791050.html](https://www.realclearscience.com/articles/2021/08/23/lets_stop_pretending_about_the_covid-19_vaccines_791050.html)
312. CDC Newsroom. CDC. Published January 1, 2016. Accessed September 28, 2021. <https://www.cdc.gov/media/releases/2021/s0730-mmwr-covid-19.html>
313. Brueck H. CDC: Everyone should mask up indoors — whether they're fully vaccinated or not — as the Delta variant sweeps the US. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/cdc-fully-vaccinated-new-guidelines-wear-masks-indoors-delta-2021-7>
314. Lasting immunity found after recovery from COVID-19. National Institutes of Health (NIH). Published January 25, 2021. Accessed September 28, 2021. <https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19>
315. Gazit S, Shlezinger R, Perez G, et al. *Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections versus Breakthrough Infections.*; 2021:2021.08.24.21262415. doi:10.1101/2021.08.24.21262415
316. Accelerated Covid-19 Vaccine Clinical Trials. JD Supra. Accessed September 28, 2021. <https://www.jdsupra.com/legalnews/accelerated-covid-19-vaccine-clinical-95853/>
317. Were the COVID-19 vaccines rushed? Here's how the vaccines were developed so fast. Accessed September 28, 2021. <https://www.nebraskamed.com/COVID/were-the-covid-19-vaccines-rushed>
318. Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. *Ther Deliv.* 2016;7(5):319-334. doi:10.4155/tde-2016-0006
319. Without these lipid shells, there would be no mRNA vaccines for COVID-19. Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mrna-vaccines/99/i8>
320. CDC. Understanding mRNA COVID-19 Vaccines. Centers for Disease Control and Prevention. Published March 4, 2021. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html>
321. What are mRNA vaccines and how do they work?: MedlinePlus Genetics. Accessed September 28, 2021. <https://medlineplus.gov/genetics/understanding/therapy/mrnavaccines/>
322. Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature.* 2020;586(7830):567-571. doi:10.1038/s41586-020-2622-0
323. PhD SM. How mRNA vaccines from Pfizer and Moderna work, why they're a breakthrough and why they need to be kept so cold. The Conversation. Accessed September 28, 2021. <http://theconversation.com/how-mrna-vaccines-from-pfizer-and-moderna-work-why-theyre-a-breakthrough-and-why-they-need-to-be-kept-so-cold-150238>
324. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. *Front Immunol.* 2021;12:2774. doi:10.3389/fimmu.2021.701501
325. Prompetchara E, Ketloy C, Tharakhet K, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. *PLOS ONE.* 2021;16(3):e0248007. doi:10.1371/journal.pone.0248007

326. COVID-19 Viral Vector Vaccines. Accessed September 28, 2021. <https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/covid-19-viral-vector-vaccines/>
327. Zimmerman RK. Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines. *Vaccine*. 2021;39(31):4242-4244. doi:10.1016/j.vaccine.2021.06.027
328. The Ethics of the SARS-CoV-2 Vaccines Revisited. Christian Medical & Dental Associations® (CMDA). Published September 15, 2021. Accessed September 28, 2021. <https://cmda.org/the-ethics-of-the-sars-cov-2-vaccines-revisited/>
329. Canadian Covid Care Alliance. Accessed September 28, 2021. <https://mailchi.mp/5666d252288c/canadian-covid-care-alliance>
330. Juraszek J, Rutten L, Blokland S, et al. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat Commun*. 2021;12(1):244. doi:10.1038/s41467-020-20321-x
331. The tiny tweak behind COVID-19 vaccines. Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/pharmaceuticals/vaccines/tiny-tweak-behind-COVID-19/98/i38>
332. SARS-COV-2 mRNA Vaccine (BNT162, PF-07302048) 2.6.4 Overview of Pharmacokinetic Test | BibSonomy. Accessed September 28, 2021. <https://www.bibsonomy.org/bibtex/29920ce3643fa2f4fdbeccfa57790d2d/fordham1>
333. Krantz MS, Liu Y, Phillips EJ, Stone CA. COVID-19 vaccine anaphylaxis: PEG or not? *Allergy*. 2021;76(6):1934-1937. doi:10.1111/all.14722
334. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. *Mol Ther*. 2021;29(3):898-900. doi:10.1016/j.ymthe.2021.01.030
335. Overview of translation (article). Khan Academy. Accessed September 28, 2021. <https://www.khanacademy.org/science/ap-biology/gene-expression-and-regulation/translation/a/translation-overview>
336. Thomas EN, Kim KQ, McHugh EP, Marcinkiewicz T, Zaher HS. Alkylative damage of mRNA leads to ribosome stalling and rescue by trans translation in bacteria. Dever TE, Storz G, eds. *eLife*. 2020;9:e61984. doi:10.7554/eLife.61984
337. Karamyshev AL, Karamysheva ZN. Lost in Translation: Ribosome-Associated mRNA and Protein Quality Controls. *Front Genet*. 2018;9:431. doi:10.3389/fgene.2018.00431
338. Mendonsa S, von Kuegelgen N, Bujanic L, Chekulaeva M. Charcot–Marie–Tooth mutation in glycyl-tRNA synthetase stalls ribosomes in a pre-accommodation state and activates integrated stress response. *Nucleic Acids Res*. 2021;49(17):10007-10017. doi:10.1093/nar/gkab730
339. Zuko A, Mallik M, Thompson R, et al. tRNA overexpression rescues peripheral neuropathy caused by mutations in tRNA synthetase. *Science*. 2021;373(6559):1161-1166. doi:10.1126/science.abb3356
340. Zhang S, Chen Y, Wang Y, Zhang P, Chen G, Zhou Y. Insights Into Translatomics in the Nervous System. *Front Genet*. 2020;11:1682. doi:10.3389/fgene.2020.599548
341. Klein T, Eckhard U, Dufour A, Solis N, Overall CM. Proteolytic Cleavage—Mechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification. *Chem Rev*. 2018;118(3):1137-1168. doi:10.1021/acs.chemrev.7b00120
342. Örd M, Faustova I, Loog M. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. *Sci Rep*. 2020;10(1):16944. doi:10.1038/s41598-020-74101-0
343. Lemmin T, Kalbermatter D, Harder D, Plattet P, Fotiadis D. Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. *J Struct Biol X*. 2020;4:100038. doi:10.1016/j.yjsbx.2020.100038

344. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci*. 2009;106(14):5871-5876. doi:10.1073/pnas.0809524106
345. Ogata AF, Cheng C-A, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. *Clin Infect Dis*. 2021;(ciab465). doi:10.1093/cid/ciab465
346. Peacock TP, Goldhill DH, Zhou J, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nat Microbiol*. 2021;6(7):899-909. doi:10.1038/s41564-021-00908-w
347. Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance*. 2020;3(9). doi:10.26508/lsa.202000786
348. Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. *Proc Natl Acad Sci*. 2020;117(41):25254-25262. doi:10.1073/pnas.2010722117
349. Brown M, Bhardwaj N. Super(antigen) target for SARS-CoV-2. *Nat Rev Immunol*. 2021;21(2):72-72. doi:10.1038/s41577-021-00502-5
350. Föhse K, Geckin B, Overheul G, et al. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune response. Published online 2021. doi:10.1101/2021.05.03.21256520
351. Wang H, Chen Q, Hu Y, et al. Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV viruses. Published online September 28, 2021. doi:10.21203/rs.3.rs-612103/v2
352. says R to the document-WB. Summary: Covid-19 Vaccine Concerns. Dr. Rich Swier. Published September 18, 2021. Accessed September 28, 2021. <https://drrichswier.com/2021/09/18/summary-covid-19-vaccine-concerns/>
353. Commissioner O of the. Coronavirus (COVID-19) Update: July 13, 2021. FDA. Published July 13, 2021. Accessed September 28, 2021. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021>
354. Bell's Palsy After COVID Vaccines Still Very Rare. Published August 16, 2021. Accessed September 28, 2021. <https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94061>
355. Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümpefel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. *J Neurol*. Published online June 11, 2021. doi:10.1007/s00415-021-10648-w
356. Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. *Nat Microbiol*. 2021;6(10):1219-1232. doi:10.1038/s41564-021-00958-0
357. Perez-Miller S, Patek M, Moutal A, et al. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry. *ACS Chem Neurosci*. 2021;12(8):1299-1312. doi:10.1021/acchemneuro.0c00619
358. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science*. 2020;370(6518):861-865. doi:10.1126/science.abd3072
359. Nader D, Fletcher N, Curley GF, Kerrigan SW. SARS-CoV-2 uses major endothelial integrin  $\alpha\beta3$  to cause vascular dysregulation in-vitro during COVID-19. *PLOS ONE*. 2021;16(6):e0253347. doi:10.1371/journal.pone.0253347
360. Petruk G, Puthia M, Petrlova J, et al. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. *J Mol Cell Biol*. 2020;12(12):916-932. doi:10.1093/jmcb/mjaa067
361. Suzuki YJ, Gychka SG. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. *Vaccines*. 2021;9(1):36. doi:10.3390/vaccines9010036

362. Liu S, Selvaraj P, Lien CZ, et al. The PRRA Insert at the S1/S2 Site Modulates Cellular Tropism of SARS-CoV-2 and ACE2 Usage by the Closely Related Bat RaTG13. *J Virol*. 95(11):e01751-20. doi:10.1128/JVI.01751-20
363. Johnson BA, Xie X, Kalveram B, et al. Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. *bioRxiv*. Published online August 26, 2020:2020.08.26.268854. doi:10.1101/2020.08.26.268854
364. Deigin Y. Lab-made? CoV2 genealogy through the lens of gain-of-function research. Medium. Published May 3, 2020. Accessed September 28, 2021. <https://yurideigin.medium.com/lab-made-cov2-genealogy-through-the-lens-of-gain-of-function-research-f96dd7413748>
365. Tetz G, Tetz V. SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2. Published online March 29, 2020. doi:10.20944/preprints202003.0422.v1
366. Fryer HR, McLean AR. There Is No Safe Dose of Prions. *PLOS ONE*. 2011;6(8):e23664. doi:10.1371/journal.pone.0023664
367. Seneff S, Nigh G. Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19. *Int J Vaccine Theory Pract Res*. 2021;2(1):38-79. Accessed September 28, 2021. <https://ijvtpr.com/index.php/IJVTPr/article/view/23>
368. Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. *Biochem Biophys Res Commun*. 2021;554:94-98. doi:10.1016/j.bbrc.2021.03.100
369. Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. *Nat Neurosci*. 2021;24(3):368-378. doi:10.1038/s41593-020-00771-8
370. Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. *Signal Transduct Target Ther*. 2021;6(1):1-12. doi:10.1038/s41392-021-00719-9
371. Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. *Neurobiol Dis*. 2020;146:105131. doi:10.1016/j.nbd.2020.105131
372. Ricke DO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. *Front Immunol*. 2021;12:640093. doi:10.3389/fimmu.2021.640093
373. Halstead SB, Katzelnick L. COVID 19 Vaccines: Should we fear ADE? *J Infect Dis*. Published online August 12, 2020:jiaa518. doi:10.1093/infdis/jiaa518
374. Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? *J Infect*. 2021;0(0). doi:10.1016/j.jinf.2021.08.010
375. (STUDY) Why so many vaccinated people are getting sick: Antibody Dependent Enhancement (ADE) | Sharyl Attkisson. Accessed September 28, 2021. <https://sharylattkisson.com/2021/08/study-why-so-many-vaccinated-people-are-getting-sick/>
376. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol*. 2020;5(10):1185-1191. doi:10.1038/s41564-020-00789-5
377. Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. *Int J Infect Dis*. 2020;100:483-489. doi:10.1016/j.ijid.2020.09.015
378. Wan Y, Shang J, Sun S, et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. *J Virol*. 2020;94(5):e02015-19. doi:10.1128/JVI.02015-19
379. Liu Y, Arase N, Kishikawa J, et al. *The SARS-CoV-2 Delta Variant Is Poised to Acquire Complete Resistance to Wild-Type Spike Vaccines.*; 2021:2021.08.22.457114. doi:10.1101/2021.08.22.457114
380. Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original Antigenic Sin: How First Exposure Shapes Lifelong Anti–Influenza Virus Immune Responses. *J Immunol*. 2019;202(2):335-340. doi:10.4049/jimmunol.1801149

381. Brown EL, Essigmann HT. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19. *mSphere*. 6(2):e00056-21. doi:10.1128/mSphere.00056-21
382. Antibody Dependent Enhancement - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/antibody-dependent-enhancement>
383. ADE. Accessed September 28, 2021. <https://www.cdc.gov/dengue/training/cme/ccm/page57857.html>
384. Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. *Front Cell Infect Microbiol*. 2020;10:597. doi:10.3389/fcimb.2020.572681
385. Scientists Discover How Dengue Vaccine Fails to Protect Against Disease. Newsroom. Published June 23, 2021. Accessed September 28, 2021. <https://news.unchealthcare.org/2021/06/scientists-discover-how-dengue-vaccine-fails-to-protect-against-disease/>
386. Mahalingam S, Herring BL, Halstead SB. Call to Action for Dengue Vaccine Failure. *Emerg Infect Dis*. 2013;19(8):1335-1337. doi:10.3201/eid1908.121864
387. How the World's First Dengue Vaccination Drive Ended in Disaster. Scientific American. doi:10.1038/scientificamerican0419-38
388. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. *PLOS ONE*. 2012;7(4):e35421. doi:10.1371/journal.pone.0035421
389. Zhang L, Richards A, Khalil A, et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. *BioRxiv Prepr Serv Biol*. Published online December 13, 2020:2020.12.12.422516. doi:10.1101/2020.12.12.422516
390. MIT & Harvard Study Suggests mRNA Vaccine Might Permanently Alter DNA After All. Rights and Freedoms. Published August 13, 2021. Accessed September 28, 2021. <https://rightsfreedoms.wordpress.com/2021/08/13/mit-harvard-study-suggests-mrna-vaccine-might-permanently-alter-dna-after-all/>
391. The Injection Fraud – It's Not a Vaccine – Solari Report. Accessed September 28, 2021. <https://home.solari.com/deep-state-tactics-101-the-covid-injection-fraud-its-not-a-vaccine/>
392. Dec 19 LS| NE| CN|, 2017. Feds lift gain-of-function research pause, offer guidance. CIDRAP. Accessed September 28, 2021. <https://www.cidrap.umn.edu/news-perspective/2017/12/feds-lift-gain-of-function-research-pause-offer-guidance>
393. Begley, STAT S. U.S. Lifts Moratorium on Funding Controversial, High-Risk Virus Research. Scientific American. Accessed September 28, 2021. <https://www.scientificamerican.com/article/u-s-lifts-moratorium-on-funding-controversial-high-risk-virus-research/>
394. NIH Lifts Funding Pause on Gain-of-Function Research. National Institutes of Health (NIH). Published December 18, 2017. Accessed September 28, 2021. <https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-lifts-funding-pause-gain-function-research>
395. Ralph S. Baric, PhD. UNC Gillings School of Global Public Health. Accessed September 28, 2021. [https://sph.unc.edu/adv\\_profile/ralph-s-baric-phd/](https://sph.unc.edu/adv_profile/ralph-s-baric-phd/)
396. Ralph Baric: On the Front Lines of Coronavirus for Three Decades - UNC General Alumni Association. Accessed September 28, 2021. <https://alumni.unc.edu/news/ralph-baric-on-the-front-lines-of-coronavirus-for-three-decades/>
397. Menachery VD, Yount BL, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nat Med*. 2015;21(12):1508-1513. doi:10.1038/nm.3985
398. Inside the risky bat-virus engineering that links America to Wuhan. MIT Technology Review. Accessed September 28, 2021. <https://www.technologyreview.com/2021/06/29/1027290/gain-of-function-risky-bat-virus-engineering-links-america-to-wuhan/>

399. Suryanarayanan S. Items from coronavirus expert Ralph Baric's emails. U.S. Right to Know. Published December 14, 2020. Accessed September 28, 2021. <https://usrtk.org/biohazards-blog/ralph-baric-emails/>
400. Newsweek Op-Ed: "Congress Must Pursue Answers About the Origin of COVID-19" | Senator Rand Paul. Accessed September 28, 2021. <https://www.paul.senate.gov/newsweek-op-ed-congress-must-pursue-answers-about-origin-covid-19>
401. Baker N. The Lab-Leak Hypothesis. *Intelligencer*. Published January 4, 2021. Accessed September 28, 2021. <https://nymag.com/intelligencer/article/coronavirus-lab-escape-theory.html>
402. Lerner S, Hvistendahl M, Hibbett M. NIH Documents Provide New Evidence U.S. Funded Gain-of-Function Research in Wuhan. *The Intercept*. Published September 10, 2021. Accessed September 28, 2021. <https://theintercept.com/2021/09/09/covid-origins-gain-of-function-research/>
403. BOMBHELL: Fauci Kept Funding Peter Daszak's Wuhan "Gain of Function" Experiments with \$7.5 Million after Trump Canceled Grant. *National File*. Published June 3, 2021. Accessed September 28, 2021. <https://nationalfile.com/bombshell-fauci-kept-funding-peter-daszaks-wuhan-gain-of-function-experiments-with-7-5-million-after-trump-canceled-grant/>
404. miningawareness. USAID (PREDICT) & NIH Gave \$ 1.9 Million to the Wuhan (WIV) Lab Through Daszak-EcoHealth Alliance; Daszak Talks China Partners' Work on "Killer" Viruses; Biden Budget Requests More USAID Money for Similar Projects. *Mining Awareness +*. Published June 11, 2021. Accessed September 28, 2021. <https://miningawareness.wordpress.com/2021/06/11/usaid-predict-nih-gave-1-9-million-to-the-wuhan-wiv-lab-through-daszak-ecohealth-alliance-daszak-talks-china-partners-work-on-killer-viruses-biden-admin-plans/>
405. Gallagher: This is Bigger than Dr. Fauci. Congressman Mike Gallagher. Published May 20, 2021. Accessed September 28, 2021. <https://gallagher.house.gov/media/press-releases/gallagher-bigger-dr-fauci>
406. Blog A. EcoHealth Alliance, DARPA Toyed With Infecting Wild Chinese Bats With Covid, Leaked Docs Allege. *Algora Blog*. Published September 22, 2021. Accessed September 28, 2021. [https://www.algora.com/Algora\\_blog/2021/09/22/ecohealth-alliance-darpa-toyed-with-infecting-wild-chinese-bats-with-covid-leaked-docs-allege](https://www.algora.com/Algora_blog/2021/09/22/ecohealth-alliance-darpa-toyed-with-infecting-wild-chinese-bats-with-covid-leaked-docs-allege)
407. Archive VA, feed G author R. Pentagon gave millions to EcoHealth Alliance for weapons research program. *New York Post*. Published July 2, 2021. Accessed September 28, 2021. <https://nypost.com/2021/07/01/pentagon-gave-millions-to-ecohealth-alliance-for-wuhan-lab/>
408. Judicial Watch: New Documents Show Wuhan Lab Asked NIH Official for Information on Disinfectants; Nine Fauci Agency Grants for EcoHealth Bat Coronavirus Research. *Judicial Watch*. Published July 8, 2021. Accessed September 28, 2021. <https://www.judicialwatch.org/press-releases/wuhan-lab-fauci-grants/>
409. JW v NIH Wuhan June 2021 00696. *Judicial Watch*. Accessed September 28, 2021. <https://www.judicialwatch.org/documents/jw-v-nih-wuhan-june-2021-00696/>
410. Opinion | State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses. *Washington Post*. <https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/>. Accessed September 28, 2021.
411. Panetta G. US officials were reportedly concerned that safety breaches at a Wuhan lab studying coronaviruses in bats could cause a pandemic. *Business Insider*. Accessed September 28, 2021. <https://www.businessinsider.com/us-officials-raised-alarms-about-safety-issues-in-wuhan-lab-report-2020-4>
412. (PDF) The possible origins of 2019-nCoV coronavirus. Accessed September 28, 2021. [https://web.archive.org/web/20200214144447/https://www.researchgate.net/publication/339070128\\_The\\_possible\\_origins\\_of\\_2019-nCoV\\_coronavirus](https://web.archive.org/web/20200214144447/https://www.researchgate.net/publication/339070128_The_possible_origins_of_2019-nCoV_coronavirus)

413. Crist C. 3 Wuhan Lab Workers' 2019 Illness Raises Concerns. WebMD. Accessed September 28, 2021. <https://www.webmd.com/lung/news/20210524/wuhan-lab-researchers-illness>
414. Williams J. Fauci calls on China to release medical records of Wuhan researchers. TheHill. Published June 4, 2021. Accessed September 28, 2021. <https://thehill.com/policy/healthcare/556815-fauci-calls-on-china-to-release-medical-records-of-wuhan-researchers>
415. Confidential Documents reveal Moderna sent mRNA Coronavirus Vaccine Candidate to University Researchers weeks before emergence of Covid-19. Rights and Freedoms. Published June 26, 2021. Accessed September 28, 2021. <https://rightsfreedoms.wordpress.com/2021/06/26/confidential-documents-reveal-moderna-sent-mrna-coronavirus-vaccine-candidate-to-university-researchers-weeks-before-emergence-of-covid-19/>
416. Confidential Documents reveal Moderna sent mRNA Coronavirus Vaccine Candidate to University Researchers weeks before emergence of Covid-19 – The Expose. Accessed September 28, 2021. <https://theexpose.uk/2021/06/18/confidential-documents-reveal-moderna-sent-mrna-coronavirus-vaccine-candidate-to-university-researchers-weeks-before-emergence-of-covid-19/>
417. Jan 11 LS| NE| CN|, 2020. China releases genetic data on new coronavirus, now deadly. CIDRAP. Accessed September 28, 2021. <https://www.cidrap.umn.edu/news-perspective/2020/01/china-releases-genetic-data-new-coronavirus-now-deadly>
418. Whole genome of novel coronavirus, 2019-nCoV, sequenced. ScienceDaily. Accessed September 28, 2021. <https://www.sciencedaily.com/releases/2020/01/200131114748.htm>
419. Bendix SN Andrew Dunn, Aria. Moderna's groundbreaking coronavirus vaccine was designed in just 2 days. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/moderna-designed-coronavirus-vaccine-in-2-days-2020-11>
420. Moderna designed its coronavirus vaccine in 2 days — here's how - National | Globalnews.ca. Global News. Accessed September 28, 2021. <https://globalnews.ca/news/7492076/moderna-coronavirus-vaccine-technology-how-it-works/>
421. Wallace-Wells D. We Had the Vaccine the Whole Time. Intelligencer. Published December 7, 2020. Accessed September 28, 2021. <https://nymag.com/intelligencer/2020/12/moderna-covid-19-vaccine-design.html>
422. The Board of Directors of bioMérieux, chaired by Alain Mérieux, has appointed Stephane Bancel Directeur General delegate (Chief Executive Officer) of bioMérieux starting January 1, 2007. bioMérieux Corporate Website. Accessed September 28, 2021. <https://www.biomerieux.com/en/board-directors-biomerieux-chaired-alain-merieux-has-appointed-stephane-bancel-directeur-general>
423. Stéphane Bancel | HIMSS. Published September 24, 2021. Accessed September 28, 2021. <https://www.himss.org/global-conference/speaker-stephane-bancel>
424. Alain Mérieux receives the prestigious Chinese Reform Friendship Award. Mérieux Foundation. Published September 17, 2013. Accessed September 28, 2021. <https://www.fondation-merieux.org/en/news/alain-merieux-receives-the-prestigious-chinese-reform-friendship-award/>
425. Beijing JXTWLCI. The Wuhan lab at the core of a virus controversy. Accessed September 28, 2021. <https://medicalxpress.com/news/2020-04-wuhan-lab-core-virus-controversy.html>
426. China Inaugurates the first biocontainment level 4 laboratory in Wuhan----Wuhan Institute of Virology. Accessed September 28, 2021. [http://english.whiov.cas.cn/ne/201712/t20171212\\_187624.html](http://english.whiov.cas.cn/ne/201712/t20171212_187624.html)
427. RaTG13 is fake. Nerd Has Power. Accessed September 28, 2021. <https://nerdhaspower.weebly.com/ratg13-is-fake.html>
428. RaTG13 – the Undeniable Evidence That the Wuhan Coronavirus Is Man-Made. GNEWS. Published May 2, 2020. Accessed September 28, 2021. <https://gnews.org/192144>
429. Scientific history of RaTG13. Peak Prosperity. Accessed September 28, 2021. <https://www.peakprosperity.com/forum-topic/scientific-history-of-ratg13/>



430. No one can find the animal that gave people covid-19. MIT Technology Review. Accessed September 28, 2021. <https://www.technologyreview.com/2021/03/26/1021263/bat-covid-coronavirus-cause-origin-wuhan/>
431. How WHO is working to track down the animal reservoir of the SARS-CoV-2 virus. Accessed September 28, 2021. <https://www.who.int/news-room/feature-stories/detail/how-who-is-working-to-track-down-the-animal-reservoir-of-the-sars-cov-2-virus>
432. Jewers C. More Lancet letter signatories found to have links to Wuhan. Mail Online. Published September 11, 2021. Accessed September 28, 2021. <https://www.dailymail.co.uk/news/article-9980015/26-Lancet-scientists-trashed-theory-Covid-leaked-Chinese-lab-links-Wuhan.html>
433. Wang N, Li S-Y, Yang X-L, et al. Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. *Viol Sin*. 2018;33(1):104-107. doi:10.1007/s12250-018-0012-7
434. Daszak and scientists stand by Lancet letter condemning Wuhan lab “conspiracy theories.” MSN. Accessed September 28, 2021. <https://www.msn.com/en-us/health/medical/daszak-and-scientists-stand-by-lancet-letter-condemning-wuhan-lab-conspiracy-theories/ar-AALT8w6>
435. Albaugh G. Journal That Mocked COVID Lab-Leak As “Conspiracy” Recants. Citizens Journal. Published September 22, 2021. Accessed September 28, 2021. <https://www.citizensjournal.us/journal-that-mocked-covid-lab-leak-as-conspiracy-recants/>
436. Calisher C, Carroll D, Colwell R, et al. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. *The Lancet*. 2020;395(10226):e42-e43. doi:10.1016/S0140-6736(20)30418-9
437. Lancet’s COVID origins panel disbands over ties to Peter Daszak’s EcoHealth Alliance. swiftheadline. Published September 26, 2021. Accessed September 28, 2021. <https://swiftheadline.com/lancets-covid-origins-panel-disbands-over-ties-to-peter-daszaks-ecohealth-alliance/>
438. WHO Covid Expert Peter Daszak’s Alleged China Connection and CCP Money Trail: What’s the Truth? Published February 11, 2021. Accessed September 28, 2021. <https://www.ibtimes.sg/who-covid-expert-peter-daszaks-alleged-china-connection-ccp-money-trail-whats-truth-55511>
439. Rutz D. Media fact-checkers, Facebook cited Wuhan lab-linked scientist to knock down lab leak theory. Fox News. Published June 3, 2021. Accessed September 28, 2021. <https://www.foxnews.com/media/daszak-fact-checks-coronavirus-wuhan-lab>
440. Daszak P, Chmura A. A Fall From Grace To... Virulence? *Ecohealth*. 2008;5(1):96-97. doi:10.1007/s10393-008-0163-3
441. Bogich TL, Chunara R, Scales D, et al. Preventing pandemics via international development: a systems approach. *PLoS Med*. 2012;9(12):e1001354. doi:10.1371/journal.pmed.1001354
442. Daszak P, Howard SE, Chmura AA. Rock, paper, scissors; chicken, human, swine. *EcoHealth*. 2009;6(1):159-160. doi:10.1007/s10393-009-0245-x
443. Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. *Nature*. 2013;503(7477):535-538. doi:10.1038/nature12711
444. Latinne A, Hu B, Olival KJ, et al. Origin and cross-species transmission of bat coronaviruses in China. *BioRxiv Prepr Serv Biol*. Published online May 31, 2020:2020.05.31.116061. doi:10.1101/2020.05.31.116061
445. Li H-Y, Zhu G-J, Zhang Y-Z, et al. A qualitative study of zoonotic risk factors among rural communities in southern China. *Int Health*. 2020;12(2):77-85. doi:10.1093/inthealth/ihaa001
446. Li H, Chen Y, Machalaba CC, et al. Wild animal and zoonotic disease risk management and regulation in China: Examining gaps and One Health opportunities in scope, mandates, and monitoring systems. *One Health Amst Neth*. 2021;13:100301. doi:10.1016/j.onehlt.2021.100301

447. Nava A, Shimabukuro JS, Chmura AA, Luz SLB. The Impact of Global Environmental Changes on Infectious Disease Emergence with a Focus on Risks for Brazil. *ILAR J.* 2017;58(3):393-400. doi:10.1093/ilar/ilx034
448. Wang N, Li S-Y, Yang X-L, et al. Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. *Virology*. 2018;33(1):104-107. doi:10.1007/s12250-018-0012-7
449. Zeng L-P, Gao Y-T, Ge X-Y, et al. Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response. *J Virol.* 2016;90(14):6573-6582. doi:10.1128/JVI.03079-15
450. David Martin. *The Fauci COVID 19 Dossier.*; 2021. Accessed September 28, 2021. <http://archive.org/details/the-fauci-covid-19-dossier>
451. 161385360554578. Coronavirus patients WELDED into homes in China as death toll spirals to 813. The US Sun. Published February 9, 2020. Accessed September 28, 2021. <https://www.the-sun.com/news/378365/coronavirus-patients-welded-into-homes-in-china-as-death-toll-spirals-to-813/>
452. Archive VA, Author E the, Twitter F on, et al. COVID-19 deaths in NY nursing homes were 50 percent higher than claimed: probe. New York Post. Published January 28, 2021. Accessed September 28, 2021. <https://nypost.com/2021/01/28/ny-nursing-home-covid-deaths-50-higher-than-stated-ag-probe/>
453. Ciavaglia DR and J. Investigations into Northeast nursing homes ongoing as true COVID death toll rises by 16K. The Intelligencer. Accessed September 28, 2021. <https://www.theintell.com/story/news/coronavirus/2021/09/14/covid-nursing-homes-deaths-investigation-pa-ny-nj/8280221002/>
454. editor@palltimes.com A and SR. New York health chief, Cuomo defender, resigning. Oswego County News Now. Accessed September 28, 2021. [http://www.oswegocountynewsnow.com/news/new-york-health-chief-cuomo-defender-resigning/article\\_4e6877f6-1d7a-11ec-b7fc-23eab87d9a8a.html](http://www.oswegocountynewsnow.com/news/new-york-health-chief-cuomo-defender-resigning/article_4e6877f6-1d7a-11ec-b7fc-23eab87d9a8a.html)
455. Care homes accused of using powerful sedatives to kill corona victims quickly. The Sun. Published July 12, 2020. Accessed September 28, 2021. <https://www.thesun.co.uk/news/12100515/care-homes-accused-sedatives-coronavirus-die-quickly/>
456. Wayne Smith, The Man Exposing The Midazolam Mass Murder Care Home Scandal Found Dead - Plandemic. Accessed September 28, 2021. <https://plandemic.co/2021/08/19/wayne-smith-the-man-exposing-the-midazolam-mass-murder-care-home-scandal-found-dead/>
457. Did the 'First Wave' Mean the Mass Murder of the Elderly With Midazolam? – The White Rose. Accessed September 28, 2021. <https://thewhiterose.uk/was-this-the-first-wave-mass-murder-of-the-elderly-with-midazolam/>
458. News: Face mask shortage prompts CDC to... (The Washington Post) - Behind the headlines - NLM. NCBI. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/search/research-news/8835>
459. Evstatieva M. U.S. Companies Shifted To Make N95 Respirators During COVID. Now, They're Struggling. *NPR.* <https://www.npr.org/2021/06/25/1009858893/u-s-companies-shifted-to-make-n95-respirators-during-covid-now-theyre-struggling>. Published June 25, 2021. Accessed September 28, 2021.
460. Pandemic Market Oddity: N95 Mask Shortage Despite Availability. Verisk. Accessed September 28, 2021. <https://www.verisk.com/insurance/covid-19/iso-insights/pandemic-market-oddity-n95-mask-shortage-despite-availability/>
461. In the early days of the pandemic, the U.S. government turned down an offer to manufacture millions of N95 masks in America. *Washington Post.* [https://www.washingtonpost.com/investigations/in-the-early-days-of-the-pandemic-the-us-government-turned-down-an-offer-to-manufacture-millions-of-n95-masks-in-america/2020/05/09/f76a821e-908a-11ea-a9c0-73b93422d691\\_story.html](https://www.washingtonpost.com/investigations/in-the-early-days-of-the-pandemic-the-us-government-turned-down-an-offer-to-manufacture-millions-of-n95-masks-in-america/2020/05/09/f76a821e-908a-11ea-a9c0-73b93422d691_story.html). Accessed September 28, 2021.

462. Cheong W. The US government turned down an offer to manufacture up to 1.7 million N95 masks weekly in January: report. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/us-government-rejected-an-offer-to-manufacture-up-to-17-million-n95-masks-weekly-2020-5>
463. Dugdale CM, Walensky RP. Filtration Efficiency, Effectiveness, and Availability of N95 Face Masks for COVID-19 Prevention. *JAMA Intern Med.* 2020;180(12):1612-1613. doi:10.1001/jamainternmed.2020.4218
464. What's a PCR test cycle threshold and why it matters. Full Fact. Published 16:47:37.518768+00:00. Accessed September 28, 2021. <https://fullfact.org/health/cycle-threshold-values/>
465. Rajyalakshmi B, Samavedam S, Reddy PR, Aluru N. Prognostic Value of "Cycle Threshold" in Confirmed COVID-19 Patients. *Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med.* 2021;25(3):322-326. doi:10.5005/jp-journals-10071-23765
466. Covid Mandates: Unscientific, Irrational And Fraudulent, Dozens Of Reasons To Stop Them Now | Covid Call To Humanity. Accessed September 28, 2021. <https://covidcalltohumanity.org/2021/09/27/nicanor-perlas-covid-mandates-unscientific-irrational-and-fraudulent-dozens-of-reasons-to-stop-them-now/>
467. The COVID-19 PCR Test Is Key to the Pandemic Fraud | Principia Scientific Intl. Principia Scientific Intl. | A science-based community. Published September 8, 2020. Accessed September 28, 2021. <https://principia-scientific.com/the-covid-19-pcr-test-is-key-to-the-pandemic-fraud/>
468. Mandavilli A. Your Coronavirus Test Is Positive. Maybe It Shouldn't Be. *The New York Times.* <https://www.nytimes.com/2020/08/29/health/coronavirus-testing.html>. Published August 29, 2020. Accessed September 28, 2021.
469. The Fog of COVID-19 Data: How many cases aren't even cases? John Locke Foundation. Accessed September 28, 2021. <https://www.johnlocke.org/update/the-fog-of-covid-19-data-how-many-cases-arent-even-cases/>
470. Caught Red-Handed: CDC Changes Test Thresholds To Virtually Eliminate New COVID Cases Among Vaxx'd. Rights and Freedoms. Published May 24, 2021. Accessed September 28, 2021. <https://rightsandfreedom.wordpress.com/2021/05/24/caught-red-handed-cdc-changes-test-thresholds-to-virtually-eliminate-new-covid-cases-among-vaxxd/>
471. Trabert D. CDC: maximum 28 CT for post-vaccine COVID PCR tests. The Sentinel. Published May 3, 2021. Accessed September 28, 2021. <https://sentinelksmo.org/cdc-maximum-28-ct-for-post-vaccine-covid-pcr-tests/>
472. FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf. Accessed September 28, 2021. <https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf>
473. Kashiouris MG, L'Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The Emerging Role of Vitamin C as a Treatment for Sepsis. *Nutrients.* 2020;12(2):E292. doi:10.3390/nu12020292
474. Obi J, Pastores SM, Ramanathan LV, Yang J, Halpern NA. Treating sepsis with vitamin C, thiamine, and hydrocortisone: Exploring the quest for the magic elixir. *J Crit Care.* 2020;57:231-239. doi:10.1016/j.jcrc.2019.12.011
475. Harris R. "Tantalizing" Results For A Test Of Vitamin C For Sepsis. *NPR.* <https://www.npr.org/sections/health-shots/2019/10/01/766029397/mixed-results-for-a-test-of-vitamin-c-for-sepsis>. Published October 1, 2019. Accessed September 28, 2021.
476. nutraingredients.com. "Ethically and morally unacceptable": Reaction to vitamin C for sepsis trial. nutraingredients.com. Accessed September 28, 2021. <https://www.nutraingredients.com/Article/2020/01/28/Ethically-and-morally-unacceptable-Reaction-to-vitamin-C-for-sepsis-trial>

477. Research C for DE and. FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). FDA. Published online July 1, 2021. Accessed September 28, 2021. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>
478. FDA studies: No post-ingestion NDMA from ranitidine. Accessed September 28, 2021. <https://www.raps.org/news-and-articles/news-articles/2021/6/fda-studies-no-post-ingestion-ndma-from-ranitidine>
479. Ahmadi A, Ebrahimzadeh MA, Ahmad-Ashrafi S, Karami M, Mahdavi MR, Saravi SSS. Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists. *Fundam Clin Pharmacol*. 2011;25(1):72-79. doi:10.1111/j.1472-8206.2009.00810.x
480. Nutrition C for FS and A. LES Labs - 593764 - 07/23/2020. Center for Food Safety and Applied Nutrition. Published July 29, 2020. Accessed September 28, 2021. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/les-labs-593764-07232020>
481. US senator, NPA press FDA on NAC supplements. Natural Products INSIDER. Published August 18, 2021. Accessed September 28, 2021. <https://www.naturalproductsinsider.com/regulatory/us-senator-npa-press-fda-nac-supplements>
482. nutraingredients-usa.com. CRN: 'This is not the final word on NAC.' nutraingredients-usa.com. Accessed September 28, 2021. <https://www.nutraingredients-usa.com/Article/2021/05/11/CRN-This-is-not-the-final-word-on-NAC>
483. Amazon confirms plans on removing NAC supplements. Natural Products INSIDER. Published May 6, 2021. Accessed September 28, 2021. <https://www.naturalproductsinsider.com/regulatory/amazon-confirms-plans-removing-nac-supplements>
484. Harvard University Professor and Two Chinese Nationals Charged in Three Separate China Related Cases. Published January 28, 2020. Accessed September 28, 2021. <https://www.justice.gov/opa/pr/harvard-university-professor-and-two-chinese-nationals-charged-three-separate-china-related>
485. Research Sponsors - Lieber Research GroupThe Lieber group is focused broadly on science and technology at the nanoscale - Lieber Research Group. Accessed September 28, 2021. <http://cml.harvard.edu/resources/research-sponsors>
486. Shaw J. Virus-Sized Transistors. Harvard Magazine. Published December 16, 2010. Accessed September 28, 2021. <https://www.harvardmagazine.com/2011/01/virus-sized-transistors>
487. Why did a Chinese university hire Charles Lieber to do battery research? Accessed September 28, 2021. <https://www.science.org/content/article/why-did-chinese-university-hire-charles-lieber-do-battery-research>
488. Writer PRHS. Reading life's building blocks. Harvard Gazette. Published January 5, 2012. Accessed September 28, 2021. <https://news.harvard.edu/gazette/story/2012/01/reading-lifes-building-blocks/>
489. Correspondent CM-MH. Harvard researchers present nanowire devices update. Harvard Gazette. Published July 2, 2019. Accessed September 28, 2021. <https://news.harvard.edu/gazette/story/2019/07/harvard-researchers-present-nanowire-devices-update/>
490. Harvard University Professor Indicted on False Statement Charges. Published June 9, 2020. Accessed September 28, 2021. <https://www.justice.gov/usao-ma/pr/harvard-university-professor-indicted-false-statement-charges>
491. Barry E, Kolata G. China's Lavish Funds Lured U.S. Scientists. What Did It Get in Return? *The New York Times*. <https://www.nytimes.com/2020/02/06/us/chinas-lavish-funds-lured-us-scientists-what-did-it-get-in-return.html>. Published February 6, 2020. Accessed September 28, 2021.

492. Subbaraman N. Harvard chemistry chief's arrest over China links shocks researchers. *Nature*. Published online February 3, 2020. doi:10.1038/d41586-020-00291-2
493. Portman R, Carper T. Threats to the U.S. Research Enterprise: China's Talent Recruitment Plans. :109.
494. Krige J. Scholars or Spies? U.S.-China Tension in Academic Collaboration. China Research Center. Published October 12, 2020. Accessed September 28, 2021. [https://www.chinacenter.net/2020/china\\_currents/19-3/scholars-or-spies-u-s-china-tension-in-academic-collaboration/](https://www.chinacenter.net/2020/china_currents/19-3/scholars-or-spies-u-s-china-tension-in-academic-collaboration/)
495. FBI\_Risks\_To\_Academia.pdf. Accessed September 28, 2021. [https://www.research.psu.edu/sites/default/files/FBI\\_Risks\\_To\\_Academia.pdf](https://www.research.psu.edu/sites/default/files/FBI_Risks_To_Academia.pdf)
496. Zweig D, Kang S. AMERICA CHALLENGES CHINA'S NATIONAL TALENT PROGRAMS. :20.
497. Zhang A, Zhao Y, You SS, Lieber CM. Nanowire probes could drive high-resolution brain-machine interfaces. *Nano Today*. 2020;31:100821. doi:10.1016/j.nantod.2019.100821
498. Hong G, Lieber CM. Novel electrode technologies for neural recordings. *Nat Rev Neurosci*. 2019;20(6):330-345. doi:10.1038/s41583-019-0140-6
499. Human Cells Eat Nanowires. IEEE Spectrum. Published December 19, 2016. Accessed September 28, 2021. <https://spectrum.ieee.org/human-cells-eat-nanowires>
500. They've got the beat. Boston Herald. Published August 29, 2012. Accessed September 28, 2021. <https://www.bostonherald.com/2012/08/29/theyve-got-the-beat-2/>
501. Tian B, Liu J, Dvir T, et al. Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. *Nat Mater*. 2012;11(11):986-994. doi:10.1038/nmat3404
502. Board of Directors: Advancing mRNA Science - Moderna. Accessed September 28, 2021. <https://www.modernatx.com/modernas-board-directors>
503. Tognini G. MIT Scientist Bob Langer Becomes A Billionaire Thanks To Moderna Stock Rally. Forbes. Accessed September 28, 2021. <https://www.forbes.com/sites/giacomotognini/2020/11/12/mit-scientist-bob-langer-becomes-a-billionaire-thanks-to-moderna-stock-rally/>
504. Moderna's Stock Rally Makes Bob Langer a Billionaire. Accessed September 28, 2021. <https://www.ceotodaymagazine.com/2020/11/modernas-stock-rally-makes-bob-langer-a-billionaire/>
505. Langer Lab – MIT Department of Chemical Engineering. Accessed September 28, 2021. <https://langerlab.mit.edu/>
506. Nano-Bioelectronics. Lieber Research Group. Accessed September 28, 2021. <http://cml.harvard.edu/research/nano-bioelectronics>
507. Durden T. Klaus Schwab: Great Reset Will "Lead To Fusion Of Our Physical, Digital, & Biological Identity." Invesbrain. Published November 17, 2020. Accessed September 28, 2021. <https://invesbrain.com/klaus-schwab-great-reset-will-lead-to-fusion-of-our-physical-digital-biological-identity/>
508. Shaping the Future of the Fourth Industrial Revolution by Klaus Schwab, Nicholas Davis: 9781984822611 | PenguinRandomHouse.com: Books. Accessed September 28, 2021. <https://www.penguinrandomhouse.com/books/598250/shaping-the-future-of-the-fourth-industrial-revolution-by-klaus-schwab-founder-and-executive-chairman-world-economic-forum-with-nicholas-davis/>
509. ORWELL CITY: Official interim report of Pfizer's vaccination vial analysis explained by La Quinta Columna. ORWELL CITY. Accessed September 28, 2021. <https://www.orwell.city/2021/06/vaccination-vial-analysis-explained.html>
510. Yi J, Choe G, Park J, Lee JY. Graphene oxide-incorporated hydrogels for biomedical applications. *Polym J*. 2020;52(8):823-837. doi:10.1038/s41428-020-0350-9
511. Kim YH, Jo MS, Kim JK, et al. Short-term inhalation study of graphene oxide nanoplates. *Nanotoxicology*. 2018;12(3):224-238. doi:10.1080/17435390.2018.1431318

512. News · CBC. Potentially toxic masks distributed in schools and daycares in Quebec | CBC News. CBC. Published March 26, 2021. Accessed September 28, 2021. <https://www.cbc.ca/news/canada/montreal/masks-early-pulmonary-toxicity-quebec-schools-daycares-1.5966387>
513. HAF. BOMBHELL: Disposable Blue Face Masks Found to Contain Toxic, Asbestos-Like Substance that Destroys Lungs. <https://humansarefree.com/>. Accessed September 28, 2021. <https://humansarefree.com/2021/04/bombshell-disposable-blue-face-masks-found-to-contain-toxic-asbestos-like-substance-that-destroys-lungs.html/>
514. 崔大祥, 高昂, 梁辉, 田静, 李雪玲, 沈琦. Nano coronavirus recombinant vaccine taking graphene oxide as carrier. Published online January 15, 2021. Accessed October 8, 2021. <https://patents.google.com/patent/CN112220919A/en>
515. Xu L, Xiang J, Liu Y, et al. Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity. *Nanoscale*. 2016;8(6):3785-3795. doi:10.1039/C5NR09208F
516. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant - ScienceDirect. Accessed October 8, 2021. <https://www.sciencedirect.com/science/article/abs/pii/S1742706120303305?via%3Dihub>
517. Reuters. Japan suspends 1.6M doses of Moderna shot after contamination reports. NBC News. Accessed September 28, 2021. <https://www.nbcnews.com/news/world/japan-suspends-1-6m-doses-moderna-shot-after-contamination-reports-n1277669>
518. Contaminant in Moderna COVID-19 vaccine vials found in Japan was metallic particles: report. FiercePharma. Accessed September 28, 2021. <https://www.fiercepharma.com/pharma/contaminant-moderna-covid-19-vaccine-vials-found-japan-was-metallic-particles-report>
519. Administrator A. Japan Suspects Contaminant In Moderna Vaccines Is Metallic, 'Reacts To Magnets.' The Burning Platform. Published August 27, 2021. Accessed September 28, 2021. <https://www.theburningplatform.com/2021/08/27/japan-suspects-contaminant-in-moderna-vaccines-is-metallic-reacts-to-magnets/>
520. Franceschi Biagioni A, Cellot G, Pati E, et al. Graphene oxide prevents lateral amygdala dysfunctional synaptic plasticity and reverts long lasting anxiety behavior in rats. *Biomaterials*. 2021;271:120749. doi:10.1016/j.biomaterials.2021.120749
521. Soothing the symptoms of anxiety with graphene oxide. Graphene Flagship. Accessed September 28, 2021. <https://graphene-flagship.eu/graphene/news/soothing-the-symptoms-of-anxiety-with-graphene-oxide/>
522. SARS-CoV-2 Spike Proteins Disrupt the Blood-Brain Barrier, Potentially Raising Risk of Neurological Damage in COVID-19 Patients. Temple Health. Accessed September 28, 2021. <https://www.templehealth.org/about/news/sars-cov-2-spike-proteins-disrupt-the-blood-brain-barrier-potentially-raising-risk-of-neurological-damage-in-covid-19-patients>
523. NEUROMODULATORY EFFECTS OF SARS-COV-2 ON THE BLOOD-BRAIN BARRIER. CROI Conference. Accessed September 28, 2021. <https://www.croiconference.org/abstract/neuromodulatory-effects-of-sars-cov-2-on-the-blood-brain-barrier/>
524. Ohta S, Kikuchi E, Ishijima A, Azuma T, Sakuma I, Ito T. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening. *Sci Rep*. 2020;10(1):18220. doi:10.1038/s41598-020-75253-9
525. Vu MN, Rajasekhar P, Poole DP, et al. Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model. *ACS Appl Nano Mater*. 2019;2(4):1844-1856. doi:10.1021/acsnm.8b02056
526. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. *J Controlled Release*. 2016;235:34-47. doi:10.1016/j.jconrel.2016.05.044

527. Pappas S. Rare magnetism found in the world's strongest material. *livescience.com*. Published October 14, 2020. Accessed September 28, 2021. <https://www.livescience.com/graphene-hides-rare-magnetism.html>
528. Augustyniak-Jabłokow MA, Tadyszak K, Strzelczyk R, Fedaruk R, Carmieli R. Slow spin relaxation of paramagnetic centers in graphene oxide. *Carbon*. 2019;152:98-105. doi:10.1016/j.carbon.2019.06.024
529. Sang M, Shin J, Kim K, Yu KJ. Electronic and Thermal Properties of Graphene and Recent Advances in Graphene Based Electronics Applications. *Nanomaterials*. 2019;9(3):374. doi:10.3390/nano9030374
530. INBRAIN Neuroelectronics Secures \$17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface. Published March 30, 2021. Accessed September 28, 2021. <https://www.businesswire.com/news/home/20210330005388/en/INBRAIN-Neuroelectronics-Secures-17-Million-in-Series-A-Funding-for-First-AI-Powered-Graphene-Brain-Interface>
531. DARPA and the Brain Initiative. Accessed September 28, 2021. <https://www.darpa.mil/program/our-research/darpa-and-the-brain-initiative>
532. Six Paths to the Nonsurgical Future of Brain-Machine Interfaces. Accessed September 28, 2021. <https://www.darpa.mil/news-events/2019-05-20>
533. Neuralink and the Brain's Magical Future. Wait But Why. Published April 20, 2017. Accessed September 28, 2021. <https://waitbutwhy.com/2017/04/neuralink.html>
534. Martins NRB, Angelica A, Chakravarthy K, et al. Human Brain/Cloud Interface. *Front Neurosci*. 2019;13:112. doi:10.3389/fnins.2019.00112
535. Lee S, Shin Y, Woo S, Lee KK and H-N. *Review of Wireless Brain-Computer Interface Systems*. IntechOpen; 2013. doi:10.5772/56436
536. Researchers demonstrate first human use of high-bandwidth wireless brain-computer interface. Brown University. Accessed September 28, 2021. <https://www.brown.edu/news/2021-03-31/braingate-wireless>
537. AI and VR Transform Thoughts to Action with Wireless BCI | Psychology Today. Accessed September 28, 2021. <https://www.psychologytoday.com/us/blog/the-future-brain/202107/ai-and-vr-transform-thoughts-action-wireless-bci>
538. Haselager P. Did I Do That? Brain-Computer Interfacing and the Sense of Agency. *Minds Mach*. 2013;23(3):405-418. doi:10.1007/s11023-012-9298-7
539. Mind reading and brain computer interface technology: the future is coming, fast. Privacy SOS. Accessed September 28, 2021. [https://privacysos.org/technologies\\_of\\_controlmind\\_reading/](https://privacysos.org/technologies_of_controlmind_reading/)
540. With Magnetic Nanoparticles, Scientists Remotely Control Neurons and Animal Behavior. Accessed September 28, 2021. <http://www.buffalo.edu/news/releases/2010/07/11518.html>
541. Brain-machine interfaces may be used to study and regulate mood - Science in the News. Accessed September 28, 2021. <https://sitn.hms.harvard.edu/flash/2019/brain-machine-interfaces-may-used-study-regulate-mood/?web=1&wdLOR=c97F3B6A1-B18A-433D-96C4-477F88B46A83>
542. Shanechi MM. Brain-machine interfaces from motor to mood. *Nat Neurosci*. 2019;22(10):1554-1564. doi:10.1038/s41593-019-0488-y
543. Opinion / The Last Humans and the Next Brands - Critical Mass - Adforum.com. Accessed September 28, 2021. <https://www.adforum.com/agency/6664937/press-releases/70226/opinion-the-last-humans-and-the-next-brands>
544. Bonaci T, Herron J, Matlack C, Chizeck HJ. Securing the exocortex: A twenty-first century cybernetics challenge. In: *2014 IEEE Conference on Norbert Wiener in the 21st Century (21CW)*. ; 2014:1-8. doi:10.1109/NORBERT.2014.6893912
545. Can dark triad leaders be a good choice for a leadership position? - Egon Zehnder. Can dark triad leaders be a good choice for a leadership position? - Egon Zehnder. Accessed September 28, 2021.

<https://www.egonzehnder.com/insight/can-dark-triad-leaders-be-a-good-choice-for-a-leadership-position>

546. Silver J. The Startling Accuracy of Referring to Politicians as “Psychopaths.” The Atlantic. Published July 31, 2012. Accessed September 28, 2021.

<https://www.theatlantic.com/health/archive/2012/07/the-startling-accuracy-of-referring-to-politicians-as-psychopaths/260517/>

547. Schlesinger T. The Rise of the Psychopath and Sociopath to Political Power. World Issues — Politics, Economics, and More. Published December 1, 2020. Accessed September 28, 2021.

<https://medium.com/world-issues-politics-economics-and-more/the-rise-of-the-psychopath-and-sociopath-to-political-power-b67ef9073477>

548. Commentary: 12% of corporate leaders are psychopaths. It’s time to take this problem seriously. Fortune. Accessed September 28, 2021. <https://fortune.com/2021/06/06/corporate-psychopaths-business-leadership-csr/>

549. 21 percent of CEOs are psychopaths. Only 21 percent? *Washington Post*.

<https://www.washingtonpost.com/news/on-small-business/wp/2016/09/16/gene-marks-21-percent-of-ceos-are-psychopaths-only-21-percent/>. Accessed September 28, 2021.

550. McCullough J. The Psychopathic CEO. *Forbes*. Accessed September 28, 2021.

<https://www.forbes.com/sites/jackmccullough/2019/12/09/the-psychopathic-ceo/>

551. The brain-computer interface: new rights or new threats to fundamental freedoms? Accessed September 28, 2021. <https://pace.coe.int/en/files/28722>

---

## COPYRIGHT

The Spartacus Letter © 2021 by Spartacus is licensed under CC BY-SA 4.0. To view a copy of this license, visit <http://creativecommons.org/licenses/by-sa/4.0/>

---

## PGP

To verify, go to [keys.openpgp.org](https://keys.openpgp.org) and enter the fingerprint:

**6EACD2776157FA0F6CBB2014D1A7282D8A5559EF**

Download the public key and check the following encrypted signature against it.

All official ICENI documents will decode with the same public key. If you copy from a PDF, make sure there is a newline between the start of the PGP message and the block of encrypted text, and that the begin and end strings are on their own lines, otherwise, it will not decode properly. It should appear exactly as it does below in whatever tool you use to test the signature.

-----BEGIN PGP MESSAGE-----

```
yP8AARNcAnicrL3NjhxZliY2I60yAL2AVraYbjDR7s7w34hgLRrBCDJJhIkRzCL
nbWSubm5uzHMzbtzJ4JO9CJXgqDVYHojAdULNQQlvZAEjRbaaDWInYAB9Ar5AnoE
6XzfOffadY9gVbWgRldmhrv5tftz7jnf+f8//rP/9F8d/ev/63940v+vf/r5//7X
```



/+f/86/+k/++1/6r+L/4b/7z1xcvrl5HR6+LusmatkmjZVIFF2VVFvFdVrV19GKT  
Vqu0SNLoqiy2VbnMmuh10aR5nvHjo6OP6zS62cZVEyfy/Nu0adlq+vWXf4iu07tB  
NI6ejl5Hw/7wuH98+n30992jR0evZJSyd3T0bhcv8SaNsrr7thfXsJ6/esv/+1d  
Gq3jRZQWZbtaD46OPuFv+XCepgWmm6SLqCmj+7hJ1tG5TDdLYv64kYm9rNI0+IRW  
+SKqt1kRZYU8mhXpl7KK53kaLdlklz+jRZtikDiaZ+V9XC3jKo3iRmZyO4g+pTKZ  
vCwW0X3WrKOkblsmT+s6KuUNlcy0m85dljTZJvsqU8IMVnGdy37Nd5Hs3DZeyWc6  
tW29S9ZlXq5krnnkXlhu0ypusrKoZbRM3peUxaJNGhInhoiLqC3SPMXfPfnPOOFM  
ulwX8hqZ8CrO5CC5cNulltqm5VaewFvLtpKF5Flayza+lz82qfw+1xmtdzUns07j  
XFbJNdXtCplW8vpsl4/Wab6Lyjs5XbxAXl7VMucl/9rG8t5dGlccLJaf50vsnl6z  
THOdIVCZLEt+k9VlZqX2orxMbhfVfzXJq5v5fte9HdtXMWFPJsaHXCn5ZUbWUqD  
aRSySTlJzjhOmhpj6swT7KQ8HjecaNzoFBalnHI8I9e2NkCzxlzk0OVsGtIVTtBW  
L5fgXohTT8EtsZ3nWRltq3LDv4UgSnx98f63ry/7wzPZg2KRbrJENveqvO/JCBHm  
QsLkq+RHm3TBOac1Di6r1zgClcjPmAAOsZlvt6Vs9HqJpMDA0XILHB+S9yZe3+8  
NWmybJuolmdbuQxFldu/zFbr5vCuNGW+0B2Rmd3LuPKxPfkZsS7SIkuVSPLsLs2z  
dVku6ihb4vEqXbY1r8id0F1Wyo4Ooo9rubH38kKsLacF1E0V3wfvrbdYHiZYyyv0  
IEA38sI4333FruRpfCuvXZZIE69S3d5P7ToWeqiTTH6eLWXXt7HcjVq/3VbZlq52  
suJWlj8opOZpRTYTPhvJTLK8luGXvIDf3PxBJNO1TVFKyeoEVC6Tui9bMI61UKjM  
eAcSkh2QoTIQY5XKS19mVd30/I7W7UbmJgxADysrFrJGI2L5XdE9mX7Z5nJd8eIG  
jlq2v5EJD4Rr4soJZ639GcmDYHKxkmhaLOS9Rzd80+7o6Ndf/uk7T4MZTn+ey8nx  
lfpdf8Ks0hwLS+Nazu3m/Pqmf1H+tj+SFy9TXB+eYFYUa/bjXCO8MeyhCRuayPj  
DbYBB6c0yh+3ss6BTqatKh57JZeQ9I0bVialHMeTDLAayK/u4lpoTAAx81VG8D0v  
i9xI0N5OjqLaLNuc91O+l+ewi0kiDBA8EvP8ki1iPA2qAzvGgt0k6xQnGP329dvX  
ORP3lrLqZ2Cospelq5dWwk3/B6kDI4GltPKt60ytu53daQnBQ5CYSjfcKfYfKQ  
J6x5WqQQkDKSydMaTE3+0ValtNLtefElUzZl9p1WGzmUVhbA9cvNWqTC/hpSWo2r  
Tr65lb1c4K33IFWcchHfAVUKP/PSZitsTCYSHH6HW9mk9+CB/XlZCd2qNOcW+cmB  
UZTVBsO6FRjj1Jn+VihZbi6YbV+vPSYoX3NjwJQ65IK32y1OQWXVXLirv3KdNP4W  
94uW8Z2wXGy5vkZnKlcEPP4OVxpLk7EXVeviDEcWt8Jbqkzow+ZITAwvk0MUAioo  
qJcCMJoWvFukWVtkzc4LS3d1elGKowSvWq0fPi67tgQHMmEhq/cjlyY7GcFdfSxi  
z8nXevVF2kSfW3IWWIjbW1sol/ICmLfwE1I9WHQRreTuKVICEK44M2UAQpvdLslv  
5jE2HZIOuNc32+xWYAvZQSM3JXET2rv9m3in23Z++aIHoyd3zcvFrr9IZesXOJ20  
kOkkKU7qN1Fiv9ueyOjffKZRkbbCckGN0bKVzeO1jLkD8xaHLAQpJLxO863jeWA9  
usNy+YSB14PoPK/LnpxcuCULuaLyr9iLV0VhMfnPzm2FCKiNxEVIZOkdpLwcEaQE  
qRLTAbKN7R7I3ZqnAieEb4E+BFQIYPfkVaW6cXcQacQz2y1wE+6syB6ZWc5btM2q  
ONnpwSxEjiaN3Dx57LbWC3BeCDUJl3gZt0nGgd6VwgaK2KSlrmoA99CRb/NKuDC  
3WCfr3fLFB5eJcCdPPy91yoQNqlZN2BashN3wG/CzXEYfUCoFsil93gpciV68usv  
v5fDA7VDzvz6yz9+HwmJr3sgVmU5InQh5iHNIeaxIU0MrBatANSEelt0p9L5QrBO  
rLN/XXRkFE78UMxudklbxmriooQkKCVyMCCabJHqzXlkz93G0kF04DplreuGoMRb  
RKR7/oCNqNKOdDKHrFv8KCYbTb8k4PdGHjjyrTDVRqEluJAcDYkfCzkXNRgm5RV2  
5lOKiQvzK2XPG6MEle6FwDNlGXEO3r2L+AE5YVupMJHZNhimrVWO1nliyvlEMJQC  
5oDtgDWPPB18iWkiNVJcE3Wc0diYUDQ8qRyqlk8SB63Rg58wtZYdLmAtTIYACr  
80zWqm9VhecQDBzAAD0djArqo3YIDbNt/ohYuF4kq8Ilm3shUxJGwPt3VheNu/  
GNeluA1CXzcV0xCPjYyYikBSxqs2F4po1jvBg+m2zjAF/65UjjVWFnt+fXnTz4Xr  
RfVus23KTW0AIWs37OP49OMlqTYckFVYn4h9wZggzY3wJQh7t6V6zpDzgjZSvqEG  
lSwwJV7tuBkMRQWeHolm7bBllu+XyTeYE3aDXMiWNoud2EySvBskcyo/Hh5zgps2  
bzJocGul+qNiywXbtYbYvzhWAgnyVvu7Hq3JaPHj4S35rHgQ65hEW+ArInd9Zbd  
ZVD7OKDMqDa1gRsDLtEbTjD4CbShqomeeBpTJpAZxlBR2WBgboTc41K0rwXoSzk+  
17qO4aTeTKrm33/eGpz0ZCzpG1RsdY5tG19zQRK5J3RuN8cEsus0Wwllk7xP8fWar  
EkBfrXAwXu/GI4HBYOJ2qpuyBvbayCEJKxPco+t3KBxc0C8FHESwpJcDMILL/iIT

harXfQJpuRZ2Ngfuk++Cry76MIHCVCdTeyr85F5mQtRC60KAcksFisgfOBZhJSJB  
7S+55GkFzFLoRw/OK9k15a3qviBLB+k2To+MI9phcq47vCE6IMpTJVx9X3e/ngbS  
VhjfWo4NHw/G2PXxWRTwE9oOIJ+SUEbcXQG9jV5Ns5hg3+/JpGX9WU0wGSAMcFVH  
dUIWdZt6KA2cQagUUuMg+rTGyjKRXuFxFtW5GSmzEOKSPyGFuW/CbAqnByzdp8Z  
9PS+7q2JxN7tPa0RKxEAVekoLfZaE+EREaJeCuWVPYCC8la/DdjSZi4ipN4MJiDT  
yUkUcmkCPeMJ3AoRYIppRFtOqO3Kostqni0lLsLWs7TWrCo7H0Wz9PGGUd4xg2Q  
spzk5LQ3OfOMT0AO6bCRrCoTIG7IYM9XrzY1cu2SHQf7tcQVxWkd6Ws4SFbtKW0  
dZJuBQ/mJAiFdY6XU8XaqQlu8+mEhwKxwf54Nx2qDZGidxN/Bp7fgYwCUqwN626y  
3lWvJaWdrq7OVgX2DUjEKbnTEfjvNDo9/guMdVuU98VJA43k+7g7EDnGpFlhP5jO  
MMRpr9Kq8x5fGummhw96WRQ61oAIAI50H7+ipLJL5rfDhEvRbuYpVR25IW0cPkDi  
aAG8aMhZzytBS4PoAqauv2uFzvNdz/hcJTeGSgwEhJHKDINTk5OojWr8kkOIL5e  
E6QTvcFuMz2Tdc2G3br8RquaKTCylTP7uzZLbmWJT1LSJXkQ7RQ0BP35RbUABgF  
xq0UvKrU7iaaW0nQLQQRXIFTWckDzJ5GVLVWVFX0v607jQk0MqUpUupx474S7HdQz  
y3nzVbW1o7OPnOEA+F0ubUaVH6OJztiQRQtktfYDbqzcZKhXNZAc2RnWWzoaV2  
RyBRyOnDAFc/E9FzoG5FlixUqp9fvBgNZpPebCrAYZVWvJwFTllmTK3mRfF1J68f  
mSqf6p+nKfe4Ju79cguFt8fdMP04X5TAnaVn82Q/1+fnN4PZrDc7laHhT8U+slrg  
c9o3RLlwl5cv20AhiWGNUPjhtSVjoplgl1GmZG5PskE6iMp6A2wn1Pa9m+AjfGG+  
cy+j0uQhZ0MjLCBenEMlaNSOYmQ+AAAKoxnQz8llmZgXsdhTKrTtPBPSbEqiZrBk  
KHnBhkGu2E46Hceo8/HZHkBaGfMhRDakqrJc9PrjuxXJQhFhn0ixwUzSjtv7Ni  
bMuF+9JQtkNNRjROHVSGgciDpX8P5sBQss323u8NiUL7oodmgiSwD/hp7dbPH+NJ  
NUSolw9olUlwMBUpA+p1NorOnHcCWHAY3SN1ZzGMDbt3N+KB/UHUGKGuVZny6bLw  
uhOWI8xJQOk9LzneeDMUVgAUJgPm2TZqt0YWMtOFegmokBR2v+Sc22LhIjQLJVZ  
8FVOTLjtUw/XNzcj3g0ymY2Izfm3wTZoA6JwQakeQdHYyJb08pCTtNzQpXMKLPz2  
mmWFHM5Z9W9GggPi/LZfr+OtcMRajl8Ai+mvyvgr0VQy7MfeQH/GFpGUnaZBtN3K  
YyK+iG+owJrwF9C7WBDGCodcUCkQHJXmSwe5eGJuGzitgrglwwkHEEAj2w5gxV9R  
0crdGIV79Hvo6HBvSjncKm0otbDk5r70X8mptkBR/il+NJWJUF45227b6EkfnK17  
o44f0FvRjnkqOFu0KbkgGw9a5GHgpXol+NI2JFqIRYo7ulGsykzNn6fyfbG/2ird  
5pCZ2FuZpTASepuyz7HSonsBVwGRiXxAbiKnuEPXgrFZUZLCnRNAipPTR2SH3wQ9  
O7XZ2B3DjVW0AMRByKMWeuVJ8ipzzujm92jVpRV8VwjnyeKn7364qKMnVCW5U5Tb  
qwzilGN8Pzg5650eY1ehwNel2mjU7UYJKHuWJT1vlk+X5AKhNdGwvKgBguBCvRjB  
/klkn2gPsfjODSPJSTiUJGydhNhq0H4BY0NGYSIbCjNb+6JwqNMWYRji/SwinDd  
eSEqd5E+HCLrTABfTkeN82yHwBqLGJxCoz4dk7LUSuht2kpL3iZMsQL5S2wDeAa+  
X3N3V4qR8niXLvZuiz3D65XbAO7H+++uXsiU8ZWY9t+mZ3qb88ert9YexH7EWFjU4  
hZp+OjOjadYcTviqWo5oqqWrBH4Yocn7eDc4hVJ9xuP2vzGTlRlWHbFM5lzeSqKy  
p0keC4tedCp/LHq+QGIh1rAUvFfidwvDkVnC6D4jEd0LLleFbg5tSTYIt0XeokLd  
mwoAV7ADBA+xGRvlsppaWvmqllE7vW/OK2+ztimi01sZT0rYINdDbdREmvgDCd8  
NgXQw1rgB+EN8IQlgOdL59LS28UnBeQr1uV2iKTMkpSO933tXiQNPdZmydFhocSH  
+Nn88Rzot6L5ykWNLoViBN0KWE0yhxqqtJ86T9E3tLTBGdj2Wlk6lPpzBJQxxZp  
eB7dnshyzt99EIn3A/558f5vFN8EDV0K0A320lwXgSbdkZb1Anh2F4gROgEF3EY  
EJHT+AOKDxIdIoAhdY4+vtiqEYhy0MSrPMZZyh5hTRmB92Q20cjEW+WEAgOqFVL  
o54g1ISyEutJzxdbtJutmTiv4tFFctGVYNDej4/N3eZxDRMvEKHAv3bzvdOAZU6b  
ErsGdQx3crXiQmWbr9/f7E3y/OMHOudEKOBshsc04g3lsp9ffnil7so6db8gdxEe  
8gUH5UIORHmwrHor/z0YDscCaBrddL/g7ZC7EtEWZWSZCYBKIn0AQgG+Pf5ix68a  
jDXjWGFrh/BzHsvAyU0q81jvFIU5z8otPKRw5VKksOxdVKTpQu9ISjd7bxfBlzcU  
fHGRAhZvVPRym3795fdCv2W7xUH9+ss/2iFAAQq8zl8OR4sp/jut4Wcy80OwjfQx  
DYa0Kg5HnQqRyJrlaiAbbwIS/mMkEdu6xYW9+XgEbL0+C4WuSHwHOq1A1EP9R15  
iR58ipePe8PR5OjoMqtr9b7sjbpSc6i6oR0PymkiSa+Eomq4V+FWK+SNgyjG4FHU  
ytycy9pSLO1G3WuOZJhi9whbnmOT1I0o8kHtyV+nCNQyzjfonKFS73Ds2Ogi0h07U

3qCONwyBNfBq0/ahwBRcGP9ew3InQkz4UFnVsiW8CmMVOHmpHtmr91BRRHHo4KC6  
cVa8/la8HLORrVBHbGA9BAr0xrNv8EjTW0MbWWg/8yY1AOp4JQR7vmRgTd8HUOFC  
fq94SPBE+SVKRF3Ms3IFmaEmTT9vTKUnyOouAJKteusXd3JC8orBcKy2+5nQSGdE  
xdVPRc921l/PWoR2Viv6yTSMpU4dFIV3gmm8iDyBESIWI4wQZEz9rZNN12YuKqiO  
9uXoMlCn99ds4gQPyhRrNylVA4dj4IXh5Di6oEg0AhG4DBm7b3C26CvEFdVNX2Pr  
0qWZER1hOkSpNrGdAIXqVvmJyKilgqi7WH8Ciqp25jpSq6v6j+3UyTcUDzjAvYX5  
CyjVcA/cT6Dim/eX6oX98H4wnAx7w8ko5KmiJWzahlse3+4zaKN7iAEwRbjj3Xcq  
Pjc7wtvKcfnm8YdVt1znJfVOGv3CoQVL4DulzjjJfK4GZcoOesoUYLcyK7J3RNDU  
V5cLkKQfBoxdMEqcrGW1lCETIbmrG511LEA2xq4Wcj91g7EY9H0sOXG1Z5H/1Fp  
1es0+p16Qi2qRtYkTK7eCqOAcree3ITrJblziJwT1xJvOhwezHnipn/7B6+W/t5FX  
n4nFr158FGYv9Ds5kbM+jTpfXGgsDCJAGu/7d9qW6KNQgexn3YAERdNR5y9RTTaw  
FfYcwoAEgkNBsNK9MEzhPuWGAXQqQu3aPxrNFCw2tKLOW7lbg+gVfPdV6giRX2Xb  
LeP3Gg2GIC9l/AdENYiu5B5tEHtEG6rA/zy1QFBBBKBWnL7+Z9w4X6laldbwouvG  
MCCw9lz//ch5hF69v8gx4QapGTg8h39pbWH6cJzU9nGKalyOo2uU+eJVdCdl+q0  
ijzsBWU4Q7HNBs8izYWqVnwSDvZ53qZOWCyJo6az3nB6Ev1U5BkicYEiK1DKN670  
HrA4pEtnt+Hnr0SaVP1PaWbH9IJ2k8phbDLbOJMCZZ43d9AuL9//ZZd3oi6bfZeV  
OY3+erYRQ38rsAwSVt1WFSxgGHQZN/rmy6vzHkkp++pD9ZyVXDAAyngmCIA442ub  
5rOjo5fp+K+ivxKE9k/vR7/+v/8u+vW//HeymBE+ez/C11zX3g/45auRHLE+zAHe  
v8KvdaBX8rYHC6T39cFO9BxDok1XrfQIJBxskxDwd+zWL8CNss5JAXinJaZQ6XC  
p2hk1XkaTyuTpK2cEp97ICH0L1QTNxvoP7JRExzM0CsiQvIWQMxJLLolyCD9Kvhs  
a/wYt8LHd8tk4BSJYcekw3HR4kiB1LbewKSyXeculwJVAKaQyCdgfmorRLo4A7ED  
kOSZXBfPNSpoQUxfKZfUwvYXFcMbGsYvLovITlltegMhjNqCCfDMHRBQwtEwfXc  
dpM2MXyciRxTtmxqMwdABcLa4URRJZ8T5O9I99Yi9Uyo9dTsqB4OtyAHP8MLLjzG  
/dTrUIFxrBHYaFPPOsA0t+/Sw43EK4NhicjrnEKiUCHmqDfZF0WiwqLrFuLcPa2  
DeNsGqzhY0htV2SdZm+pkcSQfokpMWU5vwEpOVAq3uru6Giw2RwCDTdtmaOew9mh  
AMxqcuG4LxAZZ0idW92sFkvQUBbdry3oOfCoOtvDuoyEdcHxES4ajwZkNYgeifz  
igpEn9dAMJTEtXNVDyJvB+lf64bjxfV+RLmEBKG0YQUhu7QYelqzuBQesgO3+2Zh  
BbmD4Sn1uVNz0QmY7NcMFg+dxAzCibXm2TZbOGYeO3c2viGfDPgrPYVNRdRSuW9  
DdRRO2ybnUzrUDTLfCa94elUT2YBFF0jErV0waKD6D1ZMOKMMRfngFRniRDBSohi  
/lkDr1WE7IHozvuelKtCxrGYBgE3dRh66eD0+5sXNQGPX3DfhxLAgYTAfJMW8Xd6  
YsbC8mCCUIY7wyMv7ZZcq3Cz4NI7na7n1BLKNMZAl4xn6AyeJkShlew/IPxJJYJ3  
1uk/3Q9DDmtgVJZ1Kss662x6GuHgwuHaQr3yyKSw4GPGRybmITEnPNOPGAHoYnnN  
GpkgLFPv/WB4Rj18GzG/AeP659Y44MKsv901sOILw3uyYJ6Frt8FpvGLwLCIGKFS  
troGXcOspW4FJV7h4BZMs5f84Mxu7CkyKJNXN1Cn3lmb9gkymZXwYk193vSf3X1  
wlQZmPhEQ84XqSAT4ZZnRGlN3GPNkqcmYu6BNGIF67Yo7DDktAPW3hVgBjwuBPLN  
2xnlW0RRdkZWc/MyDFhu8Oj4WP43/GPBg3gGwWLH4+ju00tHP/LphJ/OEIrPPKj  
E/nfqYXGbwWMe3XWPzgyHQPOj4aj6P0d0nTynhFwELoVBGbtMaZyKzJwX112Xgtx  
PCP1WNFFa1Z079ZJqig9b7cWvV+t0xYvyxB3IUK9C7ZL6PbSndelWXqxQTeDEW2I  
o+EMyAz+63DS+8kjOrdeYDzae7jeiZQsN94tCWSCqFOPv+3try9+cmvBPdT4XOEZ  
y9wOeNDFn2RLtc88PivnaQwIRC8k3z53yEWtycw5gXBt1qlORGO7TQB2FhmXW5Mz  
xA5jdiEmgpXDmNuPLo+ljiaygC13mR+okR4fuHDVDj3tRbO6oFUX09MFu/nEGZcT  
4mRvzzLFaDIEzILGgQgD7wXBrMAeghyD+FeeADNcNFqpy8xhuqdNXXKiEwZay5E/Y  
vV3ZunenJGFEB5iJOOS1PT6pQVSNJfjBDB9E7qUBGhG3mzldOdA3d6H31MzO70eg  
F0p++MKaZN0fWtdkPPQ+pd3ZgSnwc2CU80VakIXJKWVb+jAw2yfmBOwXUUII43u9  
I+9H3lxKw6fshujSmnoC1q+Gjm+ASATt6niH+GlwsjjWiSKUx/fZbr2nK+dTMmro  
NNHmsdwohBmG5xz69OTSEAPKcb8rax8Fw0QZmFFVb1jsnXTgSAMfd2ILYFF1iVIG  
NMEK/7CchzCqKsh3dOFVVRpOqZbtmPZGo1lO1RfFu9nlCZgp5cwGawYg6CG66E60  
gg0/n7ci3OVzKN/LeCNycMHPk0w0Dftvsj8qNfjbVLD88M0k4TGMPQshWVloQs8S

Dd41Nf4+IVvRoSWefhUn62whU0hoJmEoY12qSwoRx6MxoLiTf16Bct/uxVy8LZOd  
d4M60a5IRIMxkThAve7hbu7SxvBfQv/pIl3Gclh0djtvwH8U6iKrAGgplJSa1mpb  
aN87Cw82wFCogYrBiHGrowniq7tsErA8oh4XBByJCghbno973Q+DVuamr4TdXDVi  
yzhSWIZb0VaiZSALBJvnsJdcaVHu3iFjJBodj45ISmNoa+fbKsv5iUioe5gvgnQX  
xM9kFf3T2Pe9sPX4G4kPMvAker6L6C7WcZF2VjU1s85d8oYMDX/ig6FNQ+0S6dRr  
YohxNJF7MJkFYRWGGnH7/pQMszynPeqekLonZ0jGTzug2oUNuehBH85WpPd6BkJW  
PU3ccdIGz/XUj6MigqQZU7xAOR9EI2XC5EeXGcngo5BBBmohUoYKgwWwpgGGw86bU  
yTXtkAqQx6ZhcRRWfH016M+SYoqmPsiZN+FeX4rqP741C9oNYtA90F2Y+mghUR  
VvzchlfxxPt419IY6HqrWs2mv47BLagQXViU5EcYaAwnFOSJD/glFYzi94jnzYtU  
Oagmuk43siV4RKPsfsoxz+ff1j1cXf9PICL6+Qz6orKJwQWMxMsH12FRG1Bkw6m/8  
UfrtcEGzO+erSirBzy5bi4LN4ig6PP7+i3y5oNCFtzyhlfj6hUz/xfXPfHznUG6X  
9oIZNGWpV6YxGMRsWODaNvVsaDqSczCtHXUWeFjd4YA9iNwyXsr2ydoMz1U6VfWp  
TtNbf9zQTXUyWJ1HWKob6VnkJdInmbqgd7hBXjg1ryV9SZrRYIUAZLKT6PXS4xzA  
BHK34bGQ+w42/Lrp+7hmx0HY2sOrOYA0PSIaS3VyrGrA88CfKYwi8h2KRBlgrpX  
61Sz71lwubO2mS1Cs/QrRAVunK8+1sur2RGMxX4ESbsgJvni1BBsqn7FOHdWx1V2  
l3Z0bKIJQXR1d+kc7i1KW8Djc499ENS3J9SIXSOVuuXGMMLIjHbddNwb26ZzxTOQ  
FmCzCv3ZHidku/WAeXpil1tjazprE6WplyLiBYIUnTBhgIOHGd2mcTbtCwLwa5a  
qOcT11RpPyAsxzb4AALMjHSArr2KMxRLStd3n8JQugPDUydXvEjBqaV0iyg/0O  
Z8ZSBTwa2e8m97jpkU32gfz7o3R77a6a2/MAHd475cqTRVcfokKklw+uWSAeg6zs  
WxxkYKdkh7OOLGTbYfJc1cWxhyKcV1W6opWjpkMEo82zOLTLI9ksW+gOdQjchQUu  
sR7vdQ9SbjQpwA2SFha9LoREoTujRRxkcs/0oaDWSmaSxNXpwGefXr03a0qx4M1U  
fUNPFGJKDtFMmAdM3/i3saeg5kmq6ghz0DyVz4TFzjRokBMroufCMM5NVzZw+05k  
aZyRVcwrTdrEpmFI60CYlImfrHO0mXkoV90WQ2im7Ld7GIBXTG9I3A446xgHURx  
GN3vYFNM7gaLG80mMlewIP+ZU05//eX3sv1AFum9QJm0+vWXfxxEP6eatkULSk7D  
xl3KYCSATSuljv3lyOebAMD+mg2g/1BmXRdGrjReJ6c3iRkp+oolCGlqFX6Wwhs  
WJhtDY5w2QTBSjGEW0LFSgY/Uam2X9/g5eW5T26W/Uid29uHTVK+GSjZ34VH3xOg  
M38NuzlpSPFodiq72rkJBDi9jki34BBHh0hzmmsSO+vraAI2hnAUvViOHKvuzt  
YdWsWGfzji8ZAKpgtGeAKAxt/GOGh4IIPNVJrYAAgMZ9wWmSVOTfLYrElNqS5NS  
u9jedjH3BZCBx2GGJibd7++i05Z1paMT6jUnE4rB5yJlcxy0KEbB6DCq1NG/GQ5O  
j42gXBr5tC/C3PCLjDXdA3Y+VEPLLbgAGma5ujERGWaD7g0WKu0y8Cx6HIT9WZRI  
ouZ/trDIy8a14H103br3C1OC/YUVfkrWnlkhub5QK5JtdBN/2Yplroj3FsqvYyC  
VCKCfpONTdkQbrv3EEE6efttU50yer0SIDjDOIR7Xa4/YWz3M3LgBeSp+Um4VOnaa  
qHEPukBINx9yjLmFgXbmfKWbBuvMshQeUVjQrWocuVciYF1gKi/Sujtq/maZE4tj  
/pyiMsHCPKqR3L21zABXpt5C5Gi4la9UsfJhLkUf2ErIVQoEBBPHyeiNIPUmmeY  
filLjatiWmCRIqQUQbfp/BH6wF7ESDqi68VH5spGQRM9oRA78UZ8JqK2esE96FFA  
CZ8frDLKFEKnwSLbiuRHvIKZbUJTtWeaMfe8N910dUYew2+dl0CloM7mGgupvqhA  
tbKMAy1TkjQWECYkxRSLxyz7jPdcdLxdCUuBPZyGPRokflzziA7GERyM75yBSqWl  
1pizRCMtaQXj9wErXXxGtOE3zaqnIvdOpyJbdYQssEztW766Umd0C5Q2Y9yxziYs  
48042wMbF6wc3tk1D0qDfCMw9KL8rQx1tm/pRppUxju/dlScVaxjpBcM5f/3/M4  
J4mrCi4tDUH2IEEhGmAeOgzML/HlkC7qICZm76Njqp0WMLF5cUBXHXiE3bKWJPD  
aSvhjBvD8ktR4pu035R9ZgzBbhEjt81CDIa0+yEQqYphOLOySI3NMcd+XGUOWg1Q  
PbBnTKAreOQK5uUapkvKFaIAH+HozJTeSug/aXPA1XmaA1Sh2NH+JJXlr6sGSQf  
3x0cRpSniwPW6LKiCDVcynVXaEsTMGKaGa2AgbDS1c7FlinlK8n5IYRSZAVmxJ71  
UZMtWrVCmrmvNhsU0DPpYFxfdkwNqVdJefU0NgTVNcTic1UNG72QfUqUyQtjjYa  
Tv8KDmm5/bDYuB/4IB9UgsP1FICUIFCsQtG00EeuRKKEKd+E2cUGIwVmsropz+cE  
BdQqF55T31pprBwlQv82Pc1NH4OnYmlMA+CRCFTZ7QSigODyyzHdejEoWo8IYL+  
VbzVzC19SsMidf+DXdIdshf1ZzdFZ3qbptvgOnFmSkiwXjJQBM4W57RZl2o6QsUC  
zbbpNFGbQYzVt/ROLO3qCy9EnbHemEUIHh3IVgCujrOF/lw2WODOgSpJhFSRCwZQ

8fiwfBYRgd9H+HxTVwmRdoQPw+PjYCOQ6/Xh/MP10wv5h0qDaHK82URX5x9Fc3l+  
fbX3ciY46BwZwpnPBotFCczviYK7+7SW6al7hJGy8n7hVHKCZITjW5BbRr6G/V  
SxStS5ffqyeJvM/BmA7o8bHc/rdAFAeltsKsW41aU4KG5E7vqQ22zRlh8V5pr1R4  
zmEeiPO+nAvtGB1nkHdO+M5ZdKmVshrLjMRgGogI44+Oj8c955s935S76AcE77MS  
RALpL4tei5irUs10daYMLVJhF2++27u1OhkLbquo8SghyhKgRbH6V2ceimFvVgk2  
Pj7hnPeEj1VEiy5h36pqVxQi6XDTXvEWIn+CMphrrGNQFcJ5Rzq+6FOAbdM6Y4Fo  
niwkhsgf9zKztqAaQa1XRauLadDzo8XFDGH/sepiAKjURN24TiC6gpoLtV4gtzBp  
TKjCiyuqiolCkUQLGuycAxrPH/wcxYkY/++kRdE90POOYBsvxh4A3QzGQ1LuUCj3  
6rD0nYzkd15ZojZ77bYXZhUEBTImvZxrEnlcuA31HvEuQOqRAiUHMUDyJS1hKviC  
GnsueeCgzF5YYg/uo1Xepa1QbbCCs7LUSW88nB4dnXdjHtZC7VUZM+5AB2L+i2M  
s+EuMIV/ZdzBJYm5oDc46vetj8xZsUDMnYsLo1N5gwROKwujlWwUYSHhro86kZRg  
zV6QsbNfDIBzzGsX9SRLnclST/aqJMENUPYtmFCo3/OYF4Cw9mtqXhj1URbpvfp2  
1Hnnbc7qEyEUak0V8/OYpwhzGwBPKvxm3TH7Ur35otYg6gJlUzJOxV8d2c+NZm9C  
6LvwGDnH+u+i6KnrMW1zKhKv+86y8+iiz7F6jvCA0C8ITXjWWvSqjZYrxCC2EO2xa  
8w/W67JR6Kg10BDcUm8txR7BOHS67leqW+oizCWFkBlhYdH11bmcwSILVQ05de+C  
csG9jyyS92KHnG6f/WSpqAzY9JUAEmHkCjvgcxZ4CIMDUaiLm0U6USMQtfWkBMQ  
wo43MjkwVXpEi/AVfarTBRGEU6sVNm8rMuNi0PzP3iQI7fQYOxvZ7mDWrK7cjAe  
jXrjkaLI0vzl/uOci5YH6Ey3D8sC7MVua1RCsi4tJopVdCnDDspBiA4VO4dbvli3  
NAbsMyMV1ZYGXhZ9Tb+3SnvGZDz86sqg6nU73NNvxng6JCat0+IY5CHdLhFz9xiM  
MvHT45srI97m24ui+mwRppZzrDHVj07NFawwSWeBk2qdHI+EpY6m3ME3f/IGQ5tQ  
/vN3QuVJvHcpa2qsmgTCpHxPpEwmhyqdFqWygruU2aYQ/A8KNkAjYZKAKYvKuh8P  
L6bMzHmB/BylaXwGJuuT5dmi87hzdRmHFHbrwgxVA3r14se+KHfKeV5cDy5mPk84  
SOT0Ogq8A1cuU1+FHBTlw8NkAzyn0b8sHiaCCiJWZnoie/hYaQgt4qOSpavF4OIO  
63VAa3Y2sE4fpTFQnkrUMSsjsCC6clXQIEzDKgtNUHSny8iygtDluZQ5yiwFuem7  
nG4+70qxyqMtUoUFF1UPce7qhVRWdGyN99mzML0pcfMo/9Bjs/LAj161zvtkrySH  
fEBD6ozd5C7ZSh6EdRvA5baLyxZ+XDk3irxdycBmrHPS4lyq7KKusYrQzDl1sdUW  
pR/Wd3mQhKuDMskXIDsaWIIQg78DaWDV8Fkxdzw+7o3HQTGv2BkVmUWKFDOnryO/  
ERBe0KnmzClqpH4o0Gi1hIjwm6mS1h/jllsYBo93jx8h6zoLISOPoknajZULk48Z  
PSyncpXOG1+IssvZVxuMt1RY8UurUrrQGkusE1AfFA07ECC+3mtHKw8UTKBA19SA  
MkL2dGRM47Gdwf214HeZT+xctJTOwE15m9zKdiPuBozNA2OEEAlsYdhMbdjcFWVY  
HBRQsNkXPqS7trCCgBdhYH84GheKX9fsBGE2CBf+nrgacklqHsq4kWWOhXQmsHkG  
gEUN7NVGi83171pc7woNbaJ4abaKLMhh38vLMv8B5Ks7bbbV8EIS4tfBCJnB9AH0  
VqoLXyB6rC8DrG9hDQoFmcFw3WtRc2bgk3tSyDNYwFiZHV8jhxdaEUGq4crvZ6r  
YgcHwGKgsbDBW6DvbraWuuHeCC8kR1qw7HVB8YGV+LqTphGiTITuh7UCqUgeMLT  
X6PP1wc+GH0d9thjldCZYhluVeHZyTIUKERd1M4QEIZAGwbFoNONIRyrUa4cB1t  
2wJhh/gQhIFXx+kexo5IhbYasmCQgFOWUK+R5qreB/iwQ4MLxRmKvjJQnegk4xOc  
ThD9i7lp3Tm2VVGSmXGuBQ7CoSgNPY4LH42rHoCFpzD3ZtSSEOWLgYk0GOC9sLTa  
Sr9AJdkx8fnk+OjowuR2p1R2HOIhbXUqhHy0zHe8mzKIOxATs1sjX6gaHhg1FHM5  
wnoalHsrabTOu6LWtTAWUcgSYRpAsaKQOXAhJFexThL8iRrzluwwqze+8pQraYYO  
C13NWGGOCnKm1SSoR1HV3xNGqg1wMxhPhtHHruK54gZLUAUEHjr7U7BSZQ1YbWrG  
c5RzC9m4JRQz62EKsg2O+5j6d1YXw4zSewLJtyMsAkspwaVNCyHpbfZUHsA+3Wq  
HYu3UAvC6PFkxOM9eQRY6VvhBQArss8SMCuWjbg5X/kiMDTeaSEYn7C9V9tpPBFQ  
NDmjqaZlw8A5k5rPrz4OZ6P5yHO5e+aCmWOJok6Um00H1VWAhrIRTj1UTx89cqZO  
yul/vr2eQCO6SxHHAzTCJBJeJcF4eoxa9Flfx3Ae2JhnUYWTF1LiikBjViT20KI  
wNck9zzE6KkhunQ1eZw8WK0FKgB6KuD2g/NLtbEQYuFLfZqYu+Xl/6hxUKzov88  
rmQNN5aW0oueu4JsH+K8NgeHjyqohWor5ITJ4VUML9GqqPsuKjsjX/vnkUSdTjXS  
2OqdSy4ds/LseDp9hOCYKQRNeXq5bCqGA7qAJmhoS0/YskHPF92nwiP0GPGWV  
0cfZpCstq6RsTS5vOR+a6RrBvAS7AmTKrdzeWpYm8DBDclVljsmM4U8cz44fYXKd

ctF7UDiSc2EemDMsUUQYfWhZN3CsISUvkuPsJQ62hcVfGalHf0TvF9V19otiu1hl  
77QdI3rgwRab3aZWLNbWUFI/XF+fg5LXXTQNXGichY1Cvj2IXvJDssOg1KhqQI7N  
9lwVHA1nKNTN0NWgc8G5Oic7SV8XBoWQNDh6gXA2reNnpqY1tFmi4T7LF/1mt02/  
VcbH54/I8ME2glUzAgczW6bM//LTRTiRbi7oLEuALZVUZn5rODK01m7XBkiJNwz3  
WMI+k7Bnk29y0m2F1NNcKX0Tu/wH6yCihQA73xIsnDLolInqzVodTCTH9fNLITuu  
oFC6Rf3evqsf4cGPmS3lmePNLmdeHEp0razonnBkjexy0IEA0IGHD3EI+1KXNCb3  
orfp/S56DrfQJSNsEVK8hb7Kfibn+dd1mm00fqYXBZXNVSHj/ZMTVctedueTO7HM  
U2/Pod0iUAYcfgs3dagJ31uGqtEj99naoPCoCoSPe82RTLKvpWjn6jVQ/bhoUu8R  
4te+FwSL7IXDMY3T14NiUyKDAWHHhIOXwLjAlRvK4EKRJdK+2buahuP02XkqgmO/  
HJUPD7IEAaBUKejPa0nDABgr+T1mWv/45Cx6yesXeElwvoQhuAvEmP7IHcR7ZGZW  
j8KukUvBl6kNAtSEzeysWvbM+wr8WXjCuUcWN1kRhonBDTOHkmH5E0760C0JowGt  
J+VjVjnX8oc2hlwxhv20sH5SpokGh3kOt5QxRWMfvBkyWYKp8e98alWfOC2B69y  
Dh97UeD0MYUG5IDf+0fr7ZHjoZSSqzXfGSf3nDYu9PfbEMH7aTE1YSLs8bOwJEaK  
aoHj8h6P56wdYrgzcMGxfq3TQfeqW+0Vw3iZ+Lx2VyEzHH3Pr/dI06luLIWsBeK9  
AzzxXIX8zjHiGmPwIR+1o5qgYiO9C9FLWHWskIRzwK8QBQBnfvhkj8bcOzak9KZm  
LaSp5Zo7e4uSh0X+Q6rLgGRLPWVOGUDB6UhoYiw0sZcTEXgb1dcB9dKT44EdSw0T  
2rhBw2v0zfs9IoLpckJGV97r7F32JslAV57G95J6bUWqsKi2HeQwPHSkmiHD2Uq1  
V4VrM4QECISOWJjnNgBlIvWtvVBrAvksXNyXpWSRpgonpxMAM4hu4qJcZrwaOLG7  
GLVDHNTED+3E0eEF0LdT661ChrPe27Qs36sI0g7qAxO/AXxj0X8h//5Ttgky8aO  
T0943zdZkgaw/DBCTMni1uBpxSq0kNuGxxqCo1iEhrr9o9VAE4/nH1tCT7ZyZAFv  
voCWEkWK1F6tfyXkkOVN5RetV1fr041PT7/Z6jIMwQCtdg5eXz1IIXRnreoM3sK3  
qVO4s9jz7AUjwGCLrLSANoe4vDrvHDhLkRCeYKzvjMblZsVeiWcTHW9fX73oD1GL  
VPikFr2qWR/IskLpsFykOI2duRnN1NYWzt1V6cRfLSAjGIRZyplq2ypleh544TmS  
8+gG2pAmnzn7tpavQSSWNRqjhc7M74zJgY2O1SEImm1C7XB7UONxKChvzieCw6Q  
jYVHWCYC3z/mGDk8O5gwwL3efl0GnRVosc5y7WG36Oq8OeNB3dkqH/AHdc91OT6o  
jKOT7jwfu/16dzbsw6k7/ig0HJp2a685BBGImTzkBZ0TXJ0hsxHqUZm4eNbQ+9Qx  
lbByvl7jvbV+Ynt+1qAEIRpy3Ts6NvzQATWizhznzbhBGg9flufYa62jbHPmNbOXG  
5bFHwsNrmpfrW2pBoAaLedmLfbBqSZZFG2qhDsp3OP2bOFxmGjYA1gpAdFnQnol6  
dbkLtHxwvtSrU91lAdiNRjjW3tVhDtEI403DuB56fkSLiqFXbRChMoeZpdwaQOR8  
lGa0V3PiwqXnXPg+g3sBUd7Cb+G0Gii2SF1CG0tRKVUMyOdHx8OJSOPUfOiN9sdC  
yUiZISPGwPz75bLvbt+ua58eba7hpFovVwY8GYzPCLnPJrs/OP3lIEsgoNx9q/V  
Tdtz0bsw6bN77yLoCLBMF2x/zJaCznGTx9x4WvUUtF398F4I5DrOt2vkOmlXP8Jc  
Flyzlo1cj2ZyI93gp6uL6ALNGfLoVca2PKJjVzBBxXTqxR27xtXe79yIGROPVxZ1  
TjSm3sGsZmCVOSPktFgeumcMR7vEfnb7+MHrb79Hh22AH845fHZtDc+m1nto3sz  
t4DM96afsy7e/gRxaZcilAuQXbiX3Lt1Fv1OlRjKM0uVlmsRr1oz/WnZk7J/XyHu  
unC9mX3vh/HZyd7xQNYxCCMcF6JPjV1ga0R0ZWwstJ9TftCkpVar1jauaxbtdfWy  
fClx3+iTRnhGWdHgBT8PHI5Uzhje5OoBPoS6HCVL/I6e8Gm8ZY2Nm703ewlO8LRm  
uXkiKq/Sei9WpyFqLVovEWS/4lGYHFsyZnIVdTRJ8G3qOaQQUyD/SFDRMCITPh+Q  
SRddxvXX+Haw91dUtWo/k5vmMMmLpHyIrdHPc03kHzyGTEviwvpvHk9QedAtFP09  
cg1PXnddk+VnOvbTh9+yTYHMqlppbs/rLlZ50gwuQQGYvbvwbLmS1QkFgn1UUMI  
r1NXe/BchEayi56E/YR+upHnXewqPrRff9814/mpYDLxTUPfow2C83sNNbtwK7hU  
HKxdx69ev3p69fr89aUqadm81fztZXrvds/tnL7o8uP1Of/jpxv8iiVzW5+iuju9  
fo9sfVOi9KwZBR39oNtu1zPEceY7xoJbLPDhTAaT4xFpdXp09Mjx1+3caZzqhpE9  
Nm7e/MmOtz06JecsHMB0EYdmtBIzyk6FvI8WBwl9t3Ktr8sqt6gn6obxcglDj7eq  
7MzwZ5fl25dKA0m9grGMcZQfJpiZa2TM3sNykgLmMF8LOSOrSjJEKdyXGp/M265F  
6qHEMD9BNyYuAoPrOs5EfYBnVr79shd7jtDDIEuhF8Y70VbUzrkhLUyrBO0UTain  
7aNFNOJH237SrCWHCIP/ZDjkrJMiNOwZbldUpRZ2pmxGRkDLStr9yfYxPxlYXYS  
+S5suunScKNP7Eu5Y+KA9gNxls+psZueljdgPdRUS4Ib0XwgjqHmfJ1aygfkR4BK

qllCnMVgMOSjtQqiwyqriYa4u2Lb2r5BwIGorp1rRcWahTOFsfAE3z1tBOKTseep  
LAmJfyi4zNXgjrjx7ZSsoUCAHI3v4a6i62AyHBGUXclJuyongqdYgRr+gJCY/gym  
3unXrtuli28Fx3L2E9cR04KLD1BCb08EKPWFQvwW/v0Ynqsk1Sb0a5bXgKqmAEhB  
P3Vg18AnYgcTGFbvUxftsEcjC6aqBtSnkRPohQLimQzHvckQvRRErnCjhiOUMdK9  
CqcHpwXZ5zsX3sVcNsRKnsPFQt697xqHgLS8/97CICG2BB156++etaDvXC0ueAwb  
3C/vC409C+ORha3LtKcy7Zm59NT2rKA5tIglKkYALesBo9LG9iYsW+QTDoS4PZYiO  
0BA5IWTwKlOQ+BSIIvSMHwSe3Xf9dsz0pUbFONQ9ZWInMrFTP2FSO2KDtqc5S7jr  
BWyo63YsxVvtPIFzv1UECxPRWlyGq2R2yzvhNI6GcEjOPzhn7drOO+fQ1xYAUXX  
U/7ixXvWkTC59cxDjrx+azRtDwgae/eHf66ytP2Cy/9SfgwXPbsv+dZpJWJmFURa  
9x21LCP4zOpaiNq1KkowitzT3Tj+4nii41Tncy5F71WAYGvUmo/HBx5bIGNQLWWR3  
2aJl6aB1aR2TUR7CSqy7JiJlVzPCL4z49hVXhzalkExkwg2dKVz0W6/JjdbHmVY5  
NuEwu9yekxB35+MPw3Gv6xpepT6a1zcMI90X1rzzvmmnYHrHUqzGGT8F1Ju3AtUI  
l6KaeE5vKUJOWNWK3JrFILQ1s2Fc8glXdyWcp3eXEAwyfzh+KL6TNRxzcRAG+qfZ  
JmaKZaUZqR9pQbKZPliohixQkNW9Z41RUWjfant4rW7R73XoFT+1O31iodVv0SW  
B+y78Cz4pQtzbNhkTRfnbUnXKepDu2bmiX8VW62YHLfzq7bvNh6zmpWMm8zPOUT  
FsWbjDT520RzpBFuZVYdtGw+SO7grRhMxse9yVju8GjmyHV04sxOYc1XEQc+7vwt  
bjnqJnKfSq7KF34EcMKGq+VCbkOhxn6ftNx0K8eqRd+97VJg/wSKdBle8baCFRp1  
cclhVTeyklH03l1YughlvXvqj5CStj90F1jb6zDVWZYKILpiwR3zeKwqF0DDerly  
o1eQIYQaB/EyTtJ5Wd7SQtSXVSG1XmaDwqyT8dn+FBAn6e3dZqJcNi0oGzZWIZI  
hCm423qXrFE02G2y1qw6POHaKtO1Fj00Oj4+HUwmxwfv0Ppwrk+zcuCgJnR3yEm8  
bdQfPXedB1xPL8T1x0BJXRj2RI6FjeTiRAgSslciogVIRJVQVBsxOKRew5ToUFv  
vJArotehbOeNT68KbExkMnN0xeXlLaLqacGuDauyZ8q5/cf7OJFoX9attY2PG2jj6  
t2IYWkfZfJdMHHIHXwaFOIGJ9NjvU5doY0ug8fo1GO/tVVndvFyNHfJKjQxTB9G  
uXwNs3W1eZ4dHV2ntUFXj8t5Y+7TXIPiXGTsXoKlswLGrZC4FWaG0Rfh52ATok7F  
DHkrBlitOh7B8XAm8+1nke08diw/LUmrWr4GqytnbCxHxDatI1Kd84BKTn74RSYli  
gKw0ttcJUWbW1qxylQ9hNZWV6hrhrcxhuodcYf2FR+r2CceZjFvFdllR+r422rlg6  
Kuq56QX96ccekZewyTyda3Ns2yEW/paRP8U74Qk3G6ZvhOUGKJ1sdmplbauF68a0  
8C1grR2Rpnfl7srectepjy/ir2Ueb/YdnSiN1axtX+fydbpXD/Q30VpZU25FFVpq  
R7ChooQu8ilZvS7psuwpl31ydPSJUzVNmNjok4ErxjotHK/yYNshk59uQjUHSedb  
C6mcQ7YgMS3OcjOEihRPbrd42dXZNEikVzsaGmVtft0MjZNLcKMAJOMOdgI/N9bw  
A4gNNYL1j32JtMzrR6ko9dxw7guZUQl6AA4dnZseB3XPosDRdT0uu90lrBPjHF  
RstLqxAzZ4nUaVzVLL2leG62y1vGPYms1H00nqJxzCURbRZylgHliZqsnOm+KHk  
DCsslFabNHXVCR4UyOh28bDi3YM0r6AeW09L7DTrsMNHwJHxXejB5cyQZGLLq+J  
u1WmFeNc49QgaV4W0g5cET5MwQCz8wV9uLhm9qsx3a4RCiPbkl1CEpRh1+guDIOz  
+4XznHrvmxu5K/NATyQSDOPuV66BvdZboGE3anDhaDiTTSy1cm+njNQuz0mtNiqY  
HsZ8HphmUbk6XJlrnN5G7JmVWg5mpahwLoO1opfiWxF3hoxb2UWINZymbvVWgbb  
fiJ1FbeLNqeN8KN6coix5GKhipjJc1I11RmnWNLMOu57Dbk/LzbCMT60GRjBriz  
BJ1VR9pZOHNiNyi2OMnK1edTH3ZX4LNSE415zlki8gtFMKhasJqZClruAgHSBsC  
Z4XI5EIMTh+dWjqJK+8Je4k8sbla4kGkyV41HfXT6Lu1lqsSHKeEnd3OtGAA4J12  
yGvrvVZR3j1aui2hja4rBEX7XNZQJwLyUX8kjQfocEbJut3G1Frda7tiOV4Qudq+  
KA9UB8UmQ6kMbSMPwvQsMuLORd7hfgOmJwK+T8w98PL5a3hNif3lfoCVvTOFVg72  
Zp3mMuRHgRL1OtsikadZq826qUorWTu3WrvCTwT0gT7w6a+//L4jvaDAMdpOsBof  
qSsop5iaQLTENoesr2H6vdNIA9fa9oJFtolqxrAlshhPzELBgnXmul7zEjFqqrlo  
ubV8p5mZ3yir9KDMviqueilswtY+Cs34784/vvorXyBH2zEmeijApB/iNjdlmt2y  
gPmE4YSTk5nVMkGlR3IMEB5UIX/yO3R1TL73PYJMoeDxi+/OoydXftbaQGs+8Jhd  
zsJZ32uY8sYMFnlAJ/K6U5QhduNmQaC4bMmrkavGpWyEhacabRII2WU9uzWH42Fp  
ciNuwQ4JDmilddwOunLZ1Vqxn43Qyh8r1jUyJucy5bNgb1RL0uSowIn+sAZ8HORd  
BlzbN6LzRfts8j2t2Mv8wjTnnTZfPWZ0vhF0Vai+yClDoPluukl2MGNag1xx+Rhi

nMW+JtpNCAZJ5LHAeu4spcnaLohzOjxjSmNj64T6nTfr17XODidLMzx2f69mnr90  
VvU7rgOFHyWm8YuuJKf3+e+Jfd+RVNHDX+vWe01aHoFJxYtr3wy8iyVDPGSQ6cDi  
V4ifUBMWwxRTYT3xPO8qnnsYrNFuuN0Q7z4GgtF9XQW5kqp6Z8Wjg+/1KysW9vq3  
rqaOCyN7LjyB1i7ai7Rym/mVwYQhxAtfk6vpRIFWVuuikcKKWxyag86ReiDbef36  
4r13BhikF3ZdH/rOD63igcm5F7qzdVUP7Zu2LChnidAZ8jIYS0xApLGkiDQciBN  
2qabP6oVYdYCsQyUqAnlPgisCCsCwqbexF+8949sGsHPi25MQS9bRpGjQa/dBG8M  
DAhQxIISFmWAWQZ9tMsjJMsqQ3s58Z11x2m6nR80sPjygGB17w9HJ2PtRuaMDw+G  
+FN2Pd30P+I636IFEd5WTClgztVw9LrqgQzeULIH2xvdi7SulW2mnyIYLs9QBVlf  
8h9wYbRBAFI3TYyVHKQDAV+NtWyM0Wfdaf1BWKDFjppFqBJuSWnAelifNahbGbaO  
sQpS8dYUopJUZiS4J6Ri2gOWrz6OchhuEjx1vAVRKUx2V2oTFgMrkDRmy12IB08  
WtYpOHRM7W1mafZ01GgQRb0xSqwNDyOrxvgyo/bVmcqOU2rWVguOr7rsDS6On/h6  
8ehFpm4mdkULj4qE5/K6uCXNXlstkqycRFvNVUfAxJ1Pa89z2InlumIHRnDBBKyx  
Rm1OTv8zYe8UZeg3DyruqGFBM4c0u+7o6H0RvUEg7VnnLroQoQqr29ssnWsdgFdx  
dYdU3oPxOrOq+Ye12jHNMliXyhTlqufC+Jlh18v3b7SwPYCiCNLJwVv/v8V/fCvA  
ouercxOG8zh5c1AOcw0p07BUw+X59YdzUb9fvr+51qvy/up67wRFAPHzd68/Xr+Q  
eU+jVyAydQwB4Vg+vVWVlclw+G+3WfWdS3P0tbquyY0EW18R9aFWr7Q545tFCFW  
tHAnY4uDHSJud60XqJzrtBPZzsGGrMvGn1/X6QFAANXHd9EuZTTG6Sx6pWYib7QK  
0y2D8Q4XBcst9A5dnbnSgSQL82apEdUHfrETOgq+5bCP036KF5G1wZqjIQAccxfW  
i7I4L3Rw/Y2r4rVnxg2u+BxulpBWmQBE01NuFcb1+6RRy7G5JSOjINzdCj5kqp8  
altblnqhtZ+IYRGVKT8VqCXTmwL20c8F/Zbp84ZBok/7C7Zb7u0hNESq1m6Fl+8v  
LjFfCABKXh3S/ofrC7Kfj2YNjT7GObn3NqcnIXKJwV3NYBezEdidfSdmKFPRJxTu  
qg5YE5sDqN0KBh85eN6j67+8jML2Mb6r29wCJMluCR/enmsjK+CGdAU265vaT1j4  
dlJoxH2e0KWoq//K6Xx//MZRT0U0Tx/CqmXZCXhwUPFJc+8EmCDQF7mt8hISxZvw  
rOjE2H8hjAWMDTbv3JfHchUOHk6jVMecky+bnrvlHfPmlP6wsI6fpx3aaqTM9Ik  
2iceMEsN2PR3DO+4LucIWH3LmBiRsz46K2bJC033gYUzj24G0Y8lwKYFbXe3MDa4  
YgvnVcKPUB1TVOGlrhcwjBnR+5sOeguExcWb+pyCTR2O+Bx8JL4zo3QuxjAPD0+  
7k0Rxi3DEZaCOeVnBsbwuJ8LDI3K7rrjOLnvrBTzxv5d2n+ZV/d8+rLMsgobxzx  
qAv0zKKtwzT/fzMdDB0mFgFzGXVlfr6Hm05gs4S2jDuWlUyOjp5DUTk4N4bGhCs0  
1UIABe7qFmUIPNX1or2gk6BLkm86EOYzyroHooQ0ISaS2UxlnrPox1y0uOgmWd8j  
GI2age6JjyCAoo04zKIEChpZVu3GQyFw26zRLLR1Zh/ulQL8walh67Rh8QnIjDd  
vS3Bu+wt8mTlj11bL1WnEnAnagu09cPpiR09kTWgvFWmlcZTZg3dpbnrfm2tDhi8  
Yii/6/JDD26XARq6hr2b5mE1AZePocW41FzEE0qtmXS6X9tHZolglelwppWSdl7d  
q6wxR12aP0YgmPBijTnOFh1z1j2YzWdk9orToXCCH/Yn4fo/fMm0wMbAda5QRX5t  
6YFW7Jw7I8+mKqKCgCqGHjMCOpeJdBINmfftM YagxekITj+1IWncyGGGikvUZn1D  
LQIKTixyK7NEoW+IHbser2QSYsqxS6gx9ZMJka5qy1K7+GxVQumgxqnwFZwL8V1c  
+44mB9UXnTgNS4v4QBR+wfTn6QgmveloFvkDcAm8lhZv8aFWgY06LBWPg5wPalmb  
eMX6Wjlqz3V87BltxlaFkW9+P5cnRVCyn2vjEtiViY3JGsiz+/Pn99ZeXVMYHf  
2CdO4Ra5stNWJc+5PdcOQX20xlhzmjSxf6+LorxTBekKail0XP+H/8n0N4csTP+o  
H1PNvyWC91zhXVc5Q+cHwfpV0vXwVTjeC1JscT8mVvrSwTMU1AC6RttfMtBtPx  
MEIZb+cNNXtQqDo5qda6DphwQipm1VgvdMxAlV1DgaLXaDKWvIXT7IMrzWQtCfSr  
xNrEaVm4Wr5nFEa2mRvclzJg0CSpP0u7Ngr2W05kUZUsSsi6blaqTjZhMRDFWYsL  
QFEQog5Lz8u19D09wXHTO1eLIsxnR/toq3rHJHuQa/BBi3TKGvvQC6R+p9MYatVM  
QRFEMPPpl47yfalWV2mBwUeFvyXqP9VSe7AgzI0Rxyy7iH8zhyTVUgRWbuDOVVKA  
TLDQLJQyd69yRRCqcu48x8SDcwAR3DrvT05NwdOwSfNcBQVmXY9yG0roaXR05Ovo  
MTqgDOPz7IE1RTsGGG59fvE6CrUVd8AvRGpG79r6lsd5RZgKfVvU5awVUZWUzwV  
vhEqScCzO9o9y1cnXtgybaBRN+xzv3Ci9I2WFbvMtLqSLpmoQ3LQn6CO4WNwL8F  
qSkq+Sdy7bWKpcVlQt9n7nV074b54eYdtAYhH8YwMi87cbZuTgucgUGWcYOW0jW  
DtetFU7TdUxvBsKoeMZy67UeCYBIWZns9hKHwyUB5gbUtO2iw3Xi4k3BpEWpsRE



5vsq0qVdK4vFFnnIEKzp+CCQ4/NiOKiySAVK1sAeFbZ5KfenpKjwepUxzQIOHlwrl  
u372yGLSTmZktjAlaIPEbpdIYZa7Gsxlz2cldqJtftpZ7LMTC4JHCGS64I1PZ288W  
sxWDMY7qfruFuUyAWJg95EDx73LWFFHe42zfatr/SU8xyoJuzngl63dgzyCL87s  
7bovyw44H/Q8fXRxGxR/Cm8CQURZ+dwJbmXdzj+3K6U9S9TXqciSAd9K75AxuDZK  
guEXGZ2ZpXfKutrKj0mROGp2UOg5/L0c2gJAQzgf6GmgTBB4KDzUGvJ9Uz7mliq  
wsaqPJ5s9VZnjcECSqh8y0sm1LGsfZl3QJ+azv9GO1qrUYrxbNGiXEW3KUPuhZxP  
e9OxYEWnhrT61zwQQtu3m7ZkyQ35zP2E7ZbZ7Bjwbrijk5YoGSpyFxiNESXY5+  
OFFcVI0CMjemi/mgao/4MRwbUgUyrWpuaqEQ2kpujV5WYuoKbeFDVwSamVnlSmhQ  
6ELXHb15UJ9LA3iEr0mvsu0Ya07srxxwVoxlIMoH63lqJasqvdM6i6gbisk2rA1  
l/psVVYjIqssbsU3Qga7j+u8vOfEXgkRAJkRnl8JyGayhT0aZpTfuzbr1jROWx75  
DmohNStzcxGK7sr7DXEtPoSk67RbPiO2UcwtTXO33y40umZACyIm5Jo9GlioUGhV  
uKV2Is3YBj7pPFeNZabPswXLYuD6LjTnis1FNO+BV9Q2r06/aCj0KIPyf/BWkT5Z  
HVgjGK+46FaAgsqYNERIUq5jaz1HeWXeJBBChTYXR9ukNAHAxweeQX2Cz1mSY7t  
nL0i7rr+lEooGgZE2CTYpuQPcYLZkv+yFgxE9ZqpbRyqjZB66e7SGPts3Eg4y1W  
CCussVCW91btT+rFaFYLuNtTvllK26p2jV/dJg+L0WpNOCCgYfqwMuhQNFDpl  
lZESbMfqkPE5YgT0YxMad90fzD5hJw6UIO9e0d+rUeosPOdRcB09oRFDXvTrL79P  
v5TK/3/95R9dymTp7DxRjhgDiUq8DugkyYjQIOjY9DfIM2eFkzniTe7HLWO0GAFS  
3amdldQWdGaiGppil3XeWIS4vaVLcnGve6zqrTYzla0d96aTCUvghL5q5kYoKtfd  
kTVsEe+pLNVV07Z0nq/tQJRJaLANxIUbihbJyhcgD8ZDxlgoTUFcsvz0Tli8qPC  
+JVp1ey9yppgCUQd2nTD+2BYa3Ob4kLa0TtmRnqnhFs3e1dTP1AqNzMTSVZOAK1qB  
ovWnQ4rd1sKpNzBZ35cbFwOPQlqFc0gvQbr3rMNDj2pXR6NqcW3vGNrChV3G1S37  
b8v+7rapCsGg2kql4VTqFsTVaKE0lqObQcOl5HDQzTsFEHa6Cm2zON7Hfpei1Sw  
i64COeAsuX1bNPKUS3en2SNz6/pylN38MjpvufutNjX02TMb3GfoTTIEAmxjE6P2  
k0MLetHniBBUxt5Ral3Hbe467rj7blmuFtyjfk+oxqEBFamIjBsvqzclymVNxZja  
wJ0WbnaRIDscScAfL0oHLAxttdYlwK+xL5EpO/0B2uxhb6cWi/YiZ6XbWAUjgUAM  
HOl8Kgc4yojcul1RAHSgqizJsAF3JhpkvZqWH8MGKPr4JKRm4Td+Ab3fU5+b9Dc  
e3Yjq63NNCP5ZWqag1YkZNMMe/jfW1XFHtd2mu90xZ00Ar6QXsGvfc141BdeAeFHq  
uoPGNIA/RTtqGE4NyxRvqNOpuoYV8EnQf89juGc/XiYi8v9pFsHE8KVdBi5/SYmE  
vEsrMZ0xjXXOy6v2rVzrvZeuOI3WwubC6m1qHa1SLVqtVmftbXivaYQo2wyXPIOC  
mDFrLd1NQ/Re9/s4KNttwF0gVBsHTqQ91zsTXl3UstOqXcQt49TStHK+iA9vz/td  
llhgz6E4QyxKbJUgltCgqoi1cvDBU64JqndLY56WRKheiQxhQBalsFepo6u00Jn3  
ghCloNlf2m5FlmY1z1qE4GEgCszjXca5T3lIlvtdT8VSU8597AY6kVTszqm/clk9  
DpLRkMne4q5GDjHrV5HzzBOq0fVY44dp+kgRrQcxJT7ilqHLLVzPgXNzgz354WAd  
T93CrOIUt6Z4cDuIB1j7pTC1/k9yUt5giXBZ1XHpZkdps5+uL+jy8aU29k1vO68  
RHTCIhd83ScE03AJGHXMGERrcR3pUXrCaGvPZYVsojXRtl/FsSeZ/Wg6xON0n9q  
Y3s4kQdyS0ujqL3YIYL1s1ZBqR6rxje0aF5pSa2BH1UXbeSSkHJcNV9fFkLfxDk  
EthvPVqjHaF7EqGSEcc2vNVeoDni0dAJloKs4lWH/krt0alXgH1Tff2d+sFqWZ5W  
9reLcmHndKH8NABry5QJj4QFxCdbXWWSUZiXgC0wMFZ9+uH9y26sLg/Rut2Qp7CQ  
gLWE3HnOQ+ujll7yHbPvfU5CSepaxPBSgkW2WpeB9eGw42msU2OQFwoOcnEykV1  
tliLCF7l5dyllSvxiflUEwxbJobR34MBtnrBWc6w+QyjWGNet3hVctt9oSZQxydj  
DfbUvtRbcqpLte18IX8iSRK5RLI6Jr5ZLUXznaYuhioRSK/AEstD5C4D9jm4tbdn  
n1YwEleVwWUTycEK30BOG4xJ5uJama+wPOV+ci06EWoNIC2zEYheyuQWg9jd6How  
LOJQpqlFQeAflls8W8MZNajKI/GlbdcxluCFum2Yjv7rsVDK0yiQgxeUmmJthzh  
og8xq0atf0laTf1LStHtuuxYMCUGx6nxunPObcusl20pNXZx8lsS18CCYikYVJr  
Viyc5+DpNk48EtJHXYMT+9lrxWCneKcc/gYOfBTEcByXEbha892QCxvU3gVYZOU6  
sHZobo6Yf3DFrieYwTQkxW6oOnahb6JfXxNoga1rTU/mgiZkZM0IJWyyTyzx+Za  
axb7ZpVD1mXnDxXzY10zmGnoW/koubGWEwgWqKEehy1gRvKK/l4QUXz8JoPok/w  
XtwIAEu1iVJRwy1m0Yrazpzpt66xdo7a4AuatdH8EjngpiQ7KIUYfdZWLNvwmVW

fl+VyNFkvaetSBnFCGe90117kdYLSJBR1828czsxlslBNdPg7lmenu2HaI5GwMuc  
t/we98RxnPRLY4VdHIS1PdNj2Q+iZLNkI9Zq+cy+nL4zKXsPIBWcz0dHv/7yT99R  
xKu3JTt2tvMycgaKxmjuK81m3zuwxkAy1MNZEhD5KVungYIImZWOrrhggUgzOg  
haHVWWF98eSw8J/Z7LQ4G02Zam1L6FLv8up8eDWebWsX72YliWRBCC/jFXufJO12  
t0dCH3DjXr/udftSBwxKeEqJSsSrsrFiMQU7qbDoWS7wvfbeKeHMCsBqJj8QI2d1  
alnmed+rhLUZPw9qBMnVj9XgmcRzbVIP5ZQGWae8x1I/EtDiwg0VZ7iZYomZbxw  
2t4YVpTCSmXCzSkb7FjBRjSjPFUuqb92RVhUO6seCQqFY0W5txdcB3kO+478bakS  
koEnHC5mpBYVaPX3+Vx/m8SLYqUIhx5dJEwzIHvB+Ot5q2tDIisecAnliU8I5chl  
TdXihCy57ctHfUFeAi8Ot4MJUHn36z1FhlyZwYdbbZYrinfQq3yzodhQC5nciFpj  
GLR3joOvTLXs7z2MW+mr6eqSL5wzLkZWg3YfzNeU1GWrPmGxnyGENB4rm/tsWEY  
cKNpNnYouTLsQvOyqEezcFOIwn3rS33JVhUs6lm0xtorNkhauEm+cJogicMHFLhw  
bTkj7zgMFHhitk4+OobICXEMldV9IUuwJnv5I9AND91LtW5arbzHDLWY1FOHzAOw  
POeeQgjlVWM9tXlkl6SbOuDQUQLHMKwGruLpZ/hk69r5PBY0tCspoQo5+zR2WYma  
t7hqvQkvSFO0gH2ft4AdPDovdkGEXGehvneFzhzwg6tntUqVrzul0SV5YmMYmxq  
VwyuUUCwWoHC2bj+N53uEvsEcZbDqFzTMIqISmiLRhjOTzRARnrcxf6o1FBXX+5s  
jX/NqhwJBSw89hbkn0axp6gwZwUJCoYeehB06re9tyLQ2kYKPsYsdWitMFY1Voik  
ZEYU+C4Re7xg7zrZYpldu0XCjLxj3ukKmt5fp6uN87cqS3LU2IsSjLctEfABOoYh  
vfDZGOqXEHEKIKsz1jioCcgUQqtFrvsjmhj0Ip5xnQ1NPcD5axZtkldSkrVV4DVy  
3Sfhmag7BpHs8Xfrs5NuNPIPRo+aNCi9HA+zulHcsY00DjTc3yJ2IRj3eG2unJz  
4gGOXbmami40FYymZ3ryEeqdUzRvv1iYzV5eHEzLbIQtxOp6lkKvVXdQu8Dt3hzQ  
FukP3TbTgp5d7bWN4Sz/yrnCe4ldBTmRkoJzgrOL9DmNCWwCG1RHh5ZtSShLRw8  
OnwWHer3UYmkZt/2F/QdrH6uTAPIHgFmNXs7QBCxUqneOPp83KaZxvBYeJ9rvri3  
/85cQZ6gapUbul7vPQe0NuBqA7ByG1XXh5IFA0RnTq2mYqo9kgN/fpGC/MxZaBGX  
XY7DXI2QhTAds02bG5NnaHYRtaF2Z3QDU44loQc3+Cot++8AG4SBOrtlp8B0PhLg  
ZLufpt1pYntqJQqFlwoj0zQAEimFM+L97IDn3Jebj12fe7XdpvdWrcKSzwlB6ab  
cDe80qMaGk3DYKiicDwyRb1HNnm9X7qBpUYLuYnLG32wSono1Np1hDff4aoSxst2  
hbAYMcGRCJvFT1aV1tkM69WgYruetqkzQuQsUnaADK0whR7s3HhW27iLx/Rfpw/s  
GX8GyPlxVmky70VslduxypDEmbosKqoRPUVdqEoPdRm6yR51knmOrMAxg1THEICb  
wDWsVf9mVpjQen3x4up1L2DP3wz7mriBemkXQqGqbD4G3b+FJAzda0VY60xhFLO  
KCwWWIwNA3YixGXXhV6HprRm8pBkrlO3s0BqqCXRIcusg8NTX7+izCrpPlzY3M4q  
aXrQ/Z5tktdvyVKt3GI5SLuyHYiGU24H0c/m7nalFeDKRVwstAokeJtnvPLIOc31  
y8+MLBL21yjqw4WZLcTFU2meb6z9klQdv9O02IAMqEH9GSvTAejV0F1uC2jLKfYc  
WYfeWQZP0cNhrnu3J1amt9RaNjQyXcYbjeVguyo4ArFB/hgXqkc5HO3NhC/B3T9p  
OrPz7vgf8V3cL5Rn0uj+9xV5/CfzQtKT6UR+aZ1dj1A4is1ehFMchQ0H0Xdvs7nA  
zQ+96O0f/veayX8fB0HRCgaOottFL7LsGpk7Z7ttVz//hUzIFZNB3gyYd/ibyfDJ  
ePT9s/Hx+LQ/Pp5MBtjkZ8Pjwfd4bPw0bSvmjnx+mq7jeDYaH41kLr8VGBVHv+tF  
L9EFACU63/SEqNIMDSNkirA7yf69CGbA9mhdnRRqnu5rNAQMI+5VWVGjxOZvl+Gz6  
ZHg8Gk++fzacDE/68o/TYKbD2dOb4+HkuD87Gc+ejl6/H8vkT/rTo7HM9jpGD+D9  
t2kMVK2dNS1WGX31tN/e171mXkF1ly6jBo1L+mXRT1CIY1MuUqz33fP3KHDLOQ9/  
Mxo9mX3/LJ2OTsJdnY6mo6fogTnAQ/zySL7+7qLNor9FFqjg+E+96Hdy2aNxfis/  
tLlWlQlj/Xwhbj/fyEz5Yha9n0bsU8VwCqnSBH33djQ/OlzQQei3xgbWYzm2uw5Hs  
azDN8fj07OkSjag5zcFsNhiPzo6mMthf3UNDxj286UWfss+30fUPspcCoX4UgbmJ  
XoazTQ9n+yx64TMuhJ7nosbvbtHp/q+jN74o+IUMH71mQ5ncCGA4mWE3h5PpRA5/  
Ot0//M+Dz6JhY6rHg+PTgdDy0UymyrUyoO/vYc5BnoxmZ99YFQcYwH3HhrJAa0rh  
HM/k3dvc+anJnt/FhWrYN2xi1P3q7908mbV2ThCPSuLpttGct6MTJvjKFV43zbZ+  
9vTp/f39YOlmlhWDslo9dZkQT/3eo5+O7f3x6HRy+hTc8ugEtw8wVc7wTf/tINjX  
TMMaoZFpUEtVYF+iHRUv8sSxEl3Rz57MpYNHQ/7w/HYb+doNDx5utzM+9jL/vF4  
ODqSi/bdD3/4Xzfp1/67tI6jNy960Q+wCy5KuSEIQBBceAd5X0fvLuQ/2z/8L+VX

Vxvw/M2ACQ6beem3vixXbU4D/W7/3l+0ITAQxEKjScKim+xEJ3t8fDIZHR59sk3s  
WZ6/PnR0hjsFB8qVTOITmjVfozevA46ZBJNQL7bO0Opb5GkKETSInueMrlMiFOYi  
HGh8OuyPT7s9Gw5PR0+ZuclZyPvH4+mRfBF9975q0lX86y//9kP8NXor1zvelgv4  
/qNL3TNkqyUiKX5A+bGVLALe3ehSNi2sZWxl8WmQ/vWXfzivaRwBlv4jW/tMeNFd  
lt47UPUBbkrap72Z5sKzvJquLgzxgPbRAM/2Bz4UXoVUa+DLld2YPOGcHGkd47RS  
mexsehxs02z49M35q/PBENeUXx4NidvelbdrBCpGH3vRKwTPFFn0UohsHS8R7R1d  
9alXwinW2SaLnvein2XS640gi+jcPf9VQPw6+iE4X4XNuSwDtbFY805uwbPoPBLG  
ZG1Ktufoc2qKJyOh2J570r0G6mbkjzYqkW4mjTvkWZZhNFEU/ifyU2aBcR5fPK0  
HgotTPu8Smdnw2l/fDSEAP0dblk34PbwE74RPn8TF7co6Sj/28k/i+i3WFp1K4Dj  
YFHVukVdG/z/5sUR8T59csqLMzsUmI9dHHnoaDh+wDnVvY04P+ZuOu/Be07iNXJs  
9u4xp+IFDvtmxdu0BfHcWOZxyoEdLf7/yzlB4so5p2fj0WisnHMllfu8zBeVSJvo  
Ha6ic008+iAX8cccKWzXN9TJumWca89xXp7n2n7zzfm78+gD/lty/VBZmfR+cgrZ  
NDsd9WchWzg+Hj79LNhi2z3PaR1Pj4XwIUtFKMnWncv5fwLN4z9+jhnT926gmV/u  
pl7ual8EBVv9kDlGxk/c3L/HjsaoAB/QwujkyRk4/ugMLP/4kBzipNhe4Hx6PJ  
Eaj5O81WTQv6Gd6BUPPsD/8MaPlxLtK7+jaL3niYcgkjQQ1VRpvpLrXQpLODdVur  
qYzMH4WzmQGoYbspq2wBtiSLRl5kVcq1aJAWi0uKv1cCLPsf+4YsNfNFFTCKZKYC  
8Himkycnsu7pmUCHmaw3BdPZX7s20LPjmQ2Oj0dHQ8jaayF8uQRvPuCEGIhuLmS1  
z4XbiGkxDlbuDku1JA2o9cce1pd7BsMYbWH0SBsLlrdKm7gvi8x3dtGI5pmBp3kC  
FONuy5aVrVtVHF1c39P8tEZjVRfjfsqUdhVjJOWRqelc9V9oT/GQoM9GoBS5Pf2z  
SbBXlv+efi6KLCcBiMDRDH1EwFe+O58j5wBKxXWQbvvaF1sWFYnV8N35X5aptwpT  
fujVstePR1O8//T4tH+6d1Z2oeychLkeDSnnPeNB3OYHF51/EVtA2ruu8bjyJqpw  
+sGg84xclCzT9NSxvgy01xkpAlwRBUN30kavlHoj6F3z09Hj09nj4dnj0dnzZF  
EH8xjv9itJ/D8aRvx4bST52Y8l/YjT51/El/5jKP4Zn8o/xifwjKe+yBQrtXU/  
7ruchT7DGhHyFbrjP0NsG+zK0Qjo5fnXNPuaRT8KNpkvlnGYADvyjWUvgWk8nn+  
d/EGsZpyEd7Em3qdLSitn1elBnReilZELrpXYrFULxSqXWvMNv06f/xmCIZyd2MQ  
3SRZoGgNh0+GkHHTs7OAVsanT+uJXPrTPoj19Gw6HPfPjkaKN9Aq6B0ucoUeWNG5  
sP4XeXpHSPWWU3tRfN1ttLiKU7D2e94/i96W5a0auK4EwX0sS0hswYqX2QpMGbN8  
BDUEVORxw/gBbJgBMuB/s+npFPMGbhJ9d/D/it79qiRoObfNFTDCeJBXUtY7Ocs8  
E7U3TjcZ9a/to2tQz59Wame2t5nGn6Hmo5V4QBp9bpVDUYcGPZK0mCP8va9enF9/  
jH76Ua4JrG9lXRZITwkVdyH42fD0UwEzuyBvDn4gYqeM2G+p0cJgJCbRiQhgyZG  
guGvswRRZljv8xR9DaLXfuW/dWVYuxajLPVtAFijLlI5qmn9j28Ebe4oPyxiwKvE  
oKrxDdx5QFST2QmJajQ+PZ0JphsBW7yKdwgrfnfNgpmvXSU7bvFbtEH8mFYbVjh2  
8HrvTryLd7Ku6CMI8kZCPIJzqVDB79u0cJgE7IIUY4oj65LTZT5j/++fwHxF6AD  
oYotEoedRgB1u+z2xDPHdwHOvWDxHT2wsydDWfZocjINjAFnx09ZoOdsOMQ3RyOA  
l3ftrRzg5zTlkQiv8L/f99Ane7WmUhh/FsD+owHYiFoXPA5NhTJ+lblpUE9XFzuH  
mRtJJ/+A/NLdFgYbklKwHU08j252xaLyhoEnUxFVM7ncs8khiS3qL0ZWItMncouA  
aD610UVfNI232aIWfP1BkPbfZnEZ/ezJ6YHxxxINQor6j//emnHSIIXUV3nKPkQ6  
dpxVqiPvgDhvJ93GhOTT2bQ/nJ7MBukDY0YiDM9BRRFzQmDAIm/RKFVB2HOMKRV8  
sqwENr7tER7Kt4e7hAp4JXGGNUJo9tsgVJGzJHf6QUQHvFgwVaUvcf0nTetQJGp  
Sj4oOw8vxlQ0Y1yM4+PJdNQ/PhoBG1y1jG8TEXF+K+ptC63tZ5Him7IJN/0cMRi1  
K1xwzin+qFM0FcPdJlKPCxYttK9fOmB8zvDGV1awHjwYNrOVlIKgZ3k+/imzYMNP  
ZITv2AAB/lXa3Efv2cNwRQ9UZOfd4fHZ9CEasaRmVNrQQ8NjRyM1QAg5g1+3WP7b  
rA3OKiCyC23x+tiaUd3WJVNZnxzZYXWK5X9s5y2KnphNTzmBnODzzm5yJsx3Mj0w  
64FEvVnvdHZ6BF3gux84x1dC5c+pjqyA5jph9wNyxUvgbGByefu7h5iz0/leotKY  
3OP3levkxGw8OJd1IOYfG8DSezylEjWcDk/IWgx DST4dy51Y8Wd2m0dyMSZHY9rF  
07UcQYFbQfNhDbjyKs0XDYSG7fUr3l6NfwqW0FI257u9S1/vGYMtjWftJmV9KGbU  
v4yCI7xZF5enfV9tGpmoinrL7wp88GVom+Z0Tkadrdq9OBWjU+n7lanT/pfj8Y0  
ISBzF2rYj/i30NgPpf7tVLEMhVJh5TDPu3Y69yeEdnDpgWICu3ynfsApBLyY0q9q

DYex5i09qRQn0DJc82GWTaQgTukuks8T9in7oXVm/NkZz1iQe1/+cbqvWaza5nOR  
q+FxPJI7ND6CYfK7D2VbzeMVUoT6N6JMVGWppp/ncb2W/4cp7aXs/ho2o/N5ma/k  
U0Ex0atB9LarrbPM6FTar+1jpdxNVqKiSqHghSboC1TKO0+aGJWxRXGyD5FKweVM  
h8fPRBz2J6cPzJJ3Jmjh2dHQBF2Zr/rvwWCa6Of8R9vs+hSpVH0sv+7x2f8L1cf  
AZHxoc1ZBjVlzGZ+eoyDmEyG/cnkJJ76fHT4+PxbCpg2YxCJ7PT6enJ0RgS/2+z  
FAz7k1HcW0jNVxDzVS508IN80+lWpUL7T4KoBYDKOagNoxclMhMNjdW0tkfX2YR1  
oFyvrYM0pWd/3g48f3dhLBOSwNIAjoHqRHENrbczQdyj05MzRdzT8YIAuyMAVlkx  
1vl3QmCprvkSa37+GBN/zXLmdfR2t9muWZdui/6z4B0fBCmXjRb2CWwcmPNImmQb  
euhvEC27gNNER8gWamDz/D10iKjHZnQ2OmDtgddgJoxTVkErxlo0t/4NKx4X0Ys+  
arorylqRHmmdzWHpMGTOyPQWZFNuWfwd/Q7c/420MVbTlaG3s7mR73ha0DNPzY  
1oVZeK/jzR/+xyr92r9p//Dfybmv2gys/WX8WbStEoZSdxj0zSBkAzFcyj8rjiG  
ljTUy+mWvKxpYIEPkT9YkWJaWxb9BffYO7TQ/uoZPzKKE0FrE5OQp4gGtDTOSky  
e9i+PxoDI1yKdvVbuKaiS5FH2ab/k2ybvOvhNWvWnL5fsfXz9lhQ4mltTmE0G5Z  
vCJbFWoissDmOqxaLjvDnECmxd3cva5Qr53qfNujGZPhsfCnWdjUddmk/EjuvSQ  
N0QIS87xChfoO5p1rliaWkpRLarrRbLrWlrWWilbY/se9Cf6azJWWvf+UpRvjdbC  
lBlK7+vHjTcNh0aYRBAYwuBhhJl7Lwd6dW1Qumv3tEu06ptL/CkW0HcL6B9Mvu8m  
38fkYYfB5PseU7vJPz07fXqfzmHbEQY6OYLR7LsPkItxcWic22Pmv/7ye2Q3y9GV  
VexbnpTasw2Brn/WumE02iwQRDFlys1TRhNploKwL2d5ejoaHZ+enT1NOtNxx90u  
wHuebnWq/f2p9r0FSSRw38/xCC64797ApLjmBT1f5+19nGc0D/24LhfxAlf31QPj  
qKuO4/qaHGzGve/iep8iSlLqLORLo33lrt+jHpUaHvDRXztjZmg6dnjyBix+dDp7  
wOjPTibK6Idn0xPhN6D0737XzoUfROfQWpPzHJVOorc3cHRWlpvpmHoZV2tZlhyo  
fPxjW7V3GSxily+ErW5FIUnWkOnJ6WxDjwkW0G3AIWx2lq87IK750bnZlr/hCIQv  
Sz18Xm1pK2/sPzlrXw/g9PHo5DG1hU9TYo+OZ9MjuP+/+xswQBzra+Kr27Rpok+v  
HSP61LEh6iqva94t+nXK23TPoT6wD50RfgQl6ux42j8LIS58gjcfr9//+MI7BsfD  
k9PZEBsw766zHWWhMNhx6zSsovuuvJhYeRkZsBPsh6F62z+mARO/fst+dR4/9H91b  
Vh/pRjRNVO2KvTH4caUYFQMp30bD45OTYLOHk9OnVex8bEP9+mgylixikTtqL/paK  
18/Y30u/rMfU9tWhCkYcpWU4qC0+8xirk2VadOAx7+YnBIZpZ+yp/ZGth+ivcwCX  
htX+6UOV5GykD+h4fDLuy4oAM64QnLsiFyBEvPyk+qRAXrfpPSoqPydEfHNx4NJU  
43YXj6NE/kwvuhYz6ibOEGm3TCT+b7XrT92ZMPZdoEO6vaaTcX86fbiS6cxg34T2  
4Qm9GaK6/tubeB7TisW/XsULYWqqZcqfP5etYKobWr2hC+PjTfwVQQPgAlydPAYq  
e82obMbxz9PaCWFv80KRflvUTkqb9vF+jjv90+uMmvE0H6ei4oe2Gpk/YfLzAT8+  
mgBj/CCgVeb4IUPh3Bro6bxu5rAvXL0LDTCKnPIIvX5/Xi52fTbZQFzll/2QGQ8r  
ZLaz//C/nflu8z5zEplcnsNnWgnbnRUbwKiPro8Gswt8wHjcWm+cdR71dj+EkiUC  
BzrDBvSXseDF8fRsX/e6GY3kJKG0PBkNvz8+FqEn54o4hO/eZCTGNxkY2c+mP9NG  
c4OIK+Nwl8LqEEoQhq/FHVzm6R14Yz1L+SbFdlewCdzh8VY2JYa8/pdcx+FDaNd  
RwRlNrxNAUB+qHCCN4wLUUHOLAONRa33AwSDBdGBmSF236rbLllkBaOwxsCiiP5f  
6t6lt5FtSxMbp35FGGg3lKgMMh4MPpSDA4p6S5RUpDLznmMYiSAZEKMiGawlhjlp  
3MGZGIYBDwXUwegGyoP2rAZuo7qBmrg86XRP60ecX+L1rbV3xA6SOjezunwbLtTN  
l4lBcj/X81vfijLlWWnT0dtnZF7HdoOtvDLpB9LPZwbZae4FHkdunoEPYswHICXW  
JxKGN1/yLLcPkzBekUt5TduTjKe0JNYIR6Vm5O4P6bF+ti7ShOT5i30Zrl6wXRI/  
1MhkfJ7uPqCo4Mtoz324Yi46SxbC7Eq1w7d8V3UsdbEHI5RRKTJmb6LAzAj18qL0  
fnUmhHbPo0Vyyd1xXb+9nflJIF3iNDuktPc2CW9lWjLkGn/jgpmxCGZ8BHMD7ol  
Nc4KIPCFeWgDoWeUvD2qCnnYRqU4OYIGqepZLoLkO41sGJvjybj2kDybtmQdJom9  
GPNfcdR441gv2+2yQUmSjiHW6/q0UND8ks3NNO3R2gYX/XQ1n+0FjlrER1nnJwPy  
e7Rf/ydHSYOMlRiGiq8toIvdzj99jF18DH3HHmCEb4ZRwh1/wCKUjVWV9q7qXipCG  
PXR9rOwSxr7dM65ytGJlqqKCQNVbYVfOe65uhtbN9XGJxPMAI/lazbZvplv9Fllq  
ZhrTkGsoQ6qpJ/YC2A9nOelQpzmHYBgueqtaGjEucAPZlVRaRfftnK02txCCHQbd  
NUjIBDti/TpeQiKnA5HTkngJw9wgU8moOQEFsTx2btCz3AiC63IJTcPBg1Oa4DW

HetcOp50Ynvt1//Bu/6ALpuqZvhjNqVqm2kyZL/vKCTw1F7xZu+FfuBHVCFNyf3  
8YT+CUPyE/ZgHlyBvdJTOqCnlcJwR1R1qN3aXVBcyTDw1PSFHCpdecDKnY2XW6EW  
VZVnw1VC91UymYPrnXHVt6DaoiSr8CrzmgFki2VGPqusMsyjWeWG+gEM0234Tud  
evj4QPLX+L+mmTN79ZG9oPP/V1GE4RZuruQXRbw0HUkFDq+gTdIV6Fu60Dcp1xf/  
XO75MB8VfdK4PkFJBBUteW0pvulDy4QYQ+TMs60cs6OQC43AaW1HxTjH7Nhu22t5  
5KU2odHPmS/4+gJBsXvu1NlIXKsxoOTumMwij9G2hVzodt9zl1sx7KX3KNSNhP5  
RXoUEaJoDeMzTcYY9UzQZAxoUJCL9r7vmrep5deXZfVWyMXxacT0wF4TWr5LVlBM  
hjRguLSSlxJLj/S9KxKRw0MILP5x0Ccvy+ExDDayEj26iZ8inBwEtaxPuv3yrS7j  
u9GdkbmeYiQHjhHmPyEoC4/9Atu6gl/A3Tat2yhKbYi8m/t7Pof6wSHNt/KoNnAa  
nBYn5R2Q8jbc6cBxgvrj0lZyOrOhzYEMaDY6e01o8HOUW3cH5LsmLy85KZReZcc4  
fSzhp4KRQ0qRTXSAqiziShy0xONetEiGQhRPIVm5q8htuJWuNUJl02FP5pOx27u  
QQk8uQpZxp9G7lrmBrBtqBmidajCOGIZGg1wzygShak9kjg+feGcewplRaKAvLq9  
Y694UIU4Rtqsbbv7rbbTekvuc2B7nrOta9pNHRPnth072GtCb7P9fsEN/uLVlWjt  
www6y5dJNCUL1yr9mn4yi8SxNFCCipRgGo/iHRdZz+TVwe++xiZWbusa+y6vNIQ3  
fx6ld+EUZEJGj8lzpNvk3JHlWf/dWTJPrAzd3+gK7zMA4e1/b9m0SSThbbpQh+c/  
ICcX41FcW8zmtUU8ZYGJ+FQ96NBd3WtCdQ/Jk4WLA/39gRSqdXhU45kD0U+mUB/F  
UndA1F8wCS1dVfKQFvayeDe0eJV0tNLBVcuCFsw58N3WRu5iHM9HyktADGiv2WaE  
7CpiqMMgzO8R9nECIB9GuX2+csilvPwDqhDuj22saR2OJskKJH9dv+oNsdvhUI  
TT4C7cuKabslMcptBUAyS1K+yAQigifdEWq4VRCXumZmpRwyt/W+08A8bN/bgnDQ  
ZJdTpABpmiTDnY671+wwHROY7J6NJOBNczfvM/VCSnjhq4T3GsMftxRi5IYBS2a  
5HcjxBMuDaC+rsZNEy7oN6MhVd/ZDXBcG4D4eLYXbGSbF2DaRpbDWRnVrZ0JBZN  
lrdrlG+3XF57yOtlh1EJnM/+lOw7q3jucl75lGJW+EoNlBpIYfg8el1xQYJzra  
ADv9vQ3X79lRQWmeQGhCIAEyd8Us1qT1awb8/J1M0DlmaOlJnS8OWH/fAokLN734  
WRswdGvfxql9j2uy8zJyj5369eFlo+U0XldGDt25PSpj2dUISRKAcuEZFHRF+uP  
UNKlRQtqxLpLmT+/4CcyOTtwuDLG7Hij0BCpUik2LoLhWJSUQLWVq2E6t+zO3st  
n+3tOdcn7+z7u5JN0n0pQ5CsNjvhxXSOjRbbkm2y5DjvkZ0ZmE7uwZnTjpKgKc  
eBqPci3JWb4qWILqs6SCG8yztIG2LMN0hBMozGc0xCVUblUilZ83w/vAUzPqii+X  
03jvOT68uabv2k2/Enb36nhjjRwnZ68FpatGbyAr9NhtMpXmc1jENgstwa/cql47  
3dUs/JEtVSr8tuQGzu+Hp6ybe/6qKm08Z116dCyB9wf33nd2ccEfcjPiPyqGWfQ5  
lfdmrGv5XJaWiAP3lR71AH0vloGoc9E400lvZY4tdDqP6voXI+D43/gfz8JfmpY  
WiQqAG5sLbc7SleKvHDLUFzEzOjCCcTDrJbOiupeV3XOqQtesZBVJUTQLiWNbPqic  
vWS3sS077bgqvtwOylxvsaqdKtvlk4qOkxNfgpVYcQqExoghVib0qmUOW4TjnjSi  
lteilbUq+NXCSoeK9dv08l6rXSI7LsP0KbZ6h3CAjWQEN5TSx68yFHEBy4X+AGLG  
l4h8v3suX16ZnalkTR3GCnWnjjsOKTYycHbo2GTFVfoH/hbAgWSNMhKcjtTu+Xst  
aNXhejFe04ZaZSPEcQLLFmclPo+k7rlUV5dA+519DwA/oK6brY0zShfrkb9QXt1r  
Qyf2Qwm65AKDWZiVuutUw2+BoTIHJKCy+zzbNjjlgGlxSK2vnML3RhTgfs4fKaL  
jsTA34FO9jQl03fp3O21XRWYEXdrgQt1Fu2Gu0YLvgDI7R8LNFQo2Zan2Uut7kA  
GBcp/f3u4Gj41haGUG0/jYteUIWNomiNVMs0vn8li3O0W010EGUaLOsijdlutOx2  
c9svaHiemmpA1nVjD5iLN9dxtErsO5B2ZBZcgo9ROom//Tv78Nu/e8ijRYi7dgFl  
E73Yp6DJb79fWjd9DeAJDsmXczVUBnWcbFY3GsJzPvo9TlBx/ncKowzjREUkMT1  
1eDWL4AcABXUCnJPZaWRvDjwfcf2/c6mccmUrmKkMbyM9hi6tE8y/gnJW3I2b8MJ  
DOVLmDYASDKYhEsrlf7kHDn7OYmNE4nGsVYz08x+WMxpxMT9xXSkKRGjm0ibwPOW  
b4+HT+9UO+c23rsd9wDumlspidPjzzNaV0yhwVNw3L12g839hYQxi0Z0/swXbPuY  
XhfdWzK0ilZ1e0XNpA33yWyIqa6NqOIFXoH+NyrBsU3of0CrT/5cOxB5PkWdptjv  
xkLaAgqbqNGdm6MrEVjIRJfQ2SMolpX7US5+WchvxAR2wclg/mm0nrshNTUsDGW3  
9Opem7FtuaS/YrrHtLiAZ8eLNYCT591di47zuUTnVFD7Pzxl68ZoY2p8TWAQfQnX  
tfcSfITvPTWvVfODVssMcdOBqG+9vNeGkryZhQ8L9CRkeGcaQotYx2QmTtcptw+4  
2BqkZ6uui0nZDEZE7fXgXLMZlCxfV1EJ4aAIYWUtXbFYxV0SmVPqJh+PVembH

KzIEFrAYxKDKmk9I+kOusZV9HqUoONvJ6HLKEGr2bD9vXabi1Xz7K/yiJHzPWax  
nVxNt2O3gsAl19QelCMq7Te6g5FeBAzV++SuOCuqyMp63QTOKe+7cpomZmJWe5  
b4WTcCk6aJJCkTRsJyZnGmShsKTx6TMvLqgbPymtnscv+nZpDc5hJyHkzScjDDo  
b4HfizlpZ0CqxjSBYBoYCEXZQNTHHlqEeF2w8Oip/YR7AmFlmGmFLSFmGqrBKmao  
yKNVvNTIRy0EH/Y6zub6V5b8I5yM7RHOZpnVKC/wOTaBQYY6iY69oYM7uO26Emel  
Hz+6uN3XxSZpBtZe2ZewvOmAH3exVZohYwML2ub8q+/R2TFPlxt06g50Y8NzGnsd  
Ln0b98DZtLZ6gOvGs/HLeoFZgcuDIVmzMLd6J/htNLIGQlpyE0Q6feAlFnmERlsv  
m6nvw4LKw46V1CsQHeOkkiD9yH/fjiHxWzTsZtvbKhV7Xk51jTpe3utl/jiGEfOL  
NqaHqGF9RonuYJf4qhixjMogP6+S5C/qSJ7JWDpKvzKmINyeSz63l6cJg0DxfXa  
qqratt+kfE27WdOu980FvcDwUbJNb8912x/H2OlzdFs/IRAJmfUhni77iFCgnWhly  
RWy6Ch/Db/8nuXdITO4ci6c0mjQeNHsiqkAtO+G//frXZqBR1wKYG6cYzb9w91Xh  
Df2d9/5knUGDcr5ErwJdL65pagcNux00t8VbQxUzNlool+twZjeWgtJ+ZMMu2fK  
lBlZRENJEYwllWZL6+fZ/Xu4BCMartHhJmFFG2f29k7bb9sofynjdXHP4e5mSJ  
HKEROUjb7+9jIWqOC2aq19xL3W0pk6GPw3SUfKWBLVfxBOMworG4dcFesllQ4HWC  
/QAggTayq/Rv29QVrUb9cTSuDbrCnxH4kFTQ5DcZLLxPOJPTSWyddLIMXynyyypn  
vFlsnXVRI/JEv0UqjjonH+UE1i6ypT1l4WGpP8bcCdk6kxkDdgCbJIWdnIXbHg39  
MbMUiAeYwLsCgw12hWRNV0zj8t5ZN8woJ3UVG5laEliQJAjoQjW3bMf4MZ6o2rgG  
mBT2OoxwD6OMUYHDEBCso+glfGJroZ8kWbgEA1fpotExSWDQ6tpYjY5hO0xKQITo  
JEWDSw4TiUNwpGm0zlNOKpWBnyKLTyfkDoNy1L7T7HTq5xe3Sn75ToPksNcAQw0r  
+WixSMgHETYQWII60eSnXcJOSUOuctFPHNnHXlJNCLNyi44Kdl4qkPuyuaOZTp4l  
wtd8i+jZra512a5w3uA4UjQvqI5nfaUTTA7P16H5VjQqSkjliAtaXkPNmUQCihhR  
nf3mcBbCWKejCB+GpgCTpqbsXZ0A++3Xv70l0WkexMpAQSuJdujZJWGUKZA5lkrI  
G0R275gajT9OPBH/vWv69G6r7jZaXtvzPLgffq3ttZDih2HhXlako9A7Dv/p7X  
n47BQzKLaTRnNUPJ0WdKUOI8mTD9lXgtVCAqW4WMfAMGztvCVBmyaiMXrjL4bqfT  
qqoSx62d/UzHqFPza62gRQNmkPmaHkZC+C5BtyCylfkvw8pQtXIAEXu3fws3Vipr  
WdPNY+4qbJdVbFqS0btBLGLyKzqiGV5gljAMCteerkK8hITrerqaqrolusMFaNTi  
FJSq2TxBG4N5jipwTrQgxIzADOb/3ifderuyEE5td+wm9MY/P9+1nI9LEobbfo/0  
cbvT8uq0kLAmjuKvNktDIDLtj7RzWOur13li0j0Afl+zllCxDfgRdbJAKxNE24+  
ZQ0uKmt+vvV1bR6mD+ZPysmWEZrPQWLn81UdecKdZ2wmiT0w4gPlaywB2ROqp+x  
SO3Oey9ooQL6BGwZJ23zrLuBVw8fl3wka3i2Rs/WghoepVn7wu4COpyPh0hP05ei  
sScX20c48zhOH8MFSmTJz7ntv3aoVhlu5tYy+miMcS506bDhilUVW55uTvUGZ5UI  
IR+TebNDXpoKTFGtyIvH4tPdVxBJOjKkQQMPYgmFyAH55jRNGBunU8ialLSCfSIO  
UrSHh3ThGkx8Fk4XhjfZo7EnpLLpTj6msnlT21c2n0ggCsN7hIkBiAr3jOPFc27  
dAB6NZ0IZ8raeM6Lfpqb6YTOzV5gmYWcHJLQOTDFcmrhlMnUEZ0mIKVFHKBRD+t  
MMRXH+oW5evcPwV0ZdY9ODwLM5IEk/Biqche0bLGIJPM5/aWMLNNytUiZF0Takxg  
58di6Cg4hUtGWwefOSdd23e2Uqfo6UHRPOJlwpQdVvWeT1Nucj0oqlxRegH1npJn  
nEVr7J/8gjrWgXISDcE2B/FiulhMVH1VdvhT7IO11D4iy40Jn3EYVbF8cQCFolCV  
VNLdar9vu1zb2u40SWc6ZokDCZmL3rnr+oHfpDnAXuml+csImCkOJF8mU9LuiNDF  
qAM7rNwzBVKg/SsKIXGINofNTn7o/UW1j9D5rW+XvdP5dXhyUmNCfjRXZ4GIAzdN  
9cPenVyg29V+3xEMa4vUqE3/NHdkFsiEdr0anqCpsoVTTuXPlaosC77KC0ujYftD  
81R04dTHC6BGIO5AsEQinG4OdmUK5vg70MmhgxLzq0+FL4+boEOf3AA7n5GNpW5M  
ET5SOSQRHcxtQ240RwdN+LfevDcyTVfxfwQELrWgQC6nvc170LTXQQt5eY/NsDdH  
AAtYvZ7pVr1jk/drrCB72jAc6niYlhcx7M4SmEM9WapfPdub2hIXxUTKoFhDDtq  
OI7dMK8AKI/CcbZclbnjjB36vUPjdsV2OkJQGoVX3/4R4Q3on364Tu3DPDWDQJyY  
Y2vsk4ncMaPx6Lah+VVwfXVR4fFabdKr8d4g8Hc4iEW8N6AzT2ea+fuG4ShOZxxo  
v0wyIOot9q7odilkdJenT+NcGGouc1imy088Hdy22sqpMj2PEqyHgwJcnq37YuiC  
CPNUuO+9Jk5Fu9XeYjzTgVepgFDzx/loziCzPxAqiJajxJy+M+Q5UuBejs1Am98  
NAyTr2q91K+7R7dnoiQySoSd+e9jZugGMxnX1nKUKdl3J9F9x2IpMgBidrwQenK

3alM2O2uw6nMdoucKvqns0PcuJ7nep0GPUozZVX/7R/ISkOojHmCSCvPmREin0Tj  
5JlrDI7T+CVc4JebWsvXhDwMsf7zHJ3jBC2GOB7gRZPKa5HTdoP3zQOV6dhea2v5  
UzxZSc24zPR3Ei0S5snJEaHFin+MoEzihD4c+PMjMBWJQHDA8M77EBtTP+4JYQ2  
Bq1cuC12z4LRtmbd014x9JHza0BPR5xldMmARC1h1PG9RpWSIQgYSFtXr9BEmuyw  
jp8QbbjAQiZLOiZ0SD+Ra3RtWARoQEHujfqZnQH8tmarYRUdSE86skaEnTEKFXI2  
/jBbVw1eVjzN97TS+4FFvgAdh57b8EAC7G+busxsgjfUsDVBjR+lgUPI3nZ7ZyQE  
yFY6PO5d9rvXPIW8+6Ho+M766qYwA3XvCiauHLMXFVYtqkrQgFqnEBaMQKk9b7N  
mVnygO2G16gOefuT0oMOScAOkvBkDzB/Hqwka4BtgtlpoWSQdjB7V7Gzdz6kHM2I  
ZFxYqBRwHAVZEJjSr96xNt2xgJPfQdvvkMXcaO+6Y22nQYeAHqXRcjZ/hl/WXcA  
MKBT6fUx7EYyZCwR70K0nVIZR0hVTEF2u7Au+xvr2y885mFxmguYrpsL/5JkdfH  
NjB0glI56RaRqTDLNv1pWloPeX1mG2mjBLbT2OIOcwyGJujWGu2G79UOaZJMfjdl  
yLE+YmgYHFLzelsDzU1mOHxpKTq0u0u3cwp9V3XjK2Fw13sv/pzbpFG3tp5+RMJJ  
CYEDx6GzzYR2AJDgMEdcdf2XAKhAyv9nE/5aRZOYftX1za4paVpZptU/KhK7Hkll  
WO9Bo237gRhr8txWow5USdP12qR33E6z2XRaDTrkTF+nuc2PUu5seXWhCkV6tHO  
u3HnxDVh8v3Su4TMWKGR0HQ9YVzpeoUuguklfc931ZzeYtfeHUi6XowINpaRFUyF  
HQ354tT4XaFyS7OjCFawnVm6NS7yMKSrBN+toL/IABrFHdrDpk+WGTp3bwAv54K  
o/ELXVSW9UKQNKXVnfhqBq//7gntX9+8Nd1vLji/QfstckjjWaj6H42kgmIM68iu  
tCbHLKK3HOBlijxaFAj+xtjhTJGxFON1tNOCidlrBZX7RdK2TNHidZsn6GJU0KNkb  
oqneoAe1EaHl6pqZ4ZgINLomHUaONLdur8xNdY7lka+THN0wsFPZBg7Jb/0Ewrn  
hSUr02IZ3EMYOF3tLZUdpqkeN16mcQeMljGk1Z/LcdECm2GVML/Ei5ElsXIJaHhN  
XTwZcaz4NI/E0xCMgEcQafz3u0OzBOylkhfS5IFb+u4clCEaXdxdmhk7kw+VhRTd  
aLGZ7eZ2wtEnGQBub08odCGhZ8y5fBmxgX97AdMTXekHdAT0eCobrw79SAN0DVK7  
Ap9dJbojw7+4A8z4BYZQ+ov1gat/lAfL/olvm4oZhWDTfJ4vJ/VGza2BohsquU9u  
RtdCqLZM7ZJBLtjCzbGapAJGTTonOKKHllFtZTVJa983SmeCFqmj834fGFGn4eD7  
GSkej+miphOaoHVy1RdrNsH2IGfY4/biKdPfnH37hwdoxH5VS3E7AMMiLLmVUoA  
5sytFCUzXd9mdp3TVcChTI3kmssVyei8UblW7XbdbQWe3XKbfj0cjX3QKTPJ3Lf/  
4Qm5yvTbPzBx6WIO3oCQnV+CYKI3x+xR1s82wjnkQ78gVkdiet3I1fi3lj8p2XpM  
7+/AqKXbkI5LJMdWybqaLx0Wvg43ybsXxGAVI+V0pBXJZmlNBZYFDIPQmLZo0i5j  
nCeSfsOmWT2mFCCz50slttyLaqG5wer5oG5dYTKM4uzJOGk5j/NOeefrSn2g2BTa  
TuXnmRSWwhx68d7mes+3Tdrb/RUPpnQ6tSlCn+XoMnFhEq1Vs3d5AHqU4mflj91X  
J0xDSiGuhBNWtTaQGwnXy/Hfe4yvFvMo2LLpuncfxaYLyBBp1Bo+AsAnvT3ucfHm  
IS/GDS6oBv5Y/ogisO+IHsKjmtRBF4Mx2Fr1SKv7jTqZussZk+d+9upDr02mpt8o  
ilzARP+RdPDLX+XRCwMXu2lCvujGUF2xDfKB7j2zV9uaxjrTWWVWDBYoolW0Nr1vQ  
2mVWxo+wUnF224BiydmFgrxEgChh4AsN6CgZkflAP5/fiUZDL+EF1N+gE6qutycT  
9143L9o0xcrDzSxVwCERjFS+zKQg5GbE8A67GQgMIYZSoHuS4Rwp8AIXoRp3O3XW  
Ox/wuSDZ6rRbtTbNzqu1unvMS/zmw+LhGY0mfoH4SRHBWzAk5jLOMgPj89ouSNjv  
IS44f0r+V63IQJfJ1Gyk+GOHXQk8MuY+D0izBs1gKx7FdCVuG7Aqx37Zc4XfLcqz  
8RRZ1SMYakgOkApPOMWR0OVHFO3K5GICiGlazzZ6Lr1CMtcJNiHYBsdC4DVg6DFj  
W4+szRnt2iqyh/HsObSulMijP08T66iHYo54Hlrf/ifSggaDjzmiKlQNUck0Cbkv  
5X2YysGWES43sEMdVDM3PH8bL0CbOV9qAw9P0HihXy+5/cOAcUP5bPUS8ZWtXyJw  
sJEUwCzCg9pPFmD0U3HRfjjGeBnT/D1L6P3eGrbgOXT2XGZT60fxBPmG+OkxYu6Z  
lVr5LJhTvR+mL/zz2S8MCngQOICGd3Q5ZY1DPNgc73z3eA+4PH+heozel7haW2HG  
zgG5/M42ZM4IM3Y4yiWUZ/Ql6ov/XCZzXLRfklokXWmIMqRIMRwanXRUIVjuwxl  
Pn+uYYYPaSwZznDGazX46dSbsrrJPDfC8GjYnKUtQyRH5L7nK7iFf66Rc1ZlvVov  
w3rg8pCROcChxPprrhxdWz4v7LPNK8OhwbJSG16C3OaQRpdgCRflsW3laLbi6fE  
uuXiCqE+IExtYGSfDyDjdyJMxzHKnxZ0ENK0lh4ZyTxLzni0draGI5qTMsc/Zmq  
LuKAQjwnd0N0tvO+0QKss93u2O1Op0ZT4BlpYxCFmYgfwMQRGg6vpL4yWtQBghpj  
WGS41Lc/l3kSXKH2KmS0ZLoRaGwT8vWarEis9JwaGF+uGPqtBb8dRlf7JZ2m77

U/QIBl1YnYs0luJaFy1ImLXrMlzCl+gzOwKSzn1Tt+wc9/718V329oB0Zo7WGGbQ  
JGXDHSFV+OgAvOOincyFnoB1SBY27VV/Qm4IKI/EKW5zxNEDWoVEZ6m9G06jU3/U  
9J+IMrSQABNuLnt8Wgmj6TMSVAw36efkMtOKnMBuRniDxnEHA+Xh8e3vrAu7j5/z  
r/dQmohOht8VLMY4kzjMokS0lvQ3mgQafZp0IUH2e10CO0aTjc0ugS2nza4ek211  
UzIGHhnqfZU85MhlyF6ouoFp3Tus3LOiVU2qowF/8sRIP1Sl41Wal5kNRDSI3e00  
/R3UA9xAxLFbzRbl7WlyDKOOJ5NZtCLb77jL1VR/sH+G9YV2JhE2bcu22TKLTVKh  
cFUijnw+ylZ01Z5af7oCa7tZHfO5umQyum7LcFe3+tWh5YbLpFkx93z7B7pcJBZP  
S5YR3KlHOAecCyHlowjNlbPpbK0zFTiAIMGvHrWbDUTJuz+1q3IfFUZeWikYhRwk  
MibCbg98U14yXR5wz7+twN4jbsitlch9hiZ+eY0yenc34HgkiFOoBIY4m9nfSB3  
dH8z+yxeFQHqMlsZJbNnCSwqga/SNUMI8Nk43FCDx5obt4isHUXs5KYIndyJJo2q  
WJPixfF0DelVTi6hoqI0Kvt04erx4yirBW7bxSyhj48nkdALDMNZNBWmjHWWJSTT  
8q8glQgzAF9i2qRO1pziTNaZKfWcyzdnMlkWYIOxTyJZvzT7sRvM77TgstZXfB  
ezSAI8ngOG/LNFxn4Sge0Q68s86l1R9z8qFPXrf8E/KM4hSikjTkmunQrpa4U7h  
cJdqE7lqSqLEASOaQr6qzH6oFtL42PEU8fAk/R3EFkoWmnTBXM/baq5XILbQEIKf  
2GPAzJtByPV4XbiaozDL8jkEezcN71HN0KWrrFOd4PUPs1k4JRUDCZNkqli7AE3g  
DKOfCqCjet94CYosT3Xi86Jto67sWdd0ye1MZOErfNFKeX5B3V+rZQVpHUIKRdzf9  
AKR1LtOA3ZEJLpr4KnyYcsDylgyCtEftlovNkdNh/EpjMc+z+ha3t/PFP3KraYx  
1kBIMeF3k/Q4zDHRb03bN4tF3Wajno7Hc5F2TdujQfZuaahsNUTk6KXWxa2cLDqG  
UWp/iuD4a9tPkcubybMVLf6YTYI7/FTGB5Eh6TAGxrc3qRAz8tkdu9H2v+47zlvH  
8cARQMOAffApTCdzKX7s4RaCGuSKxnRCq5NI0wG2a7kz0zmgIUWoG8YORxlylSwN  
UxcZxMCjIRjFdp5PW+YHrY4Hn535r4Z0ope0hGBZT0YjxkL1SBw/WReHGyIPIIM8  
mDqv0W+//rWs0rgcWjUqXvabYEwUC0T8vLKqMAVSgmPua6RyDYrTeazKlhwfGXUk  
HNFryUzjOg1cNDJQXRt6movaa9hit/aVJuuyTUjfbB2FHMx5BHab/oC7RcTz0KbZ  
T6zLmqGmhqJQTzkPRla7Wn3MnSdtyZQHhVOg0yYGD6qUt3dnL9MonmOd/m1WogW4  
iOtaeVQKS4K4XMkn1Xa9OqrytNuFWbVldjCZ1iG9EmcvKEQLra7dR9eyfMyjl6KU  
EsNZWAebjTIRqJgo+xYtvwxGNpwykQfnqpBQV2FL1i/YTp4hNOzppjdlnjHn1fVq  
nSweQvs2WSRWHwD/HVSJLG83LARuQsKUG8zIngBFVJAXAk5UDldsXS3Of4lHwgi  
py2Lyv5gn2OugJBXWaedRn0ZzqWyv+YHNa9GErrVovE3GFVLxuskoZOAeplcDe9C  
Fsk3M7psS/ISbxCQeQrnDCjqR1n0BFKfmjR6Ykx8pY8uLfbWKeOzUymblyYp1fYD  
lfarBxVMXmm6l5sXCiVGt7xq2Z+mYgKT20EjeI2KCSG+Rtv1aVklcL+cLzPwsnZP  
tJzoHnHvWpWY4jaA4yfG4HbRNCOaoQcTPDEzQyaYFXUpfvv1b7iJQKjXpSB2QxUo  
cwpZHzl0dslZyJHliUCA9G/CGz9F3DztCoTxkh7mLKe20bRxp080117zh+HiFk5P  
rVg5NTxBR+5k/KZ/vi72VMusV4curuo8SziIz0n89QkgDTNxsMmH/lyBEbTVnEpn  
xxmaVDGZkg41TdWobGXA02ChuE9n8QM5Tc+qJBQ78iTR/wF3SxxBhNILH2MwEKG7  
4wJZrVwWkBsDvc/85tzJwv/t1//95uytkjUqO8+cVMG+Bw5hH80l6N/OBnx0nAZM  
aDGikUjvX60XD1kcwUu5TPN5vGDi0buc9ohv6m2Uwti1SPaAMK3sgKdnXoCsNPhD  
y3QNsgtVVTc9zO/5qzxeYNbMHAcLUftcllwkSx2XqHiWbvt9WzptTnc0EWT0m3b  
XsdpBXZA04IdcBc+RZMQiMWT/DH0wi/883XyiMg5d3sSgOCHSPZkGD7ID3jqrFau  
tnbKHsqJS58qawoU6jL5QqcpRw+rZxIE5KrSrK9X5IPHK1YkkzgBruTDR/vq+Oit  
pDdKOADL4QmcGKz6a8taWk9M6sq8HyKTgO1LVlLpwz+NzCplt0XaxjloV9vLiT+3  
109TvGpAQZEpwzRII0k6AUwsSTJmCrgFJG2BftrkzDEjBs30IURWpCgD3LiYxjnR  
pQ+QJGIECK+J1vx8uJklemErTPWKDMRkZp8UdERcAsni9oERanzi+/ScLvfwwX0X  
bW7JHbfbbsWyEbx0DXOd8zucMd0SYOqZ0uwoEpakX6Zhgng/+cUoOZ1oJZMstDih  
wbffvbnN3kKrfApJen/B55lyT0BeCTniq+Lk6lxxE9nCzabmDafINW3wXzj452WP  
E4ocmPxKWzyNF3++6G8J9Z8aX08jYtQzHXTSfCfc124ez9iSRknfuE9zDrloZAAG  
wYsr3aeWxVZoFfnQbnzl09F70SrOOfOmvhIB1heQdktVXie706HMBUAL9UsUzqTj  
CeBvaTgakZujCqHQDUdqTwpYgBmhQxleROzNtwdk4tvVlqJOq85JcR/lqfSgC1ff  
xp9ltzMZ2Un8QJ+xKSzLeD/MYb0AdmU1CjD4YIKrIQ2gTxl08907rNko0CyaObvv



44c8jerleNCz2Mg/jNb2zvHYajys+a67R2f2sH+rOOfQCJksqM/02e5nOEKdoLPH  
MII3p6kUvx1dl4ikXVO00IQzn6ksFwLf0gMltNOlxqbYnXRTzU0oc7uNgo79piVl  
jWeuh+CcVwEyCJR5yl2x8Y4avaPWPGze3wb3/SI8RqTpHWVVGPhZ8J/SUu4MtMXj  
cczx6xJ2QO4C3Fbajt9+/dvblMoniQokoMq2wluz4y3EOvjvLL5XWwBQzoP+kXEn  
tKpm0AWdtZnJwsbAVfwQ8peq9rJDnH/+GbZY6bM7BxFJnGbbMSOUIDD73nLp6hebN  
LVDzp7Ug96+OkJ1P8ePP52hLAMVA409pl1TpxAyx/ILypeq/c/95jS5U90+thDaa  
N7y0zoFvENOKmbyIF5nC+js+aylBjmUZnVnrkpTO+Rw8IBfsGOiwTPVaMwYVvmghy  
o/hrhcdMc8qQmIHTz+mjrNjdSaTfzi+wss5gkOBFdXC3uAYc773Xau03grcHDS9o  
+jb9WylmUFwDfc9pdll2vWGPI8hv/pKMIGRZelcgME2t7hWbWtEzqd3xNH7Chpx/  
fAf9Qnf9wbpAiez4KYUcPkRjhrSwPapu2Uz6IkdfNzNvvVrY9eD7WupKJmEKpr  
elhCYlBXSfoF5VvCJQ0Eb6m2s62FcGkh2q19ny6j16KLZtO/FdonvRAo/PFbjaZH  
Z5E54HrJF5wwsjNOEPaYPETQxDs68A4MuXCu5AJYRcu3AcxF84e5iuwjMoL9ynH9  
qEEwR7o1DpwohbGhqSdPbJQVj/Eq0bnPYG99WMSMYxayhu4kmoU4YmCfz8DQ5P6L  
EJeSavGarTotDld15QvrF6REAEI/s0+FLO/I/ktOkjxYV0hg4U+39i+6W5B9WCuD  
5Li4wBJxUzQatrq+eln9fw3dK+TveIf8FZAzR3JmwA5zYzSkGuhCCdHF8emJSXBZ  
VmaBJGwJX3smpbK1otC4KGNtofe0D9CRD9CRb7TZbXe8erRSZmqj7ZF1z9R0pzEc  
YuviBAiOMaCQ1m0XRYfok4C8HuJvScYfVWMkSW6PP5rxKV15m2SVQI3VwX1ZtML6  
HZ10ULrIs3CkGa5vuGt5wfFUTjHgPqEGyyD43Vv1UE/O8WsAtDP/3KfcugZzDfcF  
PUFTU8D7ucnOEMs/tLXO+hMPSY9h+4IzHeSKRAsmZS5FY4EwElyqltbPkYKooq2O  
hINMwBUdFt5sw7QqsvDs/oCHhU5RMsvnkXmYpGMO+omZW4zkkqmdVbPQDgjUW7bT  
aLRtSAQmUUc2XyoYtBX+XwWkwagCe2mMgwYIG6e7JuuSOS3yb3+fvFh9NMxNH779  
I2DZGUgjtqdwAAAtAxZrfFeGtbK66PxT6tSqw+uEMxkQ4Y+0kB7dhK4/L9uxrcqQ5  
uvJqXRrqTnzGgd90Gv52VVqjLi/QxLgoLebEVQ9JrnAZju1+TIZO9ExW8zVorlyv  
q3zOVv65pPS5JroSMiX7ssAvRssY3VtZEELmq+JjuJq4J6B9HKbIIBp010BzWtn  
o5+DQis0a00yt9vSzD0e5YvJA/lcp+YISRVk8Tx+Cnk7bn5nbByG0HAK5XFnS9Tw  
lkzI9zhUvLjYDPAWxHbmN2KwG+gAdwV1K3qfgyXkOIUqsVJ/ntX0Ldl/DeRgiRf  
CpK2W9lvvE7TZxsp5kKAn88hI5JYRMMnUuwwnG4LF72c/1DP/1jPvwtCHrbZ7W5Z  
zV9W091Kl2pE68cJKRPVx1v9Wf+Vb+mg4KGg86BOyHkB+jAJv1xwE7WxBJ5PtoJZ  
LrdJ9wVZ6fntFqYMy+mXafwMUiIYruEDKih7xXGMBa6BoEoRXuBbXJ5OjdOH304/  
o9fVRjv61RuRS4N8VI2HN+mLA5aLcWq2nTbNt2xjnDejic4TUy8elqGO2vrTlji  
QOxtXQ9qWwl/czjQr8BQsgzdWEqLZjTK6i5CUstTlevpMK2Qh5Jr3wwBdvz66DGs  
h9GD4zdoSlzCIP8MxHwxN32/y5IZFvgj8sZPa3bdSjcel/7czhB81Q7dQIUPEaCb  
QBmOwTMx4qviqWx1TqIlgk478LY9G7dVV6/QVDzOmOb30RMOwIAEghCb0FwyTOYU  
w3FJTCAyrGWy8CXqapT3yJkxJX+52oxCA7QBTNdochtzQA7+7NxeRA+yMCOpGAoP  
sGP0gwrsMnWvts1lrk4iafejs7AF0xLinYONnqvjset2fPIgOhKUmeNzcMuFhBb2  
D6mOCWNXy05LkaYqqVsxBRZ/VNynLJ/dF6IH9ISaIOVRYVksVnKDsACUK+Rmb0Hi  
dSU357bwwB6H6KTVCLDMYUxeUIW9zqjiB44duALNBT2KimwoNwEsYAgGB8RCAU+s  
BH2/6dOAN4kkuyX8z1x+Y7BAO++bUouy7jAcwr+zY79hQYPC+CCRPmIOfavwjnT  
7XNVVjp+mib3mQHKZkiKNdO9zGm9uYw1HCs2Zy5sNeBVE6MxrYG0OrDCnMR1ti4o  
V8PKshRNq8m+HvZQUJku6LvJAtvDbR5bLc/2q1wHDhnY03uv5nrkntLkmhw7JwGb  
cLeQYRTfoypxwur2S7K0Y4vzTGwFThJlVwoJtW2Oirng2dZOvtajdDvJyiCKyddR  
7iTDRBAEBjwQ1XO6QrRmLerhPv3vbXX8o3CEktkmjZ5J4ZPF4gucZtzzwySazoXP  
jt0eowUZEhux9D0jy0QFZrICDWN2MqmkfgGVK/Uk5wNUt2uFamKr2Wh8ovAjSLoq  
erjffv23EC4cnKD7v9HU06KTRYauNjqdDT0VbKMshFOYDddrNbds646vmGPdoNGO  
ce1gMfzn/5vucvIc/z//IOy6mzSaklk9RvEs2RLqhbLkgZzbWTznBiLkZzNnY6bZ  
S81cvSr92mG5K6u3tFoXyRlKyvGbohXa5KjSK/atHx5YyT2b5HnVhKyInxTKUAOy  
5vsdpy4wCTocHbxGE+9wOGmaMoJmEE5HZNd0yVI6nYIy4pgOyjAh3w+rcJzdC0VY  
X4AsY1YRTIdUwQXMmdWwzHIVFCQFWaNUUcPqXdOpHz0iKq6QC9B0g51daTkp2trK

iaoC27EwOSEx2uSydY/Z9nrkJ/6iYgSY32M2ClG3KX/6g3IRz6St4a39c836IN17  
jLyTIX5vBietsGQEL7rmzAXLS3fIHg1ICjtZkc0DBLXJpwu/vkWnr9XYQdbs+bpP  
p+PbzT0uKX4jNLtCFSDSP5h9tlqR2/1kQpYsQkdwaNXRMXoVnOteBWdJpoKnHMgK  
OXCaIVWHq03eL1Ou//brX/OD5xvNrUzcACfd9Lft3sA+U0EHyixE8ulxqd7BjD2t  
Su9klZ/aeoQWg1GkUyYi+CXnsPQ1yeUXQ4IdbzC6aYluaYe2ike0QJulNXTyBl/j  
Z1zsJfg402dd5cjYyN1tuT6KzefPNLjbRK4XuA4JlZUUZBvPkAz4f6rvK0DoD3Q  
YK0L2LXYL8A1R9a1fVcxAfaqgPzVok5cztKW1KZpb0onU1VjmyZqCcVWOQQN2kCB  
7RYQe62Kcpp00HGwGQ0pKrJ++SSNcz7Fj0/WH4CBIsdubp3dcl1RLNBCPZZnBjGR  
gT9KBZ2KitOKMjEcrl4SPuQzbnnPAHnWffhqMDluWSjBJLYt13fDao2/WM4m9cf  
78OR0/BovIFY9WOASbgDPU0e6D/Oa3TTFa2RYaRgKbtH3f7d0PXtjVHfy6jDrxt6  
Uls5jFVVMj6F0Rw36OLurOx8ChJB+tAFGforP3ILXzl/6DRciF+OlnJbreOmRXy  
OSTdGZJ0U3KSDfRYbwsa0o+7hzl/vOnE7KVRDZvknMog0ug/YwNI2xgVkfB/ySU  
dCYaEsseua22HbmGedtqk6MKW17JZBJkfgNSDEYISjAX1tUhNyVbZCvwQeM3kpHg  
Z4AWPTX7SW91U9Cg05VdclvNaA3I2Zozl7qVJgnODYhqQlp0BnkbPFllmH0TWWyd  
X5wfmR0bV9yucQt6TPrzWpdatu/vKHMtsMcduu+YNWYLU9oNMu2yJ2k1N+RIFINC  
9pL1rLJ//VDJZ7oMzMlC4GzG3T1iEwYN4TxgBUi3t3VwC4EhVSpnxtreFDFOXCE  
ZsF2hD2MH2bR2G7zb+jN/mrRYbNiXGzWbTq+jwPcYZfgmWOC3WXMhFQWAtJXCmVi  
5sRI5bpJJ2OJPOwoLrnnikJdUPiTDdE71zqrZgX7Lp/lhtNyzVvV8uqPJMRj9Zy8  
vucxnd11ksZFj4AHuf2DaJ6/vMRo+s1DCoXlxBiacZ7Mu88OlnKuyDoCvPFSeB3L  
hGSHozu+27B9b+v8PJHalRuZuz4Nkgv8ExjiNFlgTrLx9ImkN1ff0h+PLRA3aTp6  
Xjl4U7vHm2Z6GbBx35RSimMqe0k2/7T7SHajhIWjD2KHAqrQvL9lCuEzQctIfy  
XKHuSXLEvmgXQGIKpu1rKe7lI3MBrNgz6pWOayqVx3OjraGvj4xqHfgOFXj+Auff  
sA6CYckUnh/cBrqVevVwBy76ibnNwLPpn86GU/jleFSn0Uzq32Pyu6tv/3EZvdi3  
0SQF91pPldni33sMMY2iFxCJnRcYLKc6RiFzZh/Tfj3TH8G8/ZCDEojB0kUfC6jN  
raDXKwUJEmU1yns295r90JLXkzySoplJFyrTh2eWL8njtl1fSCgo1meHXCThgqL  
h0LNwtgbTKMcD5Kz8vWeLJMHHbIOhM8THdhsj+k6Td2c6rehlvYp+kJHglauWsjg  
H8ky/Hma04w4jXBnsfNMziSpW76UGS7SU22yduDafFsJHpZbWUDD5EZ1VsAg7V3  
lWbpEEfb8+wXGpuYD+MjiVPCZJgh97lQ5fx3ySynNbfK0rPKSAZdK5uynwzGoltX  
ijbj4CrS8NcgKaosy6PbKv3L8wCpU8fqR2/gLa67rr2tVCajMldekf9kWF60G  
S5amlGOhWvUuzrDUw419/QRrt8yld3BFd8Gi9NzDEoF2oBKD5tiG3ASU+zZKjaa  
hBZHpGzah2RGM7AbrR0r326otgmBywvUiRkfYwqkW4iseGPK3zNRwo3Mk9SKXdS  
PadhyldJDzQGNk4nJH9jn7OW/4pU+zEKJUoQVfxttd6CgywmKtAzLsne3WWY+w  
fMh51sXrelbG3+bwERldC1UNPCGlCFUu6zuLm1fGE9Uoe56PSZCtXwmDsgW/TO7o  
coqQwJwDKOghKZ01nhbJl1rZivqmeEofia4LNJNTq0ErXY8fk9r5xc1n1234nz1o  
REalGpccVsCYDXAD5XkWLdmkh5oo1/Kc1rJK869Xlg4BywQaWmmz+22moWi1Wnar  
ba5i0KxfH1/0kxCJ4AYUBLInRiQuGJFUqYck5Lg4gmyHos8hS4xDffNUZiQ5D9  
VPB+WNd4wHTqVD97Tlp8F1xBJ0zn61B9KH8pp0yB3tOw58z+QiO1aSQ2RsqYMRqp  
LSO1ZaQ2RmrzSPHUVe5zhtrvTjPVi1j4F7ozk8PRBAImVQGOmGhZVMynF+gCQ/w5  
yLQxBNPvtO2Gs1314jfrKrtRVL2A5+brnsdEe+TFHmwa+Uou7nBWaKhDNiD7qoCe  
jD4yg++ir6tKfIA9aYG7QyR919LDtZjh01b8aaDBAUiFPm9GsrPOXY+4IS/++t/6  
3c/dxWezqOnzKvlcPPR5/xdalCYPelt32ni8aJvOmSxliJPF6nOYfTZDbfU2LQqe  
Ldfhc3L/GevwWa/D55i+aRp9xjrQ0nF2loxHwuZ7E81elgi0ozAfGdGLAmRjlgmQ  
uH2n/OCXC2oXi2wGASp0a0PNtrjP3HcfCs5FVfz6KkMSgENX4VS4hXFbxaTMOKWh  
AEfVveamkpUY5HAJTy5KGfzTAL0y3Y9txJeb9U7pHZ9u9nwbB8MmXbnc6NNi8Sc  
frNwsqbNfLY+XosNbn4l/gCNwwFR7u2biXNBY0V+jE7ZszARHolfK0//N6+VX2jK  
yQYJl3LqKt3jypILsvMClFh6zN13kS8eQDyaWSeHdL67d2d/weGvhPPYJ1e9Xs/6  
o3KcrnDyC+2pBaaUFnZnSCGMv5sDCglV7WgFxpRQEDhjJWjtpRpDvidVO7WXZIOU  
f4NQkXjCfB7DRu2mJAsmzH52kiSgthB+RKOWrsqXA02IJ8u8gyS4mK4scv0gaG2E

Mu5H4xr/nb4bGvw//1+5qvbguNA4jh7HL+snXIJ+uBq/5E9GQPO4YGO7trvjaLWe  
jXEUGS67ME8cOtSA/PmdYSLDHRsIEmHdlmeEa4/ZQD0iZGEDYHyw1uimSTosxwi  
c6BSmNifV/OwbeRh2wdRM2hXFKzOw7br6pU9ruF906UIJ2PxFNJ8lcz5FKg4IEGT  
vTXjMpFUIdkKYCSfkW0I9HQakf+EACegSweaNySDg/9luq40S9BYg/b7wINI0ALb  
ftN0RttOnZw1MAdyE5s2GY3NdtAk89xTUIMVUij6Uq5MdgDc3Mwt4XRGY6BwSK5  
IBvST5CVU2U6ma5zVZzRPg+MVfQbMb3OdmQYB5CcoVXytdYZoUzA2/OYAFA0JuEB  
f6pHPnyCHC8XesfgM2Jf8pAr1+4RhgqETC/h6Nt/RL16n+uxuSUC0oiZHi7ORIUU  
2aQx4j4yTYeZEG6vmAqhtVFYkpHfCG/fiYun9RaYeIAePF+x00fxCNmXSOT0hte  
5c/LeFAxqFuBomVbDABnYKQ9MhhsNUunHDg2NmvyhowextHs3tZoWOFjLRhoukz+  
cntFCuTm+lJXbbCojEBI2jZaP0WXXjhpastEzKA1RN7DLN4czzLQsSq+pggKtQh  
efgXuyu/HTI34zS0LrrCkjaKudcseX2nYQYnyMDnLSpyyuzXdj/Ln5OvSMeynBCX  
ueimwm3Sxly+GOepalEhkVpSy+GUoax8zQ0Ca3+fQcye3fC3Mk+Pq1z1EGlzDxGX  
rrkvan42+/Z3OIZH4SIG5vNT/wOk3liGjrZ0H0Vb2Xdkdxj9V9lwPjGmoGEMXWd  
LOYJgrnD9XxJokOE81Gy1A8uZ1Ep0W6TbLXgHLuColRE3C36cC9IOFSrh1+TcgWO  
3u00qp5ygaNXr9D0ocAP0/CBxtDD9GkECESw65ajPICjbdB7tLt3cPDv77mK+piO  
2GE+iWhYkGgMRo+yTSx75SbSX2KhUpjHMxTpRdmYlcsKsSrd4w1SEGa9gvmpYWe6  
rj543wpwsF3ui2cmjYVy1mm3mx55zUxa2I+fktITCC12mSzbRP/c4+s+Vgg6vRE  
nsUh/3y1odKkcXeewieliddH5ZxVXMpSxX8qo2rossK05mQ6uA9NFM08GtPn5PPI  
uKunBBNeFloY/TUQ7b5Acvbx2jAZq+BNk8E2QctuBjWauDleYDZat5xOZQRAYZSi  
j9zFBnZlHk73kgY+ZlttjGLHmLQfKep7fi76OQ2BkpOf2fvdz7jFCEDSdlgh6SrR  
L767mRIK6A12ZuleFkxz21fbKOPG52i/lCu/HxLue87gEjTfTzmCzrRe0jEFWul+  
hd0hwb/WkidC6lOdFRL4SLA7TP0eulFNqmeDh4HUUdMOHHI47tu002y0bNKczKSI  
HNkv6xk3A78kF+NBtfaB34Ew/RTOVtbhWT1bS3e0M4iStHnhesCPbtoDFfkoHGo  
i+O12KQDIw+TzscabmZa4RbYqqo0SjPzjjBshczl7RIS8TbLpmqbpWINFvzQVbl  
b7accpgoo0MGSMenNfjI0c9ojZjocYr9ubOvUFVHwyHdaNCHzEBqBBTmxUEyKFXO  
jG55xqLAcOjY1Pt8tj3ZQsXr6skNbgKeR1v6LrpcR7U1CZpbq9OSSbi07ac0CZhl  
t6hFBTjCI1bcEfSce86rs3p2eCd9YIL8C5O4XOZzWbUimvuGbnIJW6Ew2shyc4J  
53NBpAY9Tg8mKCam36XISdkaL5OwCxmHHeaCOOiQO+ZsEMrQ/1y70fSd/VaHpu10  
GjZZVEwaye1B2FY6C788oec9DT7lit6zK+6ASeuM1kbHEXTGZNbwE53f29uutR+S  
NbFexJoVOUrI5XhrdDMs0EBc6MhAHyHC25Tb2kEVXjuEdEgtMBZG5fQVLYM+RpB8  
lkyK5lZ31yf/9PcmSpQDJuwDSisCISariT+Toge11+YEs4cOvJ4fVN3YjAzldkvF  
iclktgNaNk7aRPlcNRxCuDKGDyKZgSQL7WEMvJtRLdzVS3UOVc/hPnUukrRSoiMd  
cm7kymek0VY6e6fExY5eFW0kNXAZQV+7yV579vPt8eDu+Hp4fnPNyGKnxbkOl4QW  
s1qCTXU2B3Wo1SWVDt4KpmTlrl/xLOImu++kuG+R2NfRijnZ/sBJD3rkrDx4HUir  
cptNGxbxVbUAZeyMlPjltBmDQfXesd0lZUDJtSm0zAaRgQNX4MTRv/wCzQfZg+p  
9BggAsAqrmZQfvxLlZpCj0lno8/qWz/rb/0s3/q5+FYaIyyoj2FKFtQv78gYBJAy  
ZQ07JP/qoQJg34S6bNCfGfI+BOOrgBfsyRW2QycmmXfclfsNKRGXRETD3ZARQxCx  
282WTxLRees7Hb/Fp52pO/DB+NzTWTKCzSeY4B+McGD1HvgDbAEV26H+AKG65gAI  
fSUTXzA+5yoKJyzApUnrwWZ3WQSmGR5wnqlU+FCBw797RAJWm8kXgQ40LCLwitz  
+LbOhtjKlgyUXYRkFDhBGrapsdH4GQsRkxzoZp7p3S8MxStr3uofwyIOU9LC9hUo  
qj+WCK8sli3Gc0HoqxKmoZWePObPMBYUb7vqK8zuznCajJ+4pg8piDnncotKuDvg  
0jlKa12G+QK8UHGR5wia+y4ZgcdNwwdnKKFiRQ2Dpus6Td6T9o45oXTzxb5Dd+cM  
Xm0vRMhJgWeix8SleFTGViDBV6linzGdPW0km4ad6hnNs80w25pRvyitMrmaK1ky  
LFev1asfpWNsApWOC1TYaG1cod+rf2hVQBU98ob9Op1Tv5ZmQP00O/Vnd89jis7L  
kDxdAC1JVdOSXJFXRtojjfKvkvACvxp4BU7wbSnZh1yKPZ6u6O9DtOVGqSijik5c  
62PNdakBVxqf3JMij9LdVGeEr0MR8y6ahUJjHHsdr7rzi9zF6/T3PY+JOO+Qi/nt  
17+IJQLmBh1f0VT5YFdNpcrBMYVo70PNGt517yqJmPwBcGjP0cv3/aVrq3C1iL5k  
fDXxt1p03/ryKnaGJqthoYUC/0hfbIzIPkn93Y5TtsYJzIR/Gg8zus0U6j0EzLN

lrTNbhLjLLF+ho16GIE677DbvzXQwUWkwiwmZWtV0Lx8hTcykdUTWOIXwg2oM+oo  
YaMuBAisqjMYtQeHzSS2EcSz33QViR55sZ79hWbDIZkiwKoQyBL4AQ2NdCMzoR/f  
ndojRdL2hSwfFPKe03B2Zvccj05Qk4YCjXybLJdMJbmKHily/bhOuR+tXqDAUjIX  
7Dlidk4Cds6djCuEXYuHkrALv5TXtEf+Scot8MgJGkHlI6dRdO5x37cOekeOGzhu  
hX7Qq7uNZuC2g3ateHmZj3DqoaC7Y5jYCP4jYy6586NaBRVrwIAKI7w7OBoe7CiR  
o+PBd3aZLlveAOCnKGD7xS4MarjI4cFkrZUZlWn7ddcn50UR1jXISwGTjcdMmlb9  
9um0VhB7TeNspdIqFdSCbgqLLPMMDMaMcy/rS4x0caKbeP5eC2lwwqPf2+uElpw3  
pydovNDzR9/+YfZEVwzB2pXi0x4u4wVK+XpHEPTzCS03aVheyeMwnRkEkKWww0En  
r8XmtiXiltMZzpHBUGVbKvQDlyqqD1BBMetmkUWr3379m6so42A604Cpti257IsF  
ok4EBDPNvyosn13faTr05z2PiSt33LQJOIshEGREp+YedCzkHdFFqyCvKiKB90yK  
IM4X2Spe5SsVGRDE8v71ORiwyvNynTyL6Ozok/L93NiqDh+i1ZYAtPys2gAXTF/G  
IGxMyaYp2WpKtkzJNqdUmEi0MrAcjGv9ieOSK9m60j6Hp3ME6SCNP49QRDNEoAbN  
AKD3QHdZM0iC78j3+BEDb7Fe8TtM1eE7dbH7VHotLsZnw4ck2a0007OYe0KyCU3I  
HBFHXesLW2aTRIANqIOPTCEfZpyuwUzKj66VGAXOmoNvr6wm+YEZkbWCHtQLNpsn  
EaOU6OvEVF3iYlxtNT0GKNxPQpsHbKsB2xitrUdry2iNRdjzmOCzOxp9jKUT1GU4  
Q8s8Ps+yf5uEze+sLKSbCSWmVq2oJl9xkMb+zpmJb74kZZjPebNwEuvhaPQc04F7  
kgHw6VusbHw7dHhhitOX22P5crv8ctLtzOTZm8IOXVsXH8WIGq6YsIf+C6F4c2+I  
mXdkrfKpLDPI9s9RMetP9L1lqaajHzqD9/IGzCqL6T7XH5/HMiR1JN2679bTYhBq  
XkaNHGYCvf5htUJ5ckruSja1HsAOsBBALeBZEUs31ZvPuHTKJS5pmHROn6JoaUnf  
nGcOpEjDPmsGIBG78oIOOpZgiiLowJPoej9ku8X8YSowY3Lw18fc2bo+y8dQPfUc  
06K7x9Oyy2lhXzPzespM7FViYya2jN6m0SO577bIJKKfgtXB8wDPZDzPzKUgzS22  
EeyrrtmnjMzcv7ZuSF14qSHNscn8Xc3cUrwxmXm77qPVe4exAJfa8vpUu1yp07K  
kNFHvPaZJmRPxzpgdmqgZqcA0wJVskR6dlhks/XoTX8Ej/3pRDyzNuOAXvQYLI  
zNgCD+sL2ibaek8PUQD2wxJH9nAUpqHx1nih/m7TC7bxSjwK7WcSNKmd8UizcqCY  
RqB3Zms03HEQ4v7T2Q3ESHQvfBe4xyxl+4jg9/MUkXSbTLF81kvD+GGQ0LAFJvQD  
F3JJBx/j7Wn59tKx8F+ZnD2WMdpfpgmkTXRfYhqbxkheSjBZcx4jZttk1Qds7f/0  
7639cq/f8IErj+Ek+gLf5I9K7rqK9X8ep4wBI6Wyg+sdRQymXiCgj42SM/p3xlo  
gq2P0Yo99nAH6o19La4k/P42H+Qo6Q9kiSWsSXWyaMknrat2eFk95pkpFckEoL3B  
h/4tLLj//D/3Pwy6IKEob947mvS/le2P/UONLOpBmU3milyGCwE1SGgY8qvSB5EB  
6RfLhcKjwxrnlFaF3951FdUz+UMGo7oHe3n5GI5q7VYN0Nim9Juao//hJS7UHN+W  
oHSaMYcKaaEqe5HtgrAcS5IXmwXCokb2WCq6EeBEOkL8S4h+1Bb5niFlqujs47lw  
9iN9VuZ421TeVehBUxUoGUrelYf2SW29BR0m7ueYcvcIBIOVv0mCWDTeCCXMMfMf  
5RxlL08m9og0cFaeSWxTm00sWb5DvTLzq//A7FbFm8TRKaeYFO011VBtHirOPN09  
HmpFFWCctH4n3dPSGigGqdfqs+92gnbj3rPdYDK2XTca22GnHdjByA/CzmTccu/v  
1ToylgX6g+vQaq/kmy6NdS0Q71KUctImozhsKbcVR2aFT6XsapSp5/JGUe12CKn  
QUunnikWG2DmcRjA1Lqx/+vv6P/OHl6Q50plgkU0IYSgfarTP5NYVjVbT2XS2iiHo  
9hV4al/7zb+5TLL1rROwAsbkgDhEv5Z/IVcsMs0zLNpSAO7BNeWQPEHMs/qAEtO  
mbhIZBhaNITZyrPzE9qhJXn6Zt8BXUNb4MprG7xqwXu/0xQAv4+eg37T8N4DN6hP  
sxfBYxJrt+XS1KRuFDXOL4voMWT4/IH4nOQTBtceZzNcxdNdyXrTNliUoZBP1TiN  
6uwx5mzxO93zh4TtYvLoiG5yqkTzB25GYRmre1f2f2j40mLcQcrO3UKb1DKDrgq  
fm5wZ0WPyUl/4fafXd6IKYKYdj+Bigb6TrarSIIYEs+am6Ssn7ICIRsEaIYOe8QM  
GkW8NuU2TJa6UVyuiTqymLzb/bvkaZ28fa202w0KwhjXDA3okuiOCmAl1fAc5B6YU  
3YgeIttBV3tmw6UDGT2Y2JD7lnhMM+AwWvzdtnn8PMeHsAzaYyLNN+dZGpJLVXow  
Ylkb3aKBQh+pZiBKVTP0wPpXbn0SrmX5LyKS1OSzZBmsY/3RusB/8UU/ICsfl+o9  
ylvVDNz1WAZpWB9sJxfyjwdJDrqtBsnGiTDjuzREu9kKmq63xwQKb06iHOCEmnUa  
lw3Casxk5yjDQaWDAm2IGJn1r/x3rudAXVsfaqTvlVMpMQ0yQZ6ZoWiR5alkinrX  
h70qQLzkQ/+R0MV4MRpri96pO82616k/8Pgz020qNYFteFfkPWDwNphsZWkQEKYx  
0koVZXBKGCuUaEujomXocV8CeAXutxreE4k378qygv6uqxFnZyQ5idbCUEfnNPE

x3gOQb3JB1QHA3QjRdSlk4ABxgZc2lGliKFcD32ZfiRgcJ+N2cKFnk0TWrvVIZU22  
MSOa/pq9KZ4RVzRgRraekS0zUidNT4aWCUbVzQgArciSJJ+eqlqEiGMUyLEsX1nN  
GrxruLvDRNFPgh3KGsY/IJ79kn0RYz5aIP3exLBvwM3GoOzQcfX2dra3t1ds74Cm  
zhj0+Ry1UrBD74E3OCn386NaAutn0iy34RqPX9GJuAu/Cr0oY6a45ooWcv4jQYMX  
v28ib9O794V8y9KbDF7fyFTGbscydrVx2cbO2etohT3Hk7Ttex6zKx4vFlI3exfP  
4ocQIPJk7wlvzWjEtGA8qyLIVc7+FY6Ilk7pymydDfowwC3QY1fztwCVSaq9LTWY  
KLs9P7cGh8jNyC/yWy9cKCVp0Fuh27c93RosmDjHT6gnlRxgtlrT+EXYxkvEWgFM  
LOkwM43I3E0EwJSPJeburoyGN4UcqrFVCLzMlyttmuF1miTsF/Jthb8rRZ+YhUBL  
rsMpsuyi1zM4HaApQDFjazbY/PhAYLINPUvflm0EpcY5HyJoICRoO11KBepAqoS  
DuBYVYF53rug6eyauRRZCFsgs93cCRuVYeEogqltne93PM0S1+7Ya1oBjtlk0wQc  
k2hHm2SCIO2OgCeKreE5juPjl+gczmjepM1IDZ2BApBGTCS3rBn8fSOmMMLcBSu/  
zFMEvYSOsZz3brTdhqun+9fHyTxhx3merReqDk6++iTz1fwFG1SSS2/47qOp0JA  
2i2far+Y61NAV5fMAObTyKwjpMdyM1guJIYgeV0ZALE9VQkf1HJe5hG6nWYKkCl  
NM3k11WO51gfCSGkU629jhWku+AmY44tFq17vBYK0duBY7eDLXbGaELPGsQ8mF0g  
vvXSujktOuSdJot8Nsutox6O8zp8Qtl0pW2eAc5XRDRRqIUqRtGX4DSggmsaA8G  
N0NkKtgKy1bRksHe56SpHjaqWDzPR6O1oNHcwnjHeJxs2KLXWgA6i7bwpNMViGaA  
QHW5ArPA4CINn2E8gk3NdtKzAYqwgJvBqfjCyg5vtuljx6Bcd+d9q4H6SZTdmIlg0  
IN3Ej+NIj9Oo4Rt8nMufMiH4X04mYpDd6RYrC+MEtppCJfEgCNXiMiYtFhilCuh  
OOPKwK2MsAlQhmqShq3qDx8urf3bwfl17/z26hjEbUD+wifK4BOVnOrvrIscQXsW  
jqLZO1qfcMmHdUmbiOJ+wYRs4Zdccgfb+yQ7HJ9OY8Pfp0mesl9S05ho2H/gVYI  
ZsnxilmazspVMIDoAyXvueuPmjJDLNDeFi6wYkqk2xPOcoXSTI30eQGnraYmmb3/  
JjyXPegK+q4Gg/XI6WP+kO834sL7JZsB9F8dqnSc+hLcK2LMMFNodw4UPsD5MeAD  
DNfrxSB8N7hvKod5Gm40W5NIA1NLcE9ew000HYMiLFFfKcJmElbPi3JduxXbc9j  
/s+fJfLeLbsJznVBFJvoQl92N1AuVIALqw0jh0u6TpOfNvMQ/g8bwfNosgxJPYxw  
0Yq4JilM0g70vVk9+jqe5YBdZPW0x/VQzBNailc1Cex/N05HCXQwaz865kBJ0iCj  
xalsiT1exuhFpQq6AVLLcuScSGDxkbKrz/9I+Jrep1tX85nllxMYm2jM+pDV8bK9  
1AfPxp/FTwoZgVMP1ejticZInkQjerutDOY9hgW98fyOwt2paMgNzekwfpCkinBR  
9Qw/8TwrI+vFNmclbQr7XSU1aWBlhJAGZic0IVH8IEkVxvWYLiCAhmpc6qJ0pJHr  
jJsmHgNdGD48qCIPldWxsZWYBPoqUCCJU17kVHbLEKew3qTjJz2JhZi6DZaaG3a  
6QjOkhxxgLGZHFq+gJjwCRkQF0b2aB8CbKis5AUmHDHqITjz4hcfwEYDlijCXJ8  
iC+SRn34SXXR1vwnHWe/1W400Gja9jb46SYgZ2gqw8wLXFQ2MPPnx5hhahW2UhaZ  
tLDS80Zn/8HQNN/Q3UVa/I/WXJyFuzapniHQESBjFrVDeY1p0ZC1PGZlJssrgCw  
O+bzvE1m8SoG/RjD8HWzt8sFOWddzRtQHlgRM5rSsWdKucuQtFiq8RcSVt/lmPvO  
D0UxnqaLwquro1zIlotl/FScVds8gZUDraJA9iiaXuSghyJPbTkkdZo/A1CthzwG  
OGDB7aFBaLniQgKYunrWrX7yP1q3193hj0gkMP9U9sht191WHd1Z2p1OQL/SwKQC  
BMSRiKWdYewpgm+pVALZlltotdFFC+U67JfPw+xJN3JVN04FW7mYw1OF3lyQ3t4q  
03Q7TbsZBP6+E7xtk7Xg2x0aEAM0yclmEiuYwJ7CjCFIfrjop12m8yKrf7KCWYUu  
PyvrlHlrpuxw6HGfxDM9bLanY7YesKDi+5+EozQeZ0D5MnnZwCBm6s3QfKSvJtcb  
0n1dJDrG30BxQtMngdf0GyaCTSpl0T4O7Im+F3h7PtNinubauMNBHkazkhT8lotW  
Jl6hIYzHf5XHyWluWlo+J3HKMDoE6oGMJvMuSsc5qeclga3bovmNbXeXS0ipt2Td  
n19Y8v00QBh76yP0ijh/Hy8C9eEQV3kojX/XuW3iB9ryeOSUUVgiACCQhAvYqDW  
+dDbmZ42GhnwnO2ywNSO9JztSM/Xvsd87bSYr+3SekL9fxhax7dd66bG/9FFA1iR  
O/QDKZK4GrpNEieS3YQJlpWQ/b5qnVrBHGXAJsvp++MBPjTeUmUZJgzTT1ZNEs0  
8ShGbJPOWpUgA4auQ43YfLPsiTFaWzV6rQIRAOjymaOTLMsczsaFzZxCD+gKDK6v  
NMQoV4apiWYK6B5pPYQZ2GF1cZmSCmeVLFL9RmcAG7ejCqoKfMroo245m03fhZd  
Ny7wFUo672pDrUHHnnMwmj/O1XBsIS8ETbBZMeM36688RBNnSk/D4CkvAW34BL55  
ti4Zfvvh1y56TXdvB//p3yM2QeZmFU4DzITvhyPfc/4goYYodULZjYp2k25ARGMR  
4wjm0Dz8GgJVFC7TOK0EtsYlZD7QvaZSh3I26jczHF5U5L2VRX+l6ID4IFysVpd

luhR5RjzibMWEXcjQlPLuwS2ger3qZ1cv3Pg+h2nteWV0zFewR15VIEyfmIP28Fz  
1+n4HgGx8yc6bThpl9M8zVTb84IA3miGQLPlds1CZb8xg+irYsWOKi1J6Xw+RzH4  
30hSk2oC7IwppApnv2T2llghsxoKemOBpKiJVq6o22rtPRzDJrKBkeM1OkHTMMMy2  
a+/ICVoPtnMicu24QPmXfCZUQod0eZ5ATHh0bFANhMhv6JiRsbGD6+7GsuDyPWUW  
J18Lscl6Ec657Qy4v0rO8gldzlwJaJpuu26ztRX3C3Q1XbPdsF9oCjBV+uNLAH7X  
3PTsFDQvP3M/OhjDd6ebbWl3bRZ2S2kw3Xmytk7DdBJJpy71rklysHvabCOwQqav  
77y3SA28WGTIBl6NRgLb5Awl1VdDBRLEB0fiw40FM0+vkrXwcGABV2nNFGp4Gj6z  
9T0T9PBPaDTP7KIKNo/GFMyI5rcaokL/EUdos2XWcj4u8xq3/V5ANm+zgUvdMXxV  
sjuQpVRG7Z2ypI7AZz5LGF4LqY6MNDkJV/Hi6UfSenjPDO8pQZoK1Ffg4fnrbf6  
W329TV9v89fb8vW2TV624+z5zNX526//5ioKn9bAmxRJFXRzEy51xmwmDHZ6CJCI  
Yq0vcNqyywwo2aKfYmZx0Pv9aFGYhqe07CvPdYZBlvmTcQjIMI/QztQI7Wc1QtSf  
PMslbafitdyAJsu9R46sw7MaSOA5/DFcJUte8kmogGze8E8KfHSxJH/kKD82LIX9  
oHaV2Px4eARpdcakKBvCRGtmJjQOYZzPKN3/vCxG/Jn5zZgOSxsKn/USfW51XCdw  
xPX2hRD0qMd+FHxFOoRH1YywWfjw3aRhfDInY74jXMXVZLzDsPPbMafmOPZ9/SQtT  
Ro/IZ06LnHwvdL6k0Rxx7SDa7RrVqRzbLfkS+U/ZdZvv/4NTBYuTgf1G+0i6Elz  
VPvlvDmWQDcN2H88HUqI8SiarUJ6JI3hSmRfyFOXFz4MwY+RxVLNUED1UvojoD31  
1li9k82DydmldnlkHCG7clxBMAqTJX5p+ZmTzBEWD6uTUYPM3ZehalcNe0ckbgc  
Waj7als0GgNwujay3P+cMga97d6PW787yxjiaWH62toensk8bD0Pm+dh8zxsPQ/D  
1GVK0NPwhTxnMDtPZ9GLYC8HqvJRBQJmWZWyDctuvxG94OC7atusn2uaob0a+Cy  
LRRtZkGgkI15COon7QqfFy/X3pvk9O2a10ARYtNrmBTpJTI95QGaV5NrnMZ0Q1LF  
w14VMxvQJeJT13SCTcMfQa9MMn4Hzik6Z89EV5RfW+JVlKywi6rbTtAOfNJqzA36  
KRluyNKQ0rLFltk6hcYtwJjThJlsyYe+4M0TtGZMAIHPEuueTsGpNc6wrWdPIbiA  
MBUeRBOfqyKN1TlktoyJxg6LYoBSznlOJx6ESDF0NWSjgQX4InyakQsmrQBCfaoO  
ydr8ysZTcG0hEDIHdaaBFkRUY63sVmH53eggz00mj/CgInppIYLg0/h8o418A9Q+  
K3IT8Ag6OZN1zfygnxQBA80si9Q3gHhxRt4spB3ZORr/tEgqo8sqCSWh3OAT9K9R  
REgPCP5Dwmffx4gXLWpgA0NUqQpzyOrchkqvR12N2pbehTJeG4MrNqXe6dRjMpmZ  
bpQVzgd281ehaFyeSXG8tLJFjw8kJGVuumisZxDS3BZUNNuuXeOHBZlWYCbYF+ht  
GyRE9Wluk/ieq59X5fTm5B4ofcbsogWFanWlMbwGbsgkEW5V+DM/HcBOhTq4nZHA  
AV3Y6vsbS87lrWAj5KE/qlfXc3N966oWm8dZDHqPSdLhUo/AU3w5LFIgji65ChpZ  
p8Eub3TjXoDrg1w3BKmZMIV5EVfrZcmjjVJShKkmC65qMWLizvug3dxvtX1yXlJm  
y662MtZuS5PdFhKgnk0WK7N93k5JJvbJ9KQF3bgJ0IS39/FLICo2PFqLRcjL/U7h  
xbXREAq7nxbxmu2WtwcONFQG3bYn2gMIL9SX1FTqZQEd8b2IHLRX9JlJ801s2iZf  
bGxKKb4weHvJg2f811wGLyVXoLff0EBpa5sDL8hvmQkXAwfKbhtZGLidAXBHhOeb  
OJ6Pa9iQ/Prq2/8B7nTyCpDxPylfNihHdo9tIChzq3UUjzF3sQZd/+js4SEw8o  
NnV7GM6XMckV1s76Z3qd7m9oVburFfbzIYNvTen4TJ+iqzT2XosBHQqtV/poACO  
yuiLopf4KJZb9mrnBK9IMARutk5ocaUxTR92BXqkL6MVSkpCUMVcRqsZebA99HMG  
kpfMSyMSc2Sc9zEuFfJ9dOTHyWTD5sh4Tmo6mRXppu0qwTvNBcvGrSSmrvTQmWtW  
FtVLsmgGyp02ODy7Ha3wJVrRdpzfZQqUJ2jSTdNBVcsZcQeTUt5+t6iMJ6jKiVbr  
kjsESrgAB9vsjMPYU2GbUnyWGtpO555DLyplWB0FLTB1gDgt2jGSMBqGJlCAVh  
JlCJ3UKFkHrbTKFVnDGNelNArTSfc9vgVq6SAhkqUbbeW9OrUyAh9n0XnlUNz24w  
nUw1dqbeV+JyPKx9W7i/rWOMONNxu133YyAU8Ihc9KYpomJGveq/RgPuVbVwNUNT  
U69/1H37L4JXHc8nle8pjCteYHaj8VtGzinsLdszjC09XOwbh0DCRcj1ZVLE+c+h  
4p2H8Ww8jWvzZT1oNpsTD+zA7XF9rD5aV2cysbf66D2fCUovyNzPXiKmuH3k5HVw  
WcXhLHli7F5JBD1cMZxVw5AjmCJD2vzHq9SsqQC55mJp3M5C1nALvMoBUHj6psTY  
PlDsAfsrjcxVu0/OzxpFgeGTJbnDXcft/1vDrbhmGlvNY9F5TD2Weqddj6ElmFtU  
VuSmUPraQ9k/vL5zmx45Yic2fHt07XhrebVmrCGNJDT6TUMzn2I2TCRr80dEuofJ  
lpmvf6gybpTJezAz+m0Vfa17nY7njCO/2fDvQ+++cT8ZRePx+D4MWq2OM/EmdbId  
J9NwTnKf2UMvkuV8sfpDNMrJ0THkdhrTKVpm1jHTQCHU00sqEMBv/4v5e6g2GE5

Xc/Ql+rAuJ0+VRGGn3DCo1RxmrvnWxxKdjt+g5bT3yBuphOLNhGet8cewZt+8jCN  
5zGbMvlxzCJsEgl2y6+FOXJ1fWuLgt1hMfdNEKz73utAT7Q7bbvjbBUqred09JWk  
ov/3ybiCk5z/1ZlM2prX/k5JGmYURflgNEPbeETvS1U78Im6oKkCgMPhAOdLVi7  
5JITGHjdJaFujKcemr/ZulM7TYIbik6TeUh7ek2qPZ5bl3/5zuqPz2DjHUvjNFqw  
J3o8Hr8A5/oL87Kflak8e1rPBMSpilloGfjszwQEklhpPEpYXZCBzRR3OvEyzpnG  
ildVWTrSL7o7L7ljz+gUesynLZUoBjI1EaiPdSujg6jpdow8eislGnV5gl+gabaY  
3igN58LnDhbB8tfQ+uUaPLgZ47mMnuIH1kAN3+y9zRMUI0oMsb/Muc+HdrcKk4sd  
FMXf2zkweXvF3ML+KdJeh16lYXLPcJDNLdLmi0azt8s8eohmcAxofw7zR+aBugKa  
OHqircbw+zWuSR4nq99+/WuAQSP6712CbD059MwyPpD1uCajA+PPwMxP+j1TO5MV  
O5UJ4+YSKmpMyH5F+Zhxlo1B19LLiR9dRQ+pwrUyL2rZdfIaYPo3jEmE6goB3Tf  
Nzr7bourybicrMp30/HrizCtPzyFoxbfMib6zp8YHdjHEWKedhzZJUodS5+Lp4WT  
bbAryjnLkK+NI1yoCjbHVNr4kXXKBg03jF4ZsNHq+tSslnotZk3L328GQYeTRy6S  
RyZnr9fUN7UWjKykJp7PtNXSuPMle/bArKUCzR/Rv9M/HCrXjjFHxIstrWyCeY5  
mmDqY5kgqaVBTdd0jwFyGCoS1I1zx42wDtxm29t98jynFnQ6QYM0GHNFxs5wnOmK  
H49J/KQT68M76yi/RxssJoZDB3J0pWV088zq9RXHVDLj1ski9T+TFPjt17/pFzV9  
7wqOe6HC/O3Xv72hKfz26/+GHoqqd5NwD9F0wtRWHUQZu0FX0hAN4axCqF+wtmsk  
fFcamrpk2mNbdjTyFLr251oLXOOeHS8mlvz2v6ZcrHBC52EFquRzUnhJ8qb7zGbr  
X+UCR18pP2zo1odk98Ts2MCXzxf9qy42e5B+yxko9LmyhDL3G5d2U4ek8kg8G78  
0YWq7B/LL5KTHkTLoukf1yk0OzusqYBUf6ypVoOUFnx/Zpm8iuZz2dTLcDaCn4Al  
MzzYs5AZCuin2xn+uMIhPEnlj4Itk8KCPJUHNORIXb5Au6bDO1FOzEQZgUy8CL  
M0uS5Q4TXgzGB8OZRRpU1Stwfe0f1HwbLCb89pY+fsxGX3VlCh6g2TLjdzRL8hcc  
Xb5pufWxJxS3qxAtJ08HNbODOtGySh1hxTG1nuNQHQHOoy+NE1/MFoQ7X5IS8J8J  
6nJ3fzqnQ/vY3Hcbbw+Cdsu16R8TWKc70zltpxN4tJkQIWxsPISr0OqeiKh4sHo2  
+rRG2SNalkuPcx3ij9MxnzeIHCGi7I4BYzLhXEPddc1EinjWfrlRbwsbFvhpqCBB  
K4gXyAzcszCbh1rtg5rYL94ziMbxUIXgcN3ABvjUfb9PGnXUaAZvqwqA9EVdvUIz  
F+gA2cXj+vuFmn32QRmqHV0pmTlRaXKX55f9Ryq0b4WewDVSgqsVaqqZCuZ+1ha  
3EchrSXoC8dv2dcKPSlanQ7ZjZ3tS9IsKJRqx2nbZHEX5+YhmfaziC8hff2E5NoA  
NvZ8IKfcU1IPp387GNLtyq4pkSm0kyPodRiRch6Ffa48k2HlFdxMcJaEcYp2rzB  
sc/KJhKG7yKlif1OuS9eM3Da9VkmxGikuNs4lBokSZLyTCsyune3SZrSjbMGJcpl  
CPb8UA4R7g3iRrDxhFQTzbfAYuULEv0MAt3aKaBXklR1i8ieoi/0011vgllpemcS  
S7/latBjq2vrn2oYCTc18IKGTf9WGPgYDSPJH0HDSJ8pMw/T5AuzBB5CX34JH61r  
Ndl9Ndu3ilJho7KmbEIXDcx5TJdc8uyWt32WWi11lgLHs+luMO/lybd/mJLgvQS/  
95h8R3QWgYaeRvnMyPrhaogjOtolSm8X12NV04Tsunkmp60ofxEy6wWXSldcDsA  
bZ7JPGrk+AKGQbte0Ayg5nTurdAZyOIHJAz9jc1kaUKjeN0m42zJS2JA1GNJG5y  
B+qZwC8ahPHP50xtuugIV38mp5TpK7nmfsCFEFOw6l1zxmt+OsQ5mIM462BH0lKF  
4cjBldzADbB4ZcYrujOuFT7h+JSE7p942nGn1dSyXXqLh0iGdGODkYaUJ1mJeDB  
uRJ/9BU3SIHWKppiXy/xW+sD13QcCllLHg5OepuQVz+GeUw95NwK2nOFr6Ngtoc  
KFL+mwkyLCYo5Sb2I323Dbod+nSaojIVZpylvQ1n2drqMkrGo1R6yFUKH5HJHDDb  
6RZ+xW3+I5f36F6nk0kacZptXu1DsNp4lhwwg4C59nDKlBjqf5bMWNXIsIMLfp  
O0ums/toNoFvdBQuoidGHn77x/mS/mrd1RRimh4nyZ+tClXBbYNRWJeR8kyldSsv  
ioAQXozei6z6JfFC5to16HW2AnQw6a7hbM1eJdtwN26aLq1ugC6F67KaDVaaTMB5  
iNIXblf9kbQzeZvoZ3OM/PQC1LdDzDaagZIRKINof7nClmsdOfNqhQu8YKvqXYG  
CXrcdcHfzFL7R60YXlzu6awTfdjTbpP4iuS7mJJziHpsEWm9AAZADekam6ZAli  
wk2NpQGyqvt1ZfVc0jnXSJdlu453Y3XzDg539LjxQoNRIDWZ2+JPzdTao9jsyiC  
88h6cRnxtOExwWFijxnYfSbY9pkm8yiku3xxpbq0RqsVN7QS/7FMBZWTsF3pZmXs  
xe9shelwkyHScvbBgEtGFvnb7WbwMrs98Uk50wChmK9D5ducZJC5iqSRc57OorV1  
ij5XZNHfQm5HlwhjFFAPdUeaWxmc3qJczCl0PM//QefSUUQPAdDrrohTNZZxcmz  
n+NVMugOQAaE/hUsbeBXyiZ2ZKf4iT2fCS9vI3KWnqDeb/PVNGZsNP42Uy2AtvPQ

VYN3FC8kPqdDbUjxLJMI2ZAZXV8gl1Wjo1GSoCKQ3ljps6trLnHLEUjIVk2HcdIY  
12NSpi7btDuViOP2/eN8PKrPH8PQaWi+3IAsf8mfYutnGvrpejx9Cq3haWX44nfr  
iNsxpwoz+daiNSUjX9nCPuTU+/psR5P5oqC8B7tFXPuqzfBxM6OIHZYOvG+/aURT  
QK6rngHDmeOTXcz0l4iYI9kbgYWe7MJbGPioJ/qIYpLdDgZdRHpg/irWVvGowSaC  
cldqUVJIszvcqGy+Ydtz7Lt37Fkf/t/qvgXIsfQqzxBD8FQZbAgGpxJ8lcsQv+S  
rt7qAcZqdf0z/QLqXdmZ8t4fCVdSXda0pXv1e1uDQusKVOxTVhCTGD9gKSMWcDG  
gXJIGapleDg8qyAQSJEiEPBSxnZBME5BelbkOf8/71XUs9ua2NXka2t3e6WdHX+  
1/nP8/tCHYPgKiSkauigNnXr+QZMTuf4OgoJb0BBYLnAt2AZlRoI+Obwm/PV7I1b  
uxnzCo0MtsEnf8AoYxtMr+Faj3JoATGhUYpyepv9FRMSkuHshnTuZgv2fRqqOkMb  
05e2uwe2R5Q1JodpqcUx6d9qtVRcMjXnXybpGZrS9fok2B2ORLa5A+GaxaEYiOAw  
t6ipcGCCk1fsSdjlyO4ZBpi4d0CiZaPrIv5oYaV2iVmEAwfJYB54Gld2qCWEONX  
sYDKVDIgl1QgBldiigElNYa9W7nZBtl1BoI+BLY/dKcfS+f+35g4aUKjHag+nbDMf  
wTPg4FT6+OFW4S5L4FgD8L/X80zNIDbhBYunW0hi9CRjWudqxSKMOVC1TkP2LQuZ  
XDGFz5ySwcOwInVBDomGJplSey5yKQLzFrjCUWO1nB5kFShZFj9coAvERU7Xh5un  
JxafTcfm+B1XGMTtRS2gRnP/xgFgBq4z6k8JldHwgm6zOqaRrDgYAviKbGCeWSM  
e2Pc5brFeV2Dz6ezhBd1WwnkgvEZNN0sgy+koumcXC1UveWyyJnevdpPjFhAfd29  
cev4qBmXx2M42XyBjOlxsbtka3HRy03SrsHChlmlpGjWkta2bJI4oxnY5bX/Zny0  
9ZQZ0xkiRk+bhy2NrpUQfyW0XhuAZZ9xGmE+u1wqFddrRVVbChG224HB/CjAsqTB  
wDBoDlZ2gKgid8PmQh9G6FQNiFv7s/p5pYdD2te23aAiqKhGNpD3+8+88Rb2+gU  
oOuUzArhdJRiFFiVCzZXvsiE1+WqdFgsRXELhsWpQtboIUilyR7s6YAXEvWOn2L0  
W0k2zuow9pIGdAd6HrfbjGjPMEUB+SFBNIntfa6z5KqQe1q7kC03nMaLdHI8HXvZ  
hk4AdipkZpOByeiPG9H9QXcGAw0xv033kl47CEc2nGGXTprac9FCH6Rs6eNnC/Cx  
tGE8Bb0U7W5+kzNbHFvoWoVNizm8esPI63IzjTbkUfw2jI+uBNJ4ftXc7GqjFz5E  
qsveLpZpyCV7mbpz3O6aMDZeptHDeGh6HejfQxrVmU/P0VWUAmPod2dqM0aq3BoP  
HO0CWw/VN7ceZnCQUenHsdNHlgQVi6SG1NYyBQIJWHyMglYYC90GE7RsdOC2e9M  
77tDot0nKGUTfzplRa2D+AeluGeu1QOUKEI5LemM5ll60G2vUbxz6/c8xynNIRfv  
gH3co52a1a+RaEXGQx14bOwP6IexJ9T124gbjT3wV8Sl6crlqTPUbwROnIqjTCi2  
75P3q+OuWHw/wEVNG/52BLDozbJdvi70p6OTPN0tEyhFSXXhMWgDd90BJNq0OzAk  
h5mRFFrTBSBAvYwplAfNa4GRIB9qHT+yeedh6/ZghspL2ppzzR0pzOA+XDUacOgx  
E5PeTtazbafHLTQyzshnU5PPPSRXfKiCfljTvypNK0Bc8hwFWboK8ib7vwQeRWK  
lrS8CvJmabTM/um61m1w2ZEmn8KfA7joTQjcugFVcdMPT2YxeyUflwTY1U2NLx0a  
pEwfqz2WMmA+LsuBgdzVku4erJaUbdcuKMPlwABr8WoNodqKtAdw+EJC5mgcZNDa  
hHzq2cVliKMU2oOYB0uIHnTVrRerBVWsLuG0evc8rW1yNdo+EKsqsVdl0+I7BpGI  
aJyq/0qgyuKkLm/g59BFDCmQRAt1HCL2OqRyg0EDyPkFPm4aVjb2PPQrJGhN+1TA  
OQ6QaeRqIXDgnThnzkiKKLWochZ1MSwMxiMfSE9sqnY448PhF+Dsp5jW8fJtb9hV  
x6jMFuM3dguXG1rymWKpYtvL/sf8y1cK1eQmRzp96nRo8+6QWbUfDWl+T+i3xtaa  
pQNH+60MMP5F09Tj1EnLG69zIbdE8bbOJz7aZbF6EzfbM4Q3Z/4BF39QDokq/O+  
o+NBuxK1b5qyWQYiS24CuwaKZaQgCoWSKqRik4q5Yo00rX6rXSWrukjrWqCHkgXZ  
2gN8cej1JRB5/GDx2Ximj6ADjJF+5amagHPfHXGEYbG8eb5rY9RCQQdZWMyL6uZy  
uVJZeUbaA+ZN5IXSV5cr8+h9xRSUqZGCvpPIkybtFlg25D/femmA6YEK493+eOs  
Baf8CENE53LhVlfgcYNZ1lISayqlBmgluIBJNT+Pdg16WD9ys3xVodmhM3Kznc4o  
i3h0qVltaXyuAmP/tQbRydCBfmo6dFuRHQ8WQGIJUDqNX795E/340T1+C6rcxg6y  
X8+uF9CTTjcz7XCwmnCzinQ88TWsfTmWMqkmFnuFYz1a2y2qYzu3XkpR+4rp0vFG  
bV3kUsmXq1h8bstPCF9IaInHZ+n+W8li8EbslOisRNi/yymKU/6QhdBgflcTbD  
HBmk0ruLwT0Ux4OOb7K8wL1geRV6IWQt4wxOD/Kik0Hjk8R4GCanQMMXrMABB8to  
ARmqM+D45AbT6sY2HVlXKPBhJcl2sizU0gRxZwpDsSzcQ3bhqI3j0DL0iF1lIXYW  
6NWsi/QGaUc7b1fhcDNA4I7uiGNw3VcF4esj/2qo9dzcl0uMdTNgWBh2r9GD5oUA  
Bggyho0DkO8Gunjhgo7f40jXc0X0nZEJyTh8x6GUV4BTDQ4Rdz3snjITR93xzVz



kGDULeVHuKIkff3FXv6eKYw8imFbRfsZDmJmXU9OSJxu4Ufekpt/LriRv1oBmJBb  
KBXT6u+C4Aa/g4ZYSzuUSD5ylxPDU9DWSOcnFsAX0EIGJgMuj+gEXptmXjLCcRWg  
N9aZUPGQSON7I5fdeIT10IU2CRg/WgeLlwz/Tbejs56FdKCPHEf6t5jPl+zyBYG+  
9MtXCgzkt797bLOKRU6nXA7E5JutqN93cfLnCrT32bU94gwa7YshWZRDrpGi90ha  
sD4clk3L1XgY8Hbgul1/FF6UEFzt8DOBddgzvzvg25CQWSsZbuQHxITNZCxKdGe  
Qz2WuaYoNcLzgCVkxqLY9VVdeo90D9POI1QM5X2u+N7GjFjO3CiLvO97EqzP/M/  
x7OEF1o+2Slcj+YHI+1MHWADhPxBHhQw3xTXkqopAkWdEJwCqQ5Vz0ikepBIAQsa  
LG7xlCF+nkO5HfiZe63HrY0tx63GwePciE+qZNuIDT30etMHx22tCfI3a2R+kG/N  
CGQa9n13s1k/WuVu9brkKWSi0TjidiPUqc4YdAWWcna+WypZFKQSUK1y3FaFkix  
PMrlQyPlpn+3T47OGmhKAebF+PVk6U0ZjxJGS8aQW9sR9Ik2kiTK62l+AbFCGzG  
sesLVEvqls2cHp1jzoqUDJi2aCwl+FF6lqWao4BSwHJVcl8FiCKeF6w2zJGD3R09  
ZjPKI87A0bCv60U2laapAa7Y259on6rZSys393NrlaLfsiBfOmNHlrv8xQL0g2xo  
gDWI+1/myMyKblOL9whNBuYypjOcDLARNuhQddCWsUmb4qABXgTc7SGKA3yfkYs1  
ETYPsRNDzFzOgZ8MYJfwna6p3cZmJ3WNcDX09q28e1qMkBHEyMZilws1Lp1KEFy  
Md72+PjB8AlhVBwPSPVh2sGnRpy3j4Ljv3QPDeIqec+DCMzhD8aycze/CC0i+0Kp  
24NoSuAlaPek60dAtTCFaGRmsWgYYkWq81GxTNf2LXLc7vgRDQ7G06bbbnvj1Ty  
uy635xC+I+BadbVbJ1Wa2XamaZeeJiAkyy6N0lwpkpvUAMDpmLIG7LFLqBhj+plS  
rqr0iJryXiUKdSq5OkzoqHAdQjSulcoCUkgx81yUx1UU8YMouGERiuwQ4xoV8bC  
vXosWEqwViT3sSqtEn9WaFpSNx1zY9i5fCVfy2WXE1qQWMUSq5TEioVvWgvBCj7j  
0BwNu8bZ5WBGVlvg4L9jJvsiEXX3c7rwV7BardQ+fuaJp+jP6LMLtd5IMwDzAYDO  
i3VHcaXcXxQG0xPdqOUPHFQvh4KEm96zlkP2SpGxE+F7nLnuiXU4UVvddTVk87v  
cwfGPsyQoygAhG99TG8LwhROj/jk6XQ3SvHJyaWNjaqMJne2ONFwRY66TIgHuHGL  
FqRT/kQxelZlpkYkmZqwZOTzsmRkKtKWEVBNakyljGm5w0faBQdluK+AuWTuzCeoy  
OF2M8hdSeXwwgotAWlaDNhjPrk5fp8ZSD064IFMqAslZN+w4E0bX8IOZ+M5FRh3c  
cwNNi7BzS4b+cHOGAHPd7w2Qwjs0zGmC21T1wsyRB9Q77mDO8a/5w2H647kfuAl  
B+dHn00x6EjToGLOAcWEq3Ga09C8+IHpakL6V1ZLli58cAlae5aNmMP9jdbO1t7e  
OjotOp51E0gB8WXussnthPedE7Y+eUjY2Bg441XqB2O/MtqzN0ppqfV9ZyZQ4csYM  
52y0HwfRaAJLsC4dAUTNWUQbHtDd8l1X9Fz18/CrciT0/ZHbQb1IHecRiiQAvHF  
7rIhziMMRUETt5qbDExAESuqREY9j0sb8CBvmwDOi8el+hgX5hhG0ojjOuSeBq7A  
RzzSqu9uAvF+a3O3cfwweUTYdteBA/dKy87U4jnTbpvM+kO3d289jBOXILKx2Gqr  
42vTyVSLX9UvWcfOkO4L0Oo6pD+Cke3/EBBpIKKfKUYreZMjm1g/jYZ2lzbALmjr  
oy7yhU1kyMOpRlkX0fd9401xNsujeWBKWR8OAjo4ebRW3QzX+oqlBU1qDC/XUL0w  
fxf5Y+WsbZPSdmjv00tdr8PGHi3lqatsVYtXi24hWBmy0GfeKWsMU7oh20C5HV9D  
tpn2bPPKFNPJRMEOqB15OgXZgh59whMZl7a1MYnK6Y7ACj10xnxNCCLUCoigRgMY  
6F6lGrwNDwDiwtaJ4mM+iqjsFR0NU2OfoSbMRxclW/KrKZB+/JyBT8KmYM+khjcG  
P4vfCIB0YNN1AzIFNBuY/6Qb0apnrOUtSNZxvXlUt479GcBBoQ50ko82B8L4Mdnz  
hhPz5UF3AbmFrpgu1HDILcV9dN4P++SuoBW+f7EKza9GLcyUCPxM3kTy+LsG6p6V  
aT6fvXANBBMYMzQq0QWeGRX9OuzGLNJKEmllRp5yIMChXalh9GgaAoZaZu0MWJm  
t+prVg+ILdctJ5oOfKbkOXKFVsbCRrb0JuZQ1fKM83k8cx3kEFletfQMZBI0fWaS  
W0I5XPFKjqnlZLYqImeaaGHI1BlhceQumEcY83IK6QTiaFQZ/wDBdyRxnWlnsM4y  
J7dxC9hDoguhBeshdGk05yGDZmvLnHaZH4x0AfU4AVFG2veqdSBRUtx0dYgG5itl  
/J5kTjcYLyGxQRPfdV7EpXlcrSuAcc70A8/4eQx6MH8G41nS9xffLaxNYEbfuG2d  
8iTlxEism77EyuXK8P8W5f1/kMv0UYTZe2fqIPWryHaPvlQg//hLSTTG5DyckOKm  
JXhcv/2m6FA60p95xoinsCNCp+cCKhYcFyGKLmU4NGrmZJxd6JllaFAhnbF+IL5F  
tvUcmVv8YrxbfREp1LQqXaxdFMcfeR0tnBLhIAinRDilkiVbVhmx2PmZEyv77LNM  
swM7+shBibaDerZHWoh48WrxDkhFXG7tKN0FwjSo/AA9UQBPImbdAHUddFkzbuw  
XAszDTX9pFRJO9aE3AqgdXzSsSMj+O56QCoAAUKXTr4TjlxrMT+pdEMm8ypDF+zs  
Is0VLPeHija3H2ZDemLK+LSFi70jGGdoJZqnl7nUCNx2xhENzHucfue9QW8q2kX6

p5LVbxWUU1EDfThVtHxp8Pgs6o4rOTtfvUuC3jWC3tWC3vV7d2NB76YEpsFycw/A  
cqxGxiqkVBzMNG2x4bPW7nDlq9TEllapjXbbnt/cxWeQ7c9EjzCYTTWJBJ4V66U  
L2bTa5Ggv3vy3SRukZH+oMjJXb+hrRXaVAAs4DwJrE3ATlgGsOYa/gdVO0hq0JLJ  
EFOPZzdpxxsO14zF1ZxFMu7Qh8pDm/iONrNskSLlklrlq3SepQFVkzLDntu6huV  
q7TASgsMX0DmJCXwFcbKfBEtQc/r6sBQclUhKSOd8YzcfNlhH4MELuef4A1pQC6a  
tBTjdpotAJ57aLXdHozwOOwkwTuNR/tcuRC5GIzrjbpEJqSczZdB2xFPg4rvCSXT  
EGPAYRokM5L22eN2NzMNWIoUm3d6E/I0KJmGmH7BIUChTAMun/LfqYXhJA2jZ6Es  
5LloUrSRXXI/dJL4ONW/YzMNA/YGnWTbXsz4INImmsAYMpYGd7S66JgnRUFaJ62x  
1yyQ63Rdh269T0nKBze+nZXTboRSWigFoRjeOD1hY07pQyAaK1dIDfyhgxOoWGOB  
W5gbRKzk12KMim7cPbXpeMNVAlDmMqP/DGcuDUvNw6Gryi7Ytl2sFKsldpGg3AMN  
ZO1zq3Vg1cEBS2Z0NB6jSgsAPnr3c0SnH6DLjbEYF8yGuBeZ7CgNkilJ/Xvc8kHL  
yMzrn1zLwWxg830X7I+yF/IKXy9Wgm1fKTIyqznVibDT8MIRockY5Wdw7UEa/Vcl  
wajHdZ6Ga0E6NG86bbMClk//QC5ZivFWj5XKccjvWiASTieq0q8KQcZYPMLPCu8  
cjQMt9FMhbbk266143B9ZKy7OG7EuxXsac8SII0j5JVVWauQPisryvrTzqeEtdDXL  
4ui4LCO4che8j4IAOIGbOh/HZkLb8/fdwHOj8zXAEzAURBuVAlg+qx8wA+Fk4kMQ  
FBW4kwHq5Tc4GKcf6EZBnMLq0hIC3cpDpJ/cHqlltxNxlz37kW7w8PxXoxI94LDF  
HLY8nHe86YM/KO+iC2SCjKoLYxycjXaanjOSL+MZdcfZNuYjTk4immTeofREwKD2  
wLQJf6VJUPEkqFBPAjknmAT9IJoEJX0cmHpYna3pB39wbrYet3Z291utB8RYVsck  
HnijUKD85Cgg78B18x0XDirIJSwKS6LBwtSLbKYXRLsgV+SNDRtkSmY18hMGKnp  
MgWopkMfeBMOQZLqjR+xDU1nMccuisL00NhITZ4Xz/RrIMhDxew8rkVMiPgAGRq  
BHHIKOARqF48AoWYZxenvsQq3bvHu/DR49t7jV1JLCSen25U7MAOYU49UXIJPv+y  
9462fs8TQ8+4BzmVK6Y8NXyVMq39ybfok81GGBsAu2MQRwbcMgkRmSwLzwefohni  
iMAQFYdWEUPxNRaOSaEo+kfGOUf9xUxLfv8yw6JRueM+FjxzNvD8U1LGNdKsEleC  
kLqayv/f27WinTbtSjqHAGhd2ZiNP2aL8ikkaqsdB2fLZpS88OnVdOqMT/ggZ  
V21zoTvTvl0AyyQ/XH9tNflaWI9M8YCyTSFSjFNRxwO96jI9C3Sa+zR1YJaii+tg  
63ZrKwa8kr7v8yWG3W3XyDcmz5zxU101KuDFxrLR0ph+1iOkBo8CP0T+ZLqK4QPv  
MEk+iJmiwxGNFjfpooFlf5aWKYyl3ReGEz1wLd8gTumHSfdA+QbeSOQAGHeOKSq  
2zBiUo9PZSa9AE8Jtfz5ciErUSMGgk1DZEi5kSRedbqcMQq5DvP2ziF2IWwBrgjw  
hWvJ6qLSOzU82PHBqS/kmgsYSysFRxApGPgZulPEnkZlbbbnMvq5wr7wJN36RAP  
GQoctTWeZEQQGUOyBQlqCMhqTWRUsYAXYfNKUITRW2+4nChvZCT5pPIShy6jpcGM  
cEQGzShCE8JkSIIlkaqOIPmsw/EivU9K86+WkMK8sEmO9D8tMFy0NJORqtWqoH2j  
9VYis0oVDNOU4Ot1glo10ukBfZmxepXyCRmCqAUGGgVQngP0qVgtdWfNuoPfH1Wp  
vkM3iMv2Y01BGwExbd4IpnN8Tl3EHF2mXz9cE/8tl4oWTQla0q9Q4L5BugvsNHY3  
44TY+XyJrgm7Ct67vKqQ0NzgLelIhCaSmbAY3x8G3fzCdsChOOIsYnK9PfPEO+nv  
DJTW4UZ6XvgM8pb7rYNVkf7CsTayVBQaTmB952V1ng+1/6kVYzIve6aGspgip0rk  
nLsUjZDKCEnbQtXre8fVsZJNR4ltm7YTSfvyDSkHFIW+73dODC5uUltRD3UpiX4w  
xtx009LH1vCm3n30w+sHfdKyYx39YFOvTJOf1RQn2rEsprsFvYrWJidMD0DgUgJ  
HcbmgMOCBUcPbzbGON3RwNzwh2fol2im4a01yTWAZQVlzOiyZF3WLAw/WrKISHX1  
BGPUAeEI9pYJPc69xMEZtkxoH5Aens6DgSywx+euFoDgkMvngQISzCu3uMjJnGKP  
BydzkXZ/jYzCye4jPli9S1IVE7eekME7RE8vGb2liaLjYepJy/VS2cVysi9jhWde  
j+bD6T5Yra0Y7Jt/omAdQHqD3GSKSlh0ZURn4GIF0bnRYa6eYjnvh63AgRS6ygRi  
XTjCl8csmd+uXina/WotoLcujcaRLkl4DkgHp7jgsUWOG2g6SHO+b7vtQDy31RW9  
1xYy8bDPPaMyFVKtjBaSet2dT5E0usOp2JAiLPDLrfGyrQ/+EelClVqVRC/Iih  
dZvR9D7ceYBXOFZC6kx34Bozw7Z9/8QSPoZYM/I94ab0KnbQydg3dgGUJ46mpQui  
yA06X6Khfh51NuL+nEtsA5Ebrh/QCjSRPZyZb2I9eaXIALz6XmCg3RG5CKglqNNQ  
SRtsow7wegA+3GP/mSee5vKUIS6zazgPg4SXsYrOz4fXa2VVW7qOcgW07ufoOrLL  
BVWgr+UaNlyPA+uYEZsjFCFC+bRIUwikgoG40/Q8zNwggqkKQkUe5+soUGhI6KOMk  
cJSLJ4ckGEkXrSF+Ky4OzQOWbt1xQFkulB4EfQG+KPOOEjo/N1dkC3L7xFYybTRv

TVpyUokO7cw17IYw9IPwqkW7kXbQeE1KVtegn6AvYpWiwU8FC6BUU3Y594BJrKlc  
vIhS5yQPDJHrLpkd3DBr3YD5sWSI7KLBID6yMbykacphJ7VtjBlpyU1ZJGyjRwY1  
gXF0Ag26ISbgsQtXS7nCQ5VipfLweqlQUqXCAn7DmN9r5ys4Z0UhpJuCMRQ9NTsR  
QzMOvVNayJtJx6quyGTBAd6gEEdm9bzAH7pcLuyNjeF0+QYbBqex50B0Shmy+21a  
jfIyXuP8yzSqEjfiWjuKsaj67q6YbA/76jHUuXPr2dYdlGH51wxnDf98c+lvPS  
CK9R2ZwRWIYDZqAzZK4C8WiFfoRe7Hig6HpOdpMgTQExs6KqpUV0gKk2ubyB49D+  
JuHLVwgEhnujfo1DWsJhpnctPBcNaQ8H6xJLrZvpRHra404/aSWfx3hmcdfpynGk  
pox8wlkkzA5pEfQV67O5kR5tx5+4a3gycibGskglevWBz6QfUh+FwBjRE2JftQsA  
TWZO8Pn2b7oWBsOp4AfIO2hGKgyWdsq08q0BjbgdnUSBb91opU48nbzovtXa29Al  
pqMJQGiS7oJ53tsGNoOQYe/G0IYxKdlWnLgSeBi6JDoRvzkBrtgInPsejvVevYm0  
LylmV0uM7g39UJwjaMBS52A/nOeK0CDVf8/dF0YTFYxtB3uKYAcOz6dpmNguorm  
01KzdM8F6CzoTWM5b+/esmmROn6X4Q1oV06xrnz3CqgQw6SQdmpuP7pGwzz1h6eS  
gdEQZCm4bAZXW+gjn+vst8tXazmGty6XKgvVLqXw55PW/kKuQjdA6UqxJLczDLR9  
jn7LJpNUf4wmsokiBzfQ3feXC8Slqy0kDBAyWY9Oypt0QVceTZLgwrbLdqFaKpRz  
pVKxBHyE9ETGAMO3t/Y2tzal3XfGWBPEfuQUloO2TTgdvDzSSVxFnOqYKVSBSZC5  
yGqsrRQp4yqQYhrROImeFirVQrk0z7muxVbk/HRdtNiR/cxii8EIRqQDQIUHNOwk  
ttJiw86ucpyLwW7TBYR1qRzcpw5Ys47pMMOq3rYA9G9gyA2gHj+Yp+jgjjWOAmaF  
lGnjGqRSDhQNHwB9Ekwxrk8FxA8ZJ+vwqdrus9UVGkrW1WrilmoL6cajS3ymtIlg8  
RXqfyBAUHVuREJ7pWpOYu8rpkXyR88QVNH5Q78gNsTabrMIZd+aU4/Ax0QTtiAPS  
/nRH0XmanxS6DX1uicREGmurfSuCrgop01eRvlmUvafSrqtsn0kq8bTwPFN2Uzb  
1I4aQrioi/7TEsSaufHSI6Q9pzCT97LVfJU8WIJ8eUwPjCly3+I7Xj0h21scHvpq  
SzhVWs3UMmtnu4PcGdA7/ZFPk9ADqgDznQFn90gKug3DM7fvg0t8PJ2xx0FTe5IQ  
qp4Enz/f4Y9j8Ojsic8TMvUzFF5r/5LFUR1Io4w0KhbGBObuFt1ytVLplZXdrTjK  
tt2Oald6HZUvuE67WunWnKomwiwysC/zf8nyO50OM5OQwhUCVQ7I9yLSJm6XDSrW  
J6gC1wYhuQp0L5En8PqITHDk/RkHZV7JCADzarF4vUVEwctBR2Bg50o2KRmA9Mgm  
0EKrWMQ5b6zruUrLhl1Q5it6BuDtEVkBayzuPt9MdCQzXP6D13Xuk2E/ope4sYkJ  
K3iidIAV0UJ1CVo5OCS7CewCBuOcu2p4qRFO4vd3/KTjupY9g3gqhHgcN6bLXrla  
OvmDkQ601GhugnQqnhEvinSauhm1HRg57K1NT1IEzzxIKAb3HZOURZAjpuGFkyP  
V1+7W6S5A1pAlI+PZ+ZaXPIDlgu6kFcq+znDZwJd+XPmIF/oSdKQE2fqjKurU6PT  
MXRXZJGi83geMLyqbk5b5yCC0JGHdE9MAQI6AZEkYfS3G7R/M5mM9RBLPI9Z+zAt  
4oaQvjGQgI4SoTv0YA99U42N3VXacjttLzMejuL+XN2VFPdd846uVgswRWCFbZ0y  
HpwmVuIWrIYGzENhuNeDVXjs0xqRlXVQK6VsMLJyU3i/wHc+462tGVTBcNLvD1ll  
HRw1F+ScBHO4H/ISlg5ZrVqqVsnCRS+1ge0jD1GkwO08linUuFaCBjJSKEEd1jcX  
Kos0E2qYEmCxWu9S5ldXigl/rI8MDLYTuuwPu13mBcds7GPJW2bJNyeV7cv6KVlf  
TCSI3NwtFw7UCot4Kh+QGpCQnBLE9+LqMC/0lafZkrImfElzA9mUz7LxFGE3KRMb  
UR0C0ZSTEO22MOMR78oxpA1CJ46rd/QpNE9fk0QpNkcfUUNJLJP3j1ogDoYBQ4ix  
BaaMyBbB1wVQU9xZAbpWmi/mtldppFttV680n7t3Q/pVzihkl9llfWrjmcEvpJMT  
wZUILskzZ6xBCHh3xYInXRb0ODObbD/qltdJ1aCodCrlJ1q3nZVLVfly4/sy1on  
pyqFdq1QzOe75Zp9I40NvgKfc9PIhWkEUYLbsQ294sRHE/zFzITMEqSmHyWIQy4D  
0Kbkuq6L/1TUq6fmPXDvMZ/OAyc9muAvdiXuKktmXmSWujTSXYzNvBn16cohg3Ef  
BGPABj6ZwC0jYP4PppLXaW1xuTwaUtbws9QsQkyJNqRPqtmjrMv3HeOex3Z9mlT8  
Rn2/Ls2nYxOARHSmmpP29DL5uXct0p6wnb3nAGJ4ytOhoemKebtKo+HKbxNpd6yj  
RtOaghCzMyPjChDNLh3kYTemofbAaAAXBACXEYK6TmfOR7DL68XKeqGSKaHsovoV  
udx67rJWEJleQ6wIK2gdVGJBVCyIONUAYwsFlhAN92b00DkJByOGxm/RQMmjFtSI  
ptvtktPdXAPEQRChw5k88P6YDjTp1Ft4EGYemTge7bH5EqTj4GeiMDcYuSlayyPt  
4cHPYFLZG1YjoDlhY4mWwzpyaXOBB+aw1+NZMW9s+Z35txqY2hKHW/J5xYTIetVK  
ZPdl702UDh4DuyVXscmorZSxB6UcWlx5CWGtW4+MkxKKNW3CEwwu87V407URax9  
ukYuPmcXD3sg9QyhIumWbU39CQ78CJep9XhMlJtk+gOOWVy+3INvDBTJT/2B+WRy

59ay+Up2DBgTP0A979Ax6SgTj1NRaizKi4fCWdxePBTSO/c1LHcgl8EhJnU3geod  
4UbcGpqnogsRkEWMtm+trApTOTBvmthWEncsBcj0Gt5aTxm+ho8d5hAe+9Di5WLRl  
V7WZFNWEWmcX5/SqK3kKE/PNKpkiQbuLkX3smpp0SMXREFG7cYIsIT9/NfEkYnKY  
ChPTfgrFh2TNHfAQpoMxZqrokvSgw1B9MWuTKzzViLNjUh5TsiXlxojdymP2OeeN  
r1nsiOprAosCnPUU44MhIf9JNfWEVxT/IIBHBpFTS/+tt+f4x7YdKaOADwyjGuH  
y9nRjsxjgbqVv12zgMnv7SE1PlduePmuO/r8EB/nlyBEORie8/vp4nupV0fNDQO1  
8rcD0wa4hCSO/IGWjlGqGyg2QCd3V+1gTbvrbO2bkDAvWazO+IDf8oJpREdyBlaH  
EUPA8IJzKPB469zfuCWc35Os9B9zvYTLjbrYD0Et0npWy+SA4vxqdQFDvg8aLO  
t4M6WQxPdnZ8JfCpPzXDl6dJD0/X/gszN08mhkcXyPk5tj7jXx8HThu5ahDZbDbw  
aTOce6NoRJJbjWPhfKpbwLQ668kyl2So3X9OKLrDxalZlfka6qechCNfKOy7sK1Z  
HJVvqs6UG2zT4ujBmbPOMwMW3PZeo9FQpp5A7dePdyZDOIIMP/sdf6i2Dq7v7bZ2  
MpNubxWNbtc6dlEhIM/oiViyswkXipLstLOHvtMN4xDfKIKQ4MyEDaOb1I9HTvn1  
NWuPduGOS+ZZdA5MjwZXSjbqa2Rlcc0JgMr3XK8zAMlf6zZYNc8A6YrUKXfnIAXC  
2L8omuf60inSRFYDET/HOqZbQ5pXGffAnTDWyUE0DfQdn0p8beVraXbXWi47jmy8  
Tn8n6WFGHbY9AOQeOTC44cPuC6Qn7UXu/rul0yM3GANyAgPuAJJcck46sQCSrjk1  
kslB8vCjK2bjYNYNaPaCKTljYxeJL5r2wJDGM66DUCuC+MABczedh3MvyKQtFYOu  
XFnPF2BULCEY3+swqL9dA9xfDlnWipBiBVgb8qjZjp2klViwnopXwqjIVDDgFks  
CugwPePb6Sl+kFMeStrFHFBiZxiR9nAK8KmqpTLNOOFwiU78s5d8HDzt/LRcEQv  
kErVs6c6/PdQf2tyOg87U5+LBKW357kuEYbDHkcM59oHFAXvjg4gSWketmiBOqxY  
JYkY8M/RmM4oPQx7lqZnPSZQh7URry4vIV73KeiBMtbF33P5MMwFH8/WNa5O3GFU  
zcZSs02lpVzpqZWRWNSrzGgjNaOKJabp4Ypqg04gY9rcwmwwN52mrQs1lzdcvHqa  
UA4pyYNNcmPQh7DnupYDwWwGb0u7fqHl/jtYmqzoW7beF4sd90g6of8X9O5jHmY  
i1HQWzWvXcgvXkCGp8bdkaPus9QqEZrMBHYVBo+MvAfz/MCXq8TDDcYbgQfN2FjJ  
J1cYSeBMPHqb63hZelnmUP/F/MYKucZD0dKQZazmhZGBQJj5YcB8qg9GTtdD4nqr  
HTGdb3Tf6boDax/JKbyk6uEgcHoeXC5me/eYhM0ZwKhkytUW/ZV+bKELZcedOFNf  
o+eSNbnGLABjv+Nh4xnyS/zNPwc449RwYHmCbNchA1LEW0vNm3C30gVvfg25eJ0V  
p7WT1JngwQC08Pj2BigSuYrMmns0clKR09GpVfbLbGEITQOm2+RLZ2y6ZIU1nytn  
UGeTyeWq9Nr5ISIdj/P1wesrJ2G7Je5+xtrbaqECFAHWUo0cuSL9kKtk84Ws7q10  
4aHLh3y/yyDNU9Eq9clCB6R+OHLab+rZzTNUfDG0IEJ/wmxT31hu0DdkH3Ou4vu  
fthVQ7UQBwOoAmPDcQltmAXQAp2hUMkgVa6SL0Aymh9YXI+0rFAw0NboHqhz40/I  
egJHot7g4tChHC9dFQRxcAH40lo7R60dje3mhchwq4O1DGWp0/0w9Px11lgjQd  
2SxaYjWeOfON4DSRsIqpaWmA+QsuChWFjijXrvMAEHJPGYwgMJL9wzcdNjCeg4y  
SFI8+DnP+zlwj0hfCGxx07Ym4RQEG8clGFjJtmC9IRia6kkwGiKjoo+c+yRpR+lj  
ocVgSBajvo7IUERJyPNZSbjNq/N8Xm4RHRZZGZEFv0kZeS9YyqLYO4xqnGoUP5Ky  
Y9YkXaaNMd1qpskU/Wvg5eGyDsHdbAGJBA6XVC7EJS/OAknuQn59lcOMDI4wleFA  
+xOgPmUNjnGqHXxpOcTPT3z4041U/qI3jWWXuNyhlp0FTdZQ3San1L60m+hOgV5  
GQX2PUgZv3Q98KMJF2DLC+hOnnDnlS/Z13bgox0b20eHTYQZJOnYOR1RY2fshyjo  
fNC3XC4R3RkNM3pquK2cjjO5HPS5JFUV6uHQMMuM00+cobSA0dRUy7uPxBSKBrLP  
iVbQ7JN9p+/cX6jdTuAqeWvbqyyqFnNkHitOss3ulYRjQggjQOEiDInMFCiDmdX1  
6B6Nt2eyC+hmbB0HPXzITBY8k2SVdkFTCR0+i2E8rq3c1y6uq3YJDZ4jCGi6XoKk  
ldqRkiW3HF8bLlvq+koLkiDyFhKx/naARKp11NwBQqjrMKTh0OtJs3c78ob8lzbi  
Lal1ue7cx+V00VHjdBwQa57PIZDePH15si7owJOwNoFIBsRhwmZpsZSIRV46Q8M3  
/EBlvZm7obGv9ncSiVO4DXd4i3Y/2dYuq576oHfTozTZx9mjAT2XG7OCmOsAR3M  
aJc0woSWVBIJZZUm9E0coaMf1a1inA5UjWMS036yE21johiXS5zX932SatLuhSR  
DHpOlepyVQPYqkYXVprTDp6NUFTDWhfbZEtjFppRoNitc9bdl/s4HDAhif9EqH7  
nZObCVtGhhsfLNQu7E6t6y43zDRdZN6uPY/4ah457igUjAwYZvh+xsqkX/D9yFCm  
GqPQyMBn1ZuCFQp5x4C/fCkSG9fSIS8XimUs+VbUbsNFcMblxpiNAOpBJmWRGiTJ  
ReF0TKWLRq5N6QEMBzhE80BDpnZ8yUmMZYxpQtNI5N2iXaqWNYFUvmarPEKJ++bl

D6YQscINTRoAnGb4KgfglS4WCEixuX+2YLpPUC62nlrtY6QGEaXtBJEnkSaUzZDE  
JEMNcwlR42bg9V3cLOATHzrASQhAhoTgM75FyfCP3XGoS2LrwMpGpqLhD3V3NfsE  
xrwwrjg7FBcGPlavTuIN1JEnAieLtxf/8W4nCGlGkQO5RzbUo1AIFGAUiosqBJFJ  
xsDZbD0GMsISY4CKgGWxvbF7l+uU7x77d/VwnRXilWlor8wkjFiRAcIBza09JxpO  
s0CTDbMP/CISBhf/Y2eu12dOToTuaMnr+1vN3UbdauzU9/a2Dq6TU9fY2T2o04K3  
yOw93j08qO9Zx3V67ZguqsPrzTooptZpsumRITQ1Ff3gozb+jh+Rb7xmruIGim+M  
rud6R4Py1mUqFkHwJ6tIGLGFycSlpMD4dpVGlh6tVChPsY79rjMzfW82atarc1zw  
wo9lfrHf1SE/fgcJW+UmZZL1+rxsjJDjDslNB1oYqlJ227A/KlxOBhw8gVLHVnR  
NEcnk2CBIRtQyKlCsbTM71YtKEDvSDMeCYRrU5inmXTa2gLrp54ppGS3trbo4ECu  
eaLgxAbjmwJoUpdE5tFp8lxLBtOZ6oOvl2RNohvuvBKIQHDdRESrVJfO3dtelVG  
2vBD1JnsAKij+8B81qXtEK564EcO5InaMszrhBrqkE5d1dd+HGRQ+SzJyDkPpKM3  
sKQRYtGbZElaxwkPndMJ/lkfoJcgtjjwg15wsluRFd7rcWKJ45czdlAgpT4V9D8N  
ne9MhZbUzl+1bSa/rpG2rdWki9D5zrRQzBVJujw3ci3Cqxqb9e6pZpBkYC+NvERu  
giYHWqVXWD4xPU9jE5GNNG/OQRlgHjgGJeXywxUOEIH4kqblbKohFAi/G7TLUUXa  
tzakdARQLkxefMJ5N4Ng1Jqif6+JMCSa9oK2u0rPfk8+wLXDrMX6nkO/+FORUGP0  
2AzT46V602lgbfQ4A+i3LZlqR7UTSbm++oRTaDHSGCRVHBDGlikmMEX8qaUGwrV5  
YXo2nPQsrHK7uDQU0IMLro4MKI6lGRckBemhzc3LAhekMZdiLXH7eZv5VVMYZZy  
1zAule6tiWkOLim3fC/dXRmacr5g6EvL3Ocz9tWGlzoxYeaT7LFKbSWOJXCEUI9E  
InDpK+plxzBbbg6diIkzpz2On2ry5o4pNMOWeckMMCVhZ26HbF9cdizDiPysQaz  
EBNDcSLre1P88CrudPNPLuMWDedcb8+F93zPZTWbbgoUjA8lzY3vORp2AYnGAft  
aYxA9TEAdjmqGceokedCzR7LD2yP+TNq4mWno40C49Z0plrT0uO5aqKez8xCbTt  
iGvYdBXiNj2KUa67pKOR7MAdFl+7s7m5BX05Wz6hhSYb0lq1StWuVYvVfL5s2ygn  
AbeaNwbzgz/aYZRuGt46HR//ZBVdMJHnBPycgXIOFp3EYbZUq+ZLOZDCTkwBdY/H  
ZKoTezwmODN6TAAa1GMCIMLcbHNNtSvRlTeAaglcFe7BMzDlOsv87HNRCCo5cLHy  
WM+FQg4gxEzj7j5s3t7a27Mau8d31hOIZ7ZYvJGuBGR2+Z53HwD2b5uj7kWFvLoE  
neEM+TL3fAlwJlfdTVhfQ3MyRVs5WGnoSkh92QqT6wdn3KSB/WFKhFMyKMigjAwq  
lKE6DEoMknzHE/ZZ34XhdOSQq8aJarLxSZLrgTMZuGSolb0B4LuOQRnTyd0++K9x  
rzJAmIAdOJOEOJNOmD+cjaRfD1ncPAgAq/mCqhYqSzZUMV8VB6dQyqkaSQgL4CbN  
9p2dNesGXU9I2tCvNxJGH54qJIM9GNHSoGmTJz9uLe3PDYBNgwmCgtrenNKfOxrF  
iRv07DwK3PL5osrP9fFWSbdXioUSaOTwxoxdLNgFu0oy5nV1u/UzH7AaG41MQml/  
RLUWFYGuJ+3Ca/TakVDiWSHTMUmmskS4TVClwye/XRKR706hq22joRnl5bCr0DJ28  
lroCX1ztTowD2KF90XXouhpPSUsNs1l/KgXCE8NDqFh+RBZez1lpLbQyAis7U6qV  
y4Vq5QRtDL1op75NBmTC6rHphRM/5GKIDZQwpqpGtw1oTknwuEitn6MasB6S9TD1  
Q2IzJcfc8O9yqfFeCvwZ4hfSq8eMctx4SSKhXidVzGWp6jY+KCepmCLu6MaDUG0a  
BOAFXF1wK40cU19pMDGZMeWYMaCvXIVmDAJd0tVjUEMeA04jKR3GNf7wj37Hh9/9  
/R/5vu9bsz723qf+4KlvWrP+4F1v+Oh/ePOa9ZHv+JGPfffb6PfvfVj73jPR558  
P/34/jd95J8/rV2ndPM6vJIR24OjFINOTgVhc+FE0A3QMSz1y2lrAzi43AdgnPPI  
kj9nykmUvu/3NQOK/CnbOLDtfd6fq9m1etYd04hh9DwagXHyUU8Xm2g6Z326Db0L  
SjfoSxdkB4gTUvUojxekVDNwtjWc7r3o1NEFM+SZwnUJp94o1boK34hprL246PHA  
BO5112qVnb5KtaQKldqc21fLNkoHzVwtn6tuX2EKyhC1Xe5XZNIDZAqXNRALm3B5  
GYH1Gkg62cit5ImGLzP7F3ML67/EIW6nHWYnnpdtkU7LV3JIO58r5MixLV2jG+NL  
C5velGrTIKRUIpL66RvOxAEYtggC39CyM+V9motQ8twxnvEA9JA9jaLEGW1HMyzi  
uoTWjZxa5XNm7U6M8sGqi2/y7D0lplxAYlBlkWKBEt9gAlbInsZKSqTRGO+hGtv5  
SqVcxk1TFcxmeZMA/5hBxWWYZrFOGShfML+4OwAzA5TakTsF0EzHmph6hqRIYntD  
M6sk7lfxpfhjE/kYHyb+MdtJZFuPxDPqBwKkulCP5eRUsVS6gmhaeASCnDG4K5i  
7q+6WfpWxBGG0Ep024yTTGdLaD/9FesiYPMpTniXjr9sTsNOWPMqKsRZ+MRZ5wC  
e/KiWENI5VuODMe2PHhinpsmTs1X0lunMw1Vei4RnNLTqWeRk8zxnAU8GOnI4MGQ  
5mbw323uP6L70SPHw+nTNUmqFMR+6EywbTX1EGnXqm3etELE5JQLjGCdICdljGZo

23Cs7izsxWoQ8QtngvAFjQ1ZAU8XXTANLz6OEBi/hFbh8bnHbA3ugC4GWkzarbSq  
IUODjPBF2CCmtr9r5MiqBSXCuza6TcLUgS/j0YOA63l+9OB8UnC2Wgy9UesFczX  
c5HgvB5MjX976PSBNnpZIEj9OdUzn3Oj+I+iH0ItkED7aYHgUmiBxOqPH8QCYRk5  
5p9AFbYmsD80DAJvQTRROJkG0Pf76oNeH2gBITqXpuz+8CQwMWcwARBwwwCicYb  
3XRGaINDTd1yq8axOwli5EqknAL8iM9pWCJE/5jpQk9IAm8YYIDCBw4sra4MSglv  
PCgJ0LZIUgqSjImJNDCrzMeKfq/UmMggxJhUiq8vBhigmYVleLD1SPNw/3Dzkb36  
8WHZjrW1vb3VOG5Z9saH/IQk354YB3vbFkbe4eHm2qjWd89sDbqzeYuii8azcNd  
7nMRAN9VDN/A9xLkXz090HAdzBANYySIFgBEEdLn9ifdLat40PegFc4SdwxW1A3Lo  
2EE5iaAFQA90+/OeN2Iclfp9MjQRumw5J/hpl14m2/d4DgRAHyJ/MuXCbiTMGeYd  
botR1qZi1guAJI3U3yxh2GbjYmHAgI2cTVO5EKHXK+SrAO50B69iMM888Vb5kB4O  
fbkrDfRkfidV2VQW5xi6pJpftEwh9I0Tv61SypcKcNwYMPHWZO0foKr4nhO6JwOw  
tOGQoLx58yjWg03y/bvgcwXRml5zHaTGK7gkp04Yo+g41r5HC9obRh45nNZxNKIJ  
wS2ElsFGi+vPxCROorq1q3kQotvVYIHZ1VKKLhy3gtMJnfEoU23TIEplEp8LKRya  
lIMHVc1HgfPB7+eftt0goJkXvC6kIUlsafxXsmQ3cHcgk+Bbe5m5kTCvB7vOMuGo  
54yXcN06pP/RPaVLai5YGMZbRUSMd2zXFShtrkLUEEQhF04zFvIQ9IZNqevXlmy+  
UFovFFWxslx47Y8Dmj1ONuRkmVyxSHNQ4Z7eyYTsGiQP0QgmV54XjhLjB5u07TEO  
gMCv4SpNy1wYGVjM/UWXBf2QYzvNXJUnOiFpybXwoCUOUh/0JxqxNUBD4Y1Frti  
NvacE3XDaf/sN/kn/hnXhx47dNUC4uzmGrqy77vDzv3ZCVZ62+06QXSiU6wj9YM  
deWtIX2SFCrM26FzHnsVE04a94VtQrKQ7NkvXoH0rLY/1vvTLuXX6RjZudLi8nTk  
bZuuytEC5bE6DH4Mn2mflZrG8J0QGiHZ70TWzRsZaytJgXD11wD871zTBuxAXaAa  
38J4i/ZeJIEhwYj49Q1uDkueGUqZZxzmwUafsyhoSDVuFqwUF1oR6J01+BsVGgcj  
Je8eiKLnSziVHqZNOIkQFXmlXYk5KUmolsugu/WYJ5SrUBk0ob6rGBXb7cai62t6  
16QalyMphdXYC9NdvEg4JY4JIB6Ex4icqVyuVKhWAcaux6cWx6f0+NDKq4eHC1SG  
p+pKD4+r2Hl4Khemh+eiodHcwqjTNgPHY2XYKbAm3qOdMWtADQcTJzMyBtmNZVf  
FiHrOKovfIRcolfrkWXx4u8hYdio8s5h4QzieoQDHw37Yg0IUWwZyb7ODE+mcsPP  
Q1ouKxebmsuAVK6k8jkSiG0RTvqCm3tuhliH7TtpudB5703JU5latwdzPZH1SeAN  
LWG+vDwnPD2sHU3PBjOTBa0g1DQ28mhNxaDFAnwVWgfNDTIfSK3iuLFPmXBOcCUG  
08EsRS4uyWYeSLYx9KNues8L5fpCRhuocHa6U6hay/bo8g+1ssnRqyQM56ZQGapV  
zZ0167bv41f89eZnnsQddZDRcOXMsOWBkiYM9aICLAOBhEQkq2Vg6/CnzuCQzI6r  
lvAfmL7iSiWfLZWLbBqSC+VUCSf0adcd0SaacqWqlPoLjzqo5ej7ue4AALFnXpe8  
jzMjjuzQjhHHS2ZolwBQQFLmtYo2wEcTWnm8QeUKqmBn+etA16aMBDQUpt3c5Vm7  
1ZTiTOaO0B6ABlaqdurSf8OuUzKXjV2kZsIz8hUoNtXIEpfPxsQf5QSmBh/IMu9o  
KvvCUosiq2Qdj4/3aScVm8wRMdWSKt10Ywan2h3vCiNgvmiHLgzy0FAAmZECMwVt  
Z5jpa+awvXVpV4jTKiey5Y5IKYUok5I9uyFjM2rgzXwBF0yRDjazI82j6ZFhh4KM  
vKrl6VqtKFS4MvEMS1c88jeJibW8H1IlvetS9y5qykN5C4y0NavnMOBYQEzi2a1  
DluXb4rGJ0JfOmLSfSlg6RMuiyF9R/eulpRcDiarFZgfy1mkbctwLVWVR8dwRH4b  
uaHaFpRzP5ZcQ10gLdD0TODygFjtqNdzhn6yz1NkUGh4q2RtG4E0UWECdPuAah8y  
DxGVsNgzod0u+ZoUYCbZmugqiSOgxtRclXRIZ3icGYzmy0N7QyccSFnoXCWSSmSj  
P82UoFZBKmUkUpAoe+3MbX+V/aqz7t5h86s6tcp2YaNct9WGXa2rYqGwqWrlBmzs  
yna1ulEs16sFmoq8JG7HLvzC/f1MfAAumBnusUKthGCV0HdKhcpimVL+ITsHxNwS  
OTSlvcEn0zXlxWrVTUjIXDvGUrUrEYzJ60piJXxqTtwz6cQD0dNcRMmX4aMPaXI  
NOS06YqdHU7yqazDhzlBpeLtlUJlkWu2Aphzw5LKFgVCWUpyNLGVMsYZoaNIRhPwX  
ketwxqQ84IrtkCvmszVMzt8Q7BQNruO879KPO6hbhM1IHG33nNtT3fN1sianZ3R+  
ZoJyxWZ7hBrPWRvsp1OYowCFHbrjPtNZrWMDilGlcQkuCcG5S8BShbgoJmdm7fB  
r6mf+IDebtX+OGPvhVdct1U1jBfbyx4cNje2mse4houZcrVWqOEiLgokHHmOSNMi  
H94FtHYX12EbhKp9nBIS8J5mY3bMy6AjmjAigj++Ruu4BU7nx9zBmLFrPgWPvPTE  
cOlj9/WnNJIITuu6RngTX9Qn3bTI/Bb5UtV3IKMikRCbdS5vIplxMNF3sxXtDFOXe  
0N3voNlaMj98h7YB9DboYlxavUBTmhZ5Q+x5jw8FMx/ftuB/cr1I3hQnfYWKdvo

Uvm6oCivVBsHtEzfOEyBBpjQQKW6Uq7C93No5GdkPeY4YDwRLT8j4CfyA75zkgif  
zZdzJbl3aWYqTJ0zoHvD45KjY5mepfhG5STJqAWD0e948lsyR/AmhYLoNiIA1i4X  
1D3zxFueeel76L/6XXQ1bemiC40mBDKViyyseVwoDIJyitYrUdmg6Xz0DYVzrEZq2  
YYGyQOFzDH8Vj1JIN8woUzPpDBVDLap2ueL2arlKgbQ7zaFkjEaMb4z4jZ3/Uk4p  
xjxs5hwhcpJaBllemirAGzGz5xSYcQDZ4/rZoTtCYhPwyLr4bhpdutW2p9+dpkfN  
gR5Vy5TeDsr4sOnT0wkRz2Tg4bwd46+i9Gzr8IKRHI7RsRG/8drKMGVsR5CqD8kk  
GcYSZc8m2PZlhhctZxHoYuS2UJFhrb+L0Uhc1FH5obljwGAFb/vudiwSww1vN9p  
RMMhjFqjKpL9j9L1rcNPRh3kPbqPRnRw5Zs0VEAeo5zfiygOd31aCAYfPjZx3Qvc  
InVmMRWgEourmc8YB0vX/ve4Z1gQuA2OySXbpCYOR9ZcZl9yx7oCPV+t5PNX6J+G  
P5nx1165wooVhqgDzO49IdH5mR/k5yECnbxGW5x8WNj1XYrtaxGw9q4o1p1q5ih  
ZTgG2gCNAMwok5loouQza/QizWNcaMhQFKeodlAnyLaOfid5NDMV0ll6aPZnfvo1  
L3zBp115wWd+xqc7r3vqH77gyote8mvf/5B6yyN3Pv6w+5IXfO/WT37OG170mV95  
8AvXX3hrvfkDL/7mr/j59Q9+2j/9B4c/FRxkXv9DX/KFnzd+1/tf0W75f/0le6/7  
i//99Pe8f5h98Zt/4hvf9+I/+Zvf+osf+idXv7MWPfnUQ3/8vsf+z9edPPzam7c7  
z1g/+QUf/njlpR/6nl++a/KHB1/7ivq3ff4bf/EtR4e/9m1Pv/3H1Q//55dfe+/B  
7/78l9u/vPFLD7VfdTz635uC13+i9qUf/uNH3/afvWjP/0e76ob/Kt/+cr7n/XD  
b1x708s/t7T9j7/4862feO8X/VLxvx3e+IInv/5v3/d5d37jJe/+lt2fnJXOXvqy  
nb/6wDd/+0//+X+5Wl//8S+PfvvuV7+j/Qfhdxeuel/5+9/wgR/6hsK3v+Oz/+pN  
f6r+6AMv/7V/1Hjd/3zpa+7ffEH1V375odf+8J9eP3j79ud+xhs+8+6fX5++8vbT  
tbF/4Qfe8PRffPbdT3z43ubX/a+7mRdWPnbyhd/1S5/4499/19d89Y+tf+KzfudX  
f+rt6z/2L2b/9kff/eZbT/6zn333W77q5b/3mz/yq9XHMu/+y8IP/dyv/M2/mb3i  
xW96Z+33PvjbNx9f/7MXPvnrn7a1+SOT5h/9j1/4gZ/7r6/5+Au+9qPtlz298cyf  
PNUZBi/cfsmjv/Wh85/fbhavvXTjx//su/77m9+y9cbw9E+mr/6yb/+Bb966W/7G  
G7/+idd+2QefPP6WP/+ep37jtbUv+93e3nve++a1V5cG73znmVt4zas/9NjVX/jA  
wd0Pfef443//2r9+5OsPhy/7nT/7d5b7ee+xXvfX3/sf3/H1976gWPvbV3zrO7/t  
7zXf9ltbt+9vfflTX/zv/+bwx/d/5st9/xxc9+X8Bd+4L0g==  
=Lf/K

-----END PGP MESSAGE-----